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 In the late 1970s, during a program set to identify potential mitogenic components of serum, 
thrombin was shown to be a powerful mitogen for fibroblasts and to induce fibroblast 
migration in wound scratch assays via a direct mechanism requiring thrombin’s catalytic 
activity and involving receptor activation. The quandary as to how coagulation factors 
influenced cellular responses, which was suspected since the observation of Trousseau and the 
eponym syndrome, was elucidated by the identification of the thrombin receptor PAR-1 in 
1991. PAR-1 represented the first member of a fundamentally unique subclass within the 
seven transmembrane domain protein superfamily, as receptors in this subclass are activated 
by proteolytic cleavage.  
 
At the approximately the same time the structural homology of tissue factor (TF) with the 
class 2 cytokine receptor superfamily led to the hypothesis that binding of FVIIa to TF would 
induce intracellular signaling as well. Indeed, FVIIa binding to TF triggers signaling 
pathways. The interaction of FVIIa with TF is essential for signaling as the binding induces a 
major structural change in the serine protease domain allowing its full activity. Interestingly, 
TF/FVIIa signaling appears to be mediated via PAR-2 activation, reuniting the different 
components of the coagulation signaling-associated plasma  membrane-localized components. 
Over the last decade, a plethora of studies established the pleiotropic role of FVIIa and 
thrombin in health and disease (e.g. inflammation, cancer, angiogenesis, but also wound 
healing and bone development for thrombin. However, as an intermediate in the coagulation 
cascade, FXa has long been considered a passive bystander only, and consequently its role in 
cell biology remained relatively unexplored. It is now clear that FXa plays a crucial non-
haemostatic role. 
 
Thus, it has become clear that vitamin K-dependent coagulation factors in general and factor 
X in particular are principal players in pathophysiology. Hence understanding its biology 
better as well as its role in pathophysiology my provide exiting insights in both the 
understanding of human and animal physiology in general and provide clues to improved 
therapy in particular. In thesis I explore the biology of factor X and its associated signaling 
components, in particular factor VII. To this end, following a literature study on the molecular 
genetics and pathophysiology of coagulation FVII and FX inherited deficiencies (chapter 2), I 
start in the nucleus with a study on the regulation of splice site selection in the FVII gene as 
its intron 7 provides an excellent for such a study, with repetition of the intron 7 splice donor 
site (chapter 3). Next, I investigate the effects of coagulation FVIIa and FXa on signaling and 
 12
their functional consequences on cell biology. Subsequently it turned out that factor VII is a 
relatively minor player in pathophysiology (chapter 4)  and its downstream target, factor X 
(which acts as the point of convergence of the intrinsic and extrinsic pathways of coagulation; 
chapter 5) should actually be the focus point of relevant research. Hence,  I decided to mainly 
explore factor X biology, firstly addressing of this signalling to cell survival (of obvious 
relevance for cancer cell biology; chapter 6) and migration (chapter 7) and this notion was 
confirmed in detailed comparisons of the biochemical changes induced by the three major 
vitamin K-dependent coagulation factors (chapter 8). It appeared, however, that the effects in 
the clinically highly relevant –but underexplored-  phenomenon of fibrosis were a more 
rewarding of research and the research of these efforts are described in the remaining 
chapters. Finally I conclude that factor X is essential mediator of tissue repair, whose 
inappropriate activation may lead  to fibrotic responses. In this sense, factor X as a passive 
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Inherited Coagulation Factor VII and X Deficiencies Associated with
Severe Bleeding Diathesis: Molecular Genetics and Pathophysiology
Keren Borensztajn1 and C. Arnold Spek2,*
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Européen Georges-Pompidou, 75015 Paris, France and 2Laboratory for Experimental Internal Medicine, Academic
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Abstract: The rare inherited coagulation disorders are a fascinating group of diseases that have provided us with impor-
tant insights into the structure and functions of their respective deficient proteins. Factor (F)VII deficiency is the com-
monest of these inherited disorders of coagulation, whereas FX deficiency is one of the rarest. Genes encoding the two
proteins are located on the same chromosome at 13q34 and are separated by 2.8 kb only. Both proteins are vitamin
K–dependent coagulations factors with a very strong structural homology. This review summarizes current knowledge on
the prevalence, diagnosis and molecular pathology of FVII and FX deficiencies, and focuses on the genetic abnormalities
associated with severe deficiencies and bleeding diathesis.
Key Words: Factor X, Par 1, structure, function.
EMERGENCE OF COAGULATION FVII AND FX
GENES DURING THE EVOLUTION OF THE
COAGULATION NETWORK
In mammals, the coagulation cascade is regulated by a
complex network of interactions, involving positive and
negative feedback loops [1]. Five coagulation proteases,
factors VII (FVII), IX (FIX), X (FX), protein C (PC) and
prothrombin, interact with five cofactors, which are tissue
factor (TF), factors V (FV) and VIII (FVIII), thrombo-
modulin (TM) and protein S (PS) to control fibrin genera-
tion. The coagulation cascade is triggered by exposure of the
transmembrane receptor TF to FVII. Coagulation FVII is a
vitamin K-dependent plasma protein, which circulates
mainly in its inactive zymogen form. Very small amounts of
the active form are also present in the circulation [2], how-
ever, the activated protease (FVIIa) displays only weak
catalytic activity by itself: FVIIa has full catalytic activity
only when in complex with TF on a phospholipid surface [3,
4]. Activation of FVII to FVIIa leads to subsequent activa-
tion of FIX and FX by the TF-FVIIa complex. Coagulation
FXa generates thrombin traces which are not sufficient to
initiate fibrin polymerisation, but which do activate FV and
FVIII by limited proteolysis. This propagation step allows
the generation of sufficient amounts of thrombin resulting in
the generation of a fibrin clot (Fig. 1), and importantly this
propagation step is independent from the TF-FVIIa complex,
which is rapidly inhibited by TFPI [5, 6]. In addition, throm-
bin also has an anti-coagulant activity. Indeed, when bound
to its cellular receptor, TM, the specificity of thrombin’s
substrate is altered by an allosteric mechanism. The substrate
of the thrombin-TM complex is protein C, which is activated
into APC. When in complex with its cofactor, protein S,
*Address correspondence to this author at the Laboratory for Experimental
Internal Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ
Amsterdam, The Netherlands; Tel: +31-20-566 8750; Fax: +31-20-697 7192;
E-mail: C.A.Spek@amc.uva.nl
APC rapidly inactivates cofactors FVa and FVIIIa by prote-
olytic cleavage. These reactions involving thrombin belong
to the coagulation negative feedback loop. An additional
negative feedback loop occurs via antithrombin, which in-
hibits FIXa, FXa and thrombin activity. Protein Z, which
structure presents homologies with FVII, FIX and FX, but
which lacks the crucial histidine and serine residues of the
catalytic triad of the serine-proteases, also participates in a
negative feedback loop by inhibiting the catalytic activity of
FXa via formation of a complex between FXa, protein Z and
the protein Z-dependent inhibitor [7].
Recent amplification of cDNA sequences, presenting
strong sequences homology with mammalian sequences of
coagulation serine proteases and their cofactors, allowed to
go back millions of years in the genealogic tree of coagula-
tion proteins, before the divergence between tetrapodes and
teleostes [8]. The fish Fugu Rubripes and the chicken, two
species belonging to teleostes, have indeed a distant common
ancestor with humans. These results are consistent with the
prior identification of both prothrombin [9] and FVII [10] in
Danio rerio (zebra fish), which not only demonstrates the
presence of a coagulation cascade in these species, but also
indicates that the assembly of the different domains of the
coagulation serine proteases took place at the moment of the
divergence between humans and zebra fish about 450 mil-
lions years ago. Prothrombin differs from the others vitamin
K-dependent coagulation factors as it contains two kringle
domains instead of the EGF-like domains harboured by the
other members of the vitamin K-dependent coagulation fac-
tor family. This observation, as well as the analysis of highly
conserved residues linked to the activity of serine proteases,
led to the hypothesis that prothrombin might be the ancestor
coagulation enzyme. The ancestral prothrombin might have
had two EGF domains, which have been replaced by kringle
domains during evolution [11, 12]. The phylogenic analysis
of the different domains of the coagulation serine proteases
are very informative on the genetic events which led to the
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structure of the vertebrate genome. The proposed model of
evolution implies the occurrence of two consecutive dupli-
cations of the whole ancestral genome, at very early times of
the vertebrate lineage [13-15]. Additional events, like local
duplications, and/or translocations, may also explain the
evolution of multigenic families on separate regions of the
chromosomes. Other recombination events, like conversion
and loss of genes increase the complexity of this model.
The genes encoding two serine proteases, FIX and PC,
and two cofactors, FV and FVIII, are located on separate
chromosomes in humans [1]. This suggests that duplication
of large parts of the genome, or even the whole genome, took
place during the evolution of the mammalian coagulation
network [8]. In contrast, genes encoding FVII and FX are
both located on chromosome 13 at position q34, separated by
2.8 kb [16], which strongly suggests the tandem duplication
of an ancestral gene. Moreover, since genes encoding factors
IX and X are more homologous to the FVII gene than to the
PC gene, it has been suggested that the first whole genome
duplication during evolution generated an ancestral gene
encoding PC, and an ancestral gene for factors VII, IX and
X. This latter gene was next duplicated locally, yielding the
FVII and FX ancestral gene and the FIX gene. Subsequent
duplication of the FVII-FX gene finally led to neighbouring
genes encoding FVII and FX. In teleostes additional dupli-
cations seem to have taken place [17], as shown by the pres-
ence of three FVII-like genes (FVII, FVIIB et FVIIC) in
Fugu Rubripes. However, several features of the FVIIB and
FVIIC genes suggest that the resulting proteins do not func-
tion like serine proteases, but evolved in this specie toward
unknown functions [8].
The ancestral coagulation network is simple, with one
coagulation protein containing four domains (Gla, EGF1,
EGF2 and serine-protease), which, once in contact with TF,
directly activates the conversion of prothrombin into throm-
bin, leading to the conversion of fibrinogen into fibrin. After
two genome wide duplications and several local duplica-
tions, a more complex coagulation network appears, with an
ancient FVII which already initiates the coagulation cascade.
In this network, the ancestral FX protein is able to activate
thrombin, in a complex formed with an ancestral cofactor.
This ancestral complex is inactivated by ancestral PC. The
following general duplication finally led to the current co-
agulation cascade.
Based on the central role in the coagulation cascade, it is
evident that FVII and FX play crucial roles in triggering and
regulating the coagulation cascade [18]. Their importance is
Fig. (1). Schematic representation of the mammalian coagulation cascade. Green arrows indicate negative feedback by thrombin. TF: Tissue
Factor, PL: phospholipids
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evident from the severe phenotype associated with FVII or
FX deficiencies. Analysis of molecular abnormalities of both
coagulation factor genes is important in multiple ways. First,
it is essential to the understanding of processes underlying
both normal and pathological blood coagulation. Second, the
knowledge of the mutation spectrum responsible for inher-
ited deficiencies allows studying the correlation between
genotype and phenotype, and to verify whether the type of
mutation influences the clinical presentation. Due to the
strong sequence homology of both proteins, it also allows to
compare the clinical phenotype observed in the presence of
topologically equivalent mutations in FVII and FX proteins.
Mutation analysis is also essential for genetic counselling
and performing pre-natal diagnostics. Finally, this type of
analysis allows, in a fundamental point of view, to increase
our knowledge on the diversity of mutational mechanisms
involved in human biology.
FVII AND FX GENES AND PROTEINS
Factors VII and X Genes
The genes encoding FVII and FX are both located on
chromosome 13 at position 13q34, and the FX gene is lo-
cated 2.8 kb downstream of the FVII gene [16, 19]. This
distance is conserved in mouse and zebra-fish. As the other
vitamin K-dependent coagulation proteases, both genes con-
sist of eight exons, each of these encoding a specific func-
tional domain of the protein as depicted in Fig. 2, exon 1
encodes the signal peptide. Exon 2 encodes the propeptide
and the gamma-carboxylic acid-rich domain (Gla). Exon 3
Fig. (2). Comparison of the structure of the different coagulation factors adapted from (http://tollefsen.wustl.edu/).
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encodes a short linking segment of aromatic amino acids
known as the aromatic stack. Exons 4 and 5 encode two re-
gions which are homologous to Epidermal Growth factor
(EGF-like domains), exon 6 encodes the activation region,
which is at the amino-terminus sequence of the heavy chain.
Exons 7 and 8 encode the serine protease catalytic domain
containing the catalytic triad His{57}, Asp{102} and
Ser{195} numbered according to the conventional chymo-
trypsic labelling [20]. In FVII, the catalytic triad is consti-
tuted by the residues His193, Asp242 and Ser344, since in
FX His236, Asp282 and Ser379 are the residues which con-
stitute the catalytic triad.
The promoter regions of the FVII and FX genes have in
common that they do not contain the consensus sequence of
a TATA-box [21-24]. Furthermore, both genes are rather
differently organized. For example, unlike FVII, FX contains
a CAAT box [25, 26]. The FVII gene has an Alu sequence in
the promoter region, which does not exist in the FX gene
[24]. Another striking difference is the presence, in the hu-
man FVII gene only, of tandem repeat of monomeric ele-
ments, located in five regions of the gene [27, 28]. Several
polymorphisms exist in the sequence of both genes. How-
ever, in contrast to FVII, the polymorphism within the FX
gene [29-31] seem not to affect FX levels [32]. Detailed in-
formation on the genetic sequence and on polymorphisms
present in FVII and FX are available at:
http://www.gdb.org/gdb-bin/genera/genera/hgd/Gene?!key=
GDB%3A119897&!sub=0 for FVII and
http://www.gdb.org/gdb-bin/genera/genera/hgd/Gene?!key=
GDB%3A119890&!sub=0 for FX
FVII and FX Proteins
As expected from the high similarity in genetic se-
quences, both proteins display remarkable similarity with
40% of homology on the aminoacid level [25]. As other
members of vitamin K-dependent coagulation factors, both
FVII and FX are synthesized in the liver and are secreted as
zymogens into plasma [33, 34]. In its mature form, FVII is a
406 residue protein, with a molecular weight of 50 kDa. It
circulates at a concentration of 0.5 µg/ml. FX is a 485 resi-
due protein, which circulates at a concentration of 10 µg/ml.
Both FVII and FX are synthesized as precursor proteins,
with a pre-propeptide containing the signal peptide targeting
the protein for secretion. The pre-propeptide is followed by a
propeptide which is essential for the recognition by the he-
patic gamma-carboxylase which catalyses the carboxylation
of Glu residues at the gamma position (Fig. 1). In FVII, the
pre-pro-leader sequence contains either 38 or 60 amino-acid
residues (resulting from alternative splicing), containing a
hydrophobic region (residues -36 to -24) which targets the
protein for secretion, and a pro-sequence (residues -17 to -1)
which is important for the vitamin K-dependent gamma-
carboxylation. In FX, the signal peptide is constituted by
residues -37 to -22, and the pro-sequence by residues -18 to -
1. The pro-peptide is released from the mature protein by
cleavage between Arg-1 and Ala+1 (Fig. 3a). The domain of
recognition by hepatic carboxylase is also located in the pro-
peptide region (Fig. 3b). The mature form of both proteins
exists of a light chain (152 residues for FVII, 139 residues
for FX) and a heavy chain (253 residues in FVII, 346 resi-
dues in FX), linked by a disulfide bond between residues
Cys135 and Cys362 in FVII, and by a disulfide chain located
between residues Cys89 and Cys124 in FX.
The first region of the light chain of both coagulation
factors contains the Gla domain, which is very well con-
served (Fig. 4) within the family of vitamin K-dependent
coagulation serine proteases, allowing the anchorage of the
proteins onto the plasma membranes in the presence of cal-
cium ions. In addition, the Gla domain of FVII is involved in
its interaction with TF and with FX. The Gla domain is fol-
lowed by a short hydrophobic region, which participates in
stabilization of the protein. This hydrophobic stack is fol-
lowed by two EGF-like domains, which allow the interaction
of FVII with TF. The heavy chain of both coagulation factors
contains the catalytic domain, which structure is common to
all others serine-proteases, consisting of 12 beta-sheets sepa-
rated by loops folding in 2 beta-barrels, containing the cata-
lytic triad (His{57}, Asp{102} and Ser{195}) at their inter-
face (Fig. 5). More specifically, the catalytic triad of FVII
consist of His193, Asp242 and Ser344 whereas in FX the
residues His236, Asp282 and Ser379 constitute the catalytic
triad.
FVII and FX Activation
The active form of FVII (FVIIa is generated by cleavage
of a single peptide bond between Arg152-Ile153. It liberates
a two chain protein, linked together by the disulfide bond.
However, by itself, FVIIa has a very weak catalytic activity,
and the binding of FVIIa to its cofactor (TF) is essential for
maximal catalytic activity. Crystallographic structure analy-
sis of the zymogen form of FVII, compared to that of FVIIa
bound to TF, revealed a major change following complex
formation, occurring in the activation loop 140s that con-
nects the A2 and B2 sheets in the second beta-barrel [35-37].
In the zymogen structure, the B2-sheet and the A2-sheet dis-
play a specific configuration as shown on Fig. 6. The 140s
loop is short and includes residues {141} to {152} (or 284 to
294 according to protein numbering). In this configuration,
the Arg277 {134}, Ser279 {136}, Val281 {138} and Gly283
{140} residues of the A2-sheet have established hydrogen
bonds with respectively the Asn301 {159}, Val299 {157},
Leu297 {155} and Leu295 {153} residues of the B2-sheet.
The Glu296 {154} residue interacts with residues Val158
{21} and Cys159 {22}, which are in close proximity of the
Ile153 {16} residue. In this structure, Ile153 is not able to
insert in the core of the serine protease domain, which is
essential to form the saline bond with Asp343 necessary for
the optimal formation of the active site. In the active form
when bound to TF, the B2-sheet shifts 3 residues up on the
A2-sheet. In this new configuration, the 140s loop is pro-
longed by 3 residues and novel hydrogen bonds are estab-
lished between the two sheets. This active configuration al-
lows the insertion of Ile153 into the serine protease domain
and interaction with Asp 343 [35-37]. The active form of FX
(FXa) is generated by cleavage of the Arg194-Ile195 peptide
bond in the heavy chain of the zymogen FX. Cleavage re-
leases the 52-residue activation peptide [32]. This cleavage is
brought about by either FVIIa in the extrinsic pathway or by
FIXa in the intrinsic pathway [1]. It has been proposed that
the activation peptide serve primarily as negative autoregu-
lation mechanisms to prevent spurious activation of fX and
Inherited Coagulation Factor VII and X Deficiencies Associated Current Genomics, 2005, Vol. 6, No. 00    5




The diagnosis of inherited FVII deficiency is usually
suspected following the identification of a prolonged
prothrombin time (PT), with normal activated partial throm-
boplastin time (APTT), thrombin time and fibrinogen levels.
Vitamin K deficiency or other acquired causes of bleeding
tendency have to be ruled out to allow the diagnosis of FVII
deficiency. Specific assays for FVII are then undertaken to
confirm the deficiency. FVII activity (FVII:c) is frequently
measured using a one-stage PT-based assay using rabbit








Human factor VII R-V-F-V-T-E-E-E-A-H-G-V-L-H-R-R-R-R
Mouse factor VII A-V-F-I-T-Q-E-E-A-H-G-V-L-H-R-R-R-R
Rabbit factor VII A-V-F-I-T-Q-E-E-A-H-S-V-L-H-R-R-R-R
Human factor IX T-V-F-L-D-N-E-N-A-N-K-I-L-N-R-P-K-R
Mouse factor IX A-V-F-L-D-R-E-N-A-T-K-I-L-T-R-P-K-R
Rabbit factor IX T-V-F-L-D-H-E-N-A-T-K-I-L-N-R-A-K-R
Dog factor IX A-V-F-L-D-R-E-N-A-N-K-I-L-S-R-P-K-R
Human factor X S-L-F-I-R-R-E-Q-A-N-N-I-L-A-R-V-T-R
Bovine factor X S-V-F-L-P-R-D-Q-A-H-R-V-L-Q-R-A-R-R
Rat factor X S-V-F-I-N-R-E-R-A-N-N-V-L-Q-R-I-R-R
Rabbit factor X S-V-F-I-S-R-R-A-A-N-D-V-L-A-R-T-R-R
Chicken factor X G-V-F-I-K-K-E-S-A-Q-K-F-L-E-R-T-K-R
Human protein C S-V-F-S-S-S-E-R-A-H-Q-V-L-R-I-R-K-R
Bovine protein C S-V-F-S-S-S-Q-R-A-H-Q-V-L-R-I-R-K-R
Mouese protein C P-V-F-S-S-S-E-H-A-H-Q-V-L-R-V-R-K-R
Rat protein C P-V-F-S-S-S-E-G-A-H-Q-V-L-R-V-R-K-R
Human protein S A-N-F-L-S-K-Q-Q-A-S-Q-V-L-V-R-K-R-R
Bovine protein S A-N-F-L-S-R-Q-N-A-S-Q-V-L-I-R-R-R-R
Mouse protein S T-N-F-L-S-K-E-R-A-S-Q-V-L-V-R-K-R-R
Rat protein S T-N-F-L-S-K-E-R-A-S-Q-V-L-V-R-K-R-R
Pig protein S X-X-X-X-S-K-Q-Q-A-S-Q-V-L-I-R-K-R-R
Fig. (3). Sequences of signal peptides and propeptide of FVII and FX. (a) Comparaison of preprosequences of human vitamin K-dependent
coagulation factors (according to Cooper et al. [129]). Poly-leucine sequences are underlined. The cleavage site of the propeptide is indicated
by vertical arrow. (b) Recognition sites for the g-carboxylation of propeptides of the vitamin K-dependent coagulation factors. Phe at position
–16 and Ala at position –10 (in bold in the sequence) are highly conserved in this protein family, as well as the hydrophobic aliphatic resi-
dues at position –17 and –15. According to Furie et al. [130].
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large discrepancies in the FVII activity can be observed [38].
Indeed, in FVII Padua the FVII:c activity ranges from 9 to
105% according to the type of the thromboplastin used.
Therefore, different thromboplastins (rabbit, bovine and hu-
man) are utilized when investigating patients with suspected
FVII deficiency. FVII antigen (FVII:Ag) is measured using
an Enzyme Linked Immunoabsorbent assay (ELISA) [39].
Fig. (4). Gla domain of FVII and FX. (a) Conservation of the primary sequence of the Gla domains of vitamin K-dependent coagulation fac-
tors PC, FVII, FIX and FX in different species. Sequence alignment according to Davidson et al.  [8]. Indicated numbering corresponds to
human FVII. The g -carboxylated residues are annotated with an orange asterix. (b) Three-dimensional structure of the Gla domain of FVII,
extrapolated from the three-dimensional structure of the prothrombin Gla domain proposed by Falls et al. [131].
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FX Assays
The diagnosis of FX deficiency is usually done using
one-stage PT or APPT-based assays. However, three others
assays do exists, and due to the heterogeneous nature of con-
genital FX deficiencies, all five assays are necessary for de-
tailed protein characterization [32]. First, the Russel Viper
venom (RVV) assay: The venom of vipera russelli activates
FX directly. Performed with FX deficient plasma, it will
detect deficiencies of FX but it also allows detecting FV,
prothrombin and fibrinogen deficiencies. Alternatively, FX
activity can be determined using a Chromogenic assay. The
principle of this assay is the cleavage, by FXa, of a chro-
mogenic substrate, to release a chromophoric group. The
intensity of the colour, detected photospectrometrically, is
proportional to the FX activity present in the sample [40].
Finally, FX antigen levels are determined using an Enzyme
Linked Immunoabsorbent assay (ELISA).
INHERITED FVII AND FX DEFICIENCIES
Inherited FVII and FX deficiencies are autosomal reces-
sive disorders [41]. Therefore, these disorders are rare, and
their frequencies are increased in countries in which consan-
guineous marriage is common [42]. FVII deficiency is the
most frequent rare coagulation disorder with a prevalence of
1 in 500.000 in the general population. This disease has first
been described by Alexander et al., in 1951 [43] in a patient
with severe hemorrhagic diathesis. Remarkably, a character-
istic feature of inherited FVII deficiency is the variability of
the hemorrhagic symptoms in carriers of the disease [44].
Unlike haemophilia A and B, in which the residual activity
of the coagulation factor correlates with the severity of the
hemorrhagic syndrome, in FVII deficiency, the hemorrhagic
syndrome is poorly correlated to the biological phenotype
[42]. FX deficiency is the rarest of inherited coagulation
factor deficiencies with a prevalence of 1 in 1.000.000 in the
general population. Like for FVII deficiency, the bleeding
disorders associated with FX deficiency are rather variable
and correlate only poorly with FX levels [44].
The potential severe clinical symptoms associated with
inherited FVII and FX deficiency reflects the crucial role of
these coagulation factors in blood coagulation. Indeed, FVII
knockout mice show that the absence of FVII is not com-
patible with life [45]: mice display a normal embryonic de-
velopment, however the mice die in the perinatal period from
intra abdominal or cerebral haemorrhages. However, as a
puzzling paradox, a homozygous 2-bp deletion in the FVII
gene, leading to a complete absence of FVII in plasma, was
reported in a patient with severe bleeding diathesis compara-
ble with that observed in haemophilia A and B, suggesting
that the absence of FVII is compatible with life [46]. FX
deficient created by targeted inactivation of the factor X gene
is partly embryonic lethal. Those mice that do survive die
around birth due to intra-abdominally bleeding or die within
the first 3-4 weeks after birth due to severe bleeding in the
central nervous system [47].
CLASSIFICATION OF FVII AND FX DEFICIENCIES
As a first classification system, FVII and FX deficiencies
are classified based on both activity and antigen levels. In
type I deficiency both functional activity and antigen levels
Fig. (5). Organization in sub-domains of the catalytic domain of FVII. Adapted from Eigenbrot [35]. The three residues of the catalytic triad
located at the interface of b  barrel are indicated in red. The residues involved in calcium binding sites are indicated in yellow. The different
sites are indicated in dotted lines. The two b  sheets A2 and B2 involved in configurational changes in the catalytic domain when FVII binds
to TF are indicated in bold in this overview.
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are decreased, which is a characteristic hallmark of defective
secretion or reduced stability of the protein. In type II defi-
ciency, low coagulant activity contrasts with normal or low
borderline antigen levels, indicating the presence of a dys-
functional protein. Type III deficiency, which is specific for
FVII deficiency, is characterized by concomitantly decreased
coagulant activity and antigen levels, but the antigen level is
above the activity level. Type III defects probably result
from a combination of mutations leading to type I and type II
defects. An alternative classification system is based on the
coagulant activity only and consists of three categories: se-
vere deficiency (coagulant activity of less than 1%), moder-
ately severe deficiency (coagulant activity between 1 and
5%), and mild deficiency (coagulant activity >5%). It is
noteworthy that the underlying molecular defects are hetero-
geneous, so their phenotypic profiles differ markedly.
Fig. (6). Schematic representation of the conformation of the b  strands A2 and B2 in FVII catalytic site and ribbon representation of the acti-
vation loops. The numbering of residues is according to the chymotrypsic numbering. H-bonds between b  strands are represented by vertical
lines. (a) zymogen and zymogen like forms. The 140s loop is relatively short. The Glu154 residue interacts with Val21 and Cys22 residues
and the conformation of the region which interacts with TF is not in its favorable conformation for efficient TF binding. (b) Activated form.
The 140s loop is prolonged of 3 residues. The Val21 and Cys22 residues do not interact anymore with Glu154. The region of interaction with
TF is now in its favorable conformation to efficiently interact with TF. The H-bonds established between A2 and B2 strands are maintained
although a shift of three residues in the activated form. (c) Ribbon representation of the zymogen and zymogen-like forms. The residues of
the catalytic triad are represented by red spheres. Residues of the boucle 1 {186-194} (residues 334 to 343) are in green. Residues of loop 2
{216-223} (residues 365 to 372) are in orange, and residues of the loop 170s {168-182} (residues 310 to 329) are in pink. Residues of the
140s loop whose conformation changes when bound to TF are indicated in light blue and residues of the A2 and B2 strands are indicated in
dark blue. All these loops belong to the second b  barrel of the catalytic domain. The 140s loop appears incomplete in crystallography. It is
short and the B2 strand is shifted related to the A2 strand. (d) Activated form of FVII. Same conventional representation is used. The shift of
three residues of the B2 strand related to A2 occurred and the 140s loop is prolonged by three residues.
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CLINICAL MANIFESTATIONS
In patients with FVII deficiency, the spectrum of bleed-
ing problems is very variable and does not correlate with
FVII levels [41, 42, 44]. Individual cases with very low lev-
els of FVII present with few or even no symptoms, whereas
other cases with much higher FVII levels have significantly
bleeding diathesis [38, 48]. Remarkably, some cases of FVII
deficiency associated with thrombosis have even been re-
ported [49, 50]. A recent study demonstrated that the clinical
phenotype could be modulated by the cosegregation of mu-
tations like FV Leiden or the prothrombin G20210A muta-
tion, which are known risk factors for thrombosis [49, 51].
Generally, FVII and FX deficiency presents either early
in life as a severe hemorrhagic syndrome or later in life as a
rather mild phenotype. In the first case, which represents
around 17% of patients [41], the hemorrhagic syndrome is
associated with high morbidity and mortality quit often due
to bleeding into the central nervous system (between 15-60%
of the cases [52]). In this category of patients, joint bleedings
have also been reported, and the severity of hemarthroses
and the long-term sequelae of bleeding events is similar to
that seen in haemophilia [42]. When the hemorrhagic syn-
drome occurs later in life with less severe diathesis (50 to
60% of the cases) patients mainly present with epistaxis and
gum bleeding, menorrhagia possibly responsible for chronic
iron deficiencies and other mucous-membrane-type bleed-
ings [41, 44]. Furthermore, post-traumatic and/or post-
surgical complications can be observed [41, 42]. A pro-
longed bleeding time also has been reported in some patients
with FVII deficiency [53]. Finally, 20-30% of patients with
FVII deficiency are asymptomatic, even if they are classified
as severe FVII deficient.
In comparison to FVII deficiency, patients with a severe
FX deficiency tend to present more severe bleeding diathesis
[44]. FX deficient patients frequently present with haema-
tomas, hemarthroses, gastro-intestinal bleeding more often
than FVII deficient patients [32, 44]. Next to the more com-
mon bleeding symptoms, some FX deficient patients suffer
from bleeding in the central nervous system. As in FVII de-
ficiency, patients which less severe syndromes present often
with epistaxis and others mucous-membrane-type bleeding,
like menorrhagia.
MOLECULAR GENETIC OF FVII AND FX DEFI-
CIENCIES
For both coagulation factors, the disease causing muta-
tions are distributed all over the gene, demonstrating that all
domains of the protein are important for maintenance of its
integrity and function. However, the majority of mutations is
located in the catalytic domain of the protein which is actu-
ally also the largest domain. Most of the mutations are mis-
sense mutations, however, other gene abnormalities, like
short or long insertions/deletions, splice site mutations and
nonsense mutations, have also been reported [41, 42]. Most
mutations are unique and present only in members of the
probands family but some specific mutations are recurrent in
unrelated families with apparent different ethnic origin.
These recurrent mutation are sometimes located in CpG
dinucleotides, which are known to be hot-spots for mutations
[54, 55], and probably result from independent events. Other
recurrent mutations, like insertions/deletions, are located in
close proximity of repetitive regions which might cause slip-
page and mispairing [56]. Finally, a founder effect rather
than independent genetic events might explain recurrent
mutations when they are associated with identical haplotypes
and/or a common ethnic origin (for review [41, 42].
MUTATIONAL SPECTRUM OF FVII AND FX DEFI-
CIENCY
Most of the patients presenting with FVII deficiency dis-
play a type I deficiency, but several cases of type II defi-
ciency (normal or subnormal FVII:Ag, diminished FVII:C)
have also been reported [41, 57]. The large majority of
causative mutations identified so far are missense mutations.
In genetic disease, abnormalities located in the splice sites
are less frequent than missense mutations and on average
represent around 16% of all mutations [61]. In keeping with
this, 21 mutations have been described in the splice regions
of the FVII gene [41, 62-64], and donor splice sites are more
frequently affected than acceptor sites, which is consistent
with observations of the molecular spectrum of splice site
mutations in human diseases [61]. In addition, several non-
sense mutations have been reported, resulting either from a
nucleotide substitution resulting in a stop codon, or from
gene abnormalities (insertions or deletions leading to a
frameshift and premature introduction of stop codon during
translation). In the FVII gene 14 small insertions of 1 to 18
nucleotides [41, 65] and two large insertions, one located in
the coding region of the gene between the residues 217 and
218, the second one in the polypyrimidine-rich tract of IVS4
acceptor site, have been described [63, 66]. Finally, several
mutations have been reported in the promoter region of the
gene [41, 58-60] and these mutations and their functional
consequences are discussed below. A database[41] summa-
rising the FVII gene mutations causing FVII deficiency is
listed and fully referenced in the FVII gene mutation data-
base available on http://europium.csc.mrc.ac.uk/.
In FX deficiency, the large majority of the causative mu-
tations identified so far are missense mutations (as for FVII).
Only five splice site mutations have been identified, affect-
ing IVS1 and IVS2 splice sites [64, 67, 68], and a single
C>T transition located 40 bp upstream of the translational
initiation codon, has been reported in the promoter region of
the gene [68]. Functional analysis of luciferase reporter con-
structs revealed that the -40T allele was associated with a
reduction in promoter strength of about 30%. However, indi-
viduals homozygous for this promoter mutation have normal
(borderline) FX plasma levels, and electrophoretic mobility
shift analysis failed to provide any evidence for the binding
of transcription factors to this region of the promoter. Fi-
nally, six deletions of 1 to 3 nucleotides and one single bp
insertion have been reported so far [32, 69, 70].
SEVERE FVII AND FX DEFICIENCIES ASSOCI-
ATED WITH SEVERE BLEEDING DIATHESIS
Usually, individuals presenting with hemorrhagic syn-
dromes are homozygous or compound heterozygous for
deleterious gene defects, precluding the expression of the
protein, its secretion or leading to reduced stability. In order
to elucidate the functional consequence of identified muta-
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tions, some have been expressed and analysed in eukaryotic
systems. Alternatively, molecular modelling might provide
insight into the structure/function relationship of the protein.
The mutations causing hemorrhagic syndromes can be classi-
fied in four groups.
Mutations in the Promoter Region
The first group is constituted by mutations located in the
binding sites for transcription factors in the promoter region
of the gene. In the FVII gene, 5 mutations disrupting tran-
scription factors binding sites and causing severe bleeding
diathesis have been reported [59, 71-73]. In vitro studies
performed with reporter gene constructs demonstrated a
dramatic decrease of promoter activity for the mutant alleles.
No promoter mutations associated with severe bleeding dia-
thesis have been reported for the FX gene so far.
Splice Sites Mutations
The second group of deleterious mutations comprises
mutations located in splicing regions of the gene. Impor-
tantly, homozygous mutations affecting the invariant GT or
AG of the donor or acceptor splice site are associated with
severe and/or lethal bleeding diathesis, including intracranial
hemorrhages. This observation is consistent with the fact that
mutations occurring in these highly conserved dinucleotides
usually completely prevent normal splicing, whereas the
mutations located in less conserved nucleotides of the splic-
ing region generally are responsible for a severe phenotype
which is compatible with life [61]. In the FVII gene, in vitro
splicing assays performed to determine the consequences of
these mutations demonstrated that in most cases the splice
mutations led to skipping of the exon upstream of the mu-
tated splice donor sequence [68, 73-77]. Only the mutations
located in the IVS7 of the gene [68, 78, 79] led to activation
of a cryptic splice site located downstream in the intron.
So far, only five splice site mutations have been reported
in the FX gene, affecting the splice sites of introns 1 and 2
[80-82]. In contrast to FVII, in vitro  splicing assays of spe-
cific FX mutants consistently led to the use of cryptic splice
sites. It is interesting to note that in the case of the IVS1
mutation the activated cryptic site was stronger than the wild
type, authentic site [81]. In almost all cases, the use of cryp-
tic splice sites resulted in frameshifts introducing premature
stop codons during translation.
Nonsense Mutations and Gene Abnormalities Leading to
Frame Shifts
Another group of mutations associated with severe
bleeding diathesis includes nonsense mutations and inser-
tions/deletions leading to frameshifts and premature intro-
duction of stop codons. Several of such gene abnormalities
have been identified in FVII deficient individuals ([65, 83]
and reviewed in [41, 42]), but only few of them are associ-
ated with severe bleeding: Three nonsense mutations [65, 73,
83], four single nucleotide deletions [41, 73, 75], one 2-bp
deletion [46], one 3-bp deletion [41], a 17-bp deletion [84],
and a 18-bp deletion [65]. Two gene insertions associated
with severe bleeding diathesis were also identified, one of 15
bp in length [66] and one 251 bp in length [63].
In the FX gene, several short deletions (1 to 3 nucleo-
tides) [69, 70, 85-87] and a 17-bp deletion [81] have been
found to be associated with severe bleeding diathesis. A sin-
gle 1-bp gene insertion has been described [88]. Two large
gene deletions (more than 5kb) have also been reported [89,
90].
Missense Mutations
The last group of mutations associated with severe
bleeding diathesis consist of missense mutations. Among all
the reported missense mutations for the FVII gene, only 29
of them are responsible for severe FVII deficiency associated
with hemorrhagic syndrome, and only 18 in the FX gene.
Most of them are type I mutations and indeed in vitro ex-
pression studies showed impaired secretion due to misfold-
ing of the abnormal protein and/or accelerated clearance.
Recent advances on both coagulation protease structures [91]
allowed a better understanding of their coagulant properties,
and highlighted loss of functions associated to specific resi-
due substitutions.
Mutations Affecting the Signal Sequence
So far, no mutation in the signal peptide sequence associ-
ated with severe bleeding diathesis has been reported for the
FVII gene sequence. A specific mutation in the FX gene,
leading to FX Santo Domingo, is the Gly-20Arg substitution
[92]. This mutation is located at the critical -3 position of the
FX signal peptide cleavage site (see Fig. 3). FX Santo Do-
mingo is translocated into the endoplasmic reticulum but the
signal peptide is not removed by signal peptidase. As a con-
sequence, FX Santo Domingo is degraded and thus absent
form plasma.
Mutation Affecting the Gla Domain
In the FVII gene, four mutations associated with severe
bleeding diathesis have been identified in the Gla domain of
the protein: Leu13Gln [68], Glu16Lys [73], Ser23Pro [84]
and Glu29Lys [93]. In the FX gene, three mutations associ-
ated with severe bleeding diathesis have been reported in the
Gla domain: Glu14Gly [94], Glu19Ala [95] and Phe31Ser
[70]. As shown in Fig. 7, all these mutations are located in
the structurally highly conserved region of the Gla domain
that allows proper anchoring to the membrane and pro-
tein/protein interactions. The amino-terminal domain of all
vitamin K-dependent coagulation proteins contains 9-12
glutamic acid (glutamate) residues that undergo post-
translational carboxylation at the gamma-carbon [96]. These
gamma-carboxyglutamic acid (Gla) residues are necessary
for calcium binding, which induces a conformational change
in the Gla domain required for phospholipid binding. Three-
dimensional structures of the Gla domain suggest that these
residues are in a dynamic state in the absence of calcium but
fold in the presence of calcium into a tightly packed structure
that internalizes Gla residues and externalizes hydrophobic
residues that enhance lipid binding [96-98]. In FVII, the Gla
residues 16 and 29 are essential for the structural stability of
the protein [99, 100]. The residues Leu13 and Ser23 are
highly conserved among the vitamin K-dependent coagula-
tion proteins (Fig. 4). Therefore, their substitution by bulkier
groups (respectively Gln and Pro) likely results in partial
misfolding of Gla domain. This could probably affect con-
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formation-dependent Gla domain binding to phospholipids
of the cell membrane and normal activation. It is noteworthy
that the substitution Glu16Lys leads to type II FVII defi-
ciency.
In FX, site-directed mutagenesis of the Gla14 and Gla19
residues disrupts the formation of the ordered Gla domain
structure normally seen in the presence of calcium and would
not allow transition of the Gla domain out of a 'no calcium'
state [101]. The substitution of the aromatic side chain of
residue Phe31 by the hydroxylic group of Ser may open a
cavity inside the hydrophobic core to change the secondary
structure or result in partial misfolding of the Gla domain.
Another mutation flanking Phe31, i.e. Glu32Gln (FX Tokyo)
[102] has been shown to be pathogenic. The presence of a
topologically equivalent mutation in the FIX gene (http://
www.kcl.ac.uk/ip/petergreen/haemBdatabase.html//), Phe32-
Ser, causing haemophilia B shows the importance of this
codon in the Gla domain.
Mutations in the EGF and Activation Domains
In the FVII gene, a total of 7 missense mutations associ-
ated with severe bleeding diathesis have been reported in the
EGF region of the protein, most of them being located in
the EGF1 domain (Fig. 8): Asn57Ile [73], Cys61Phe [68],
Leu65Pro [68], Tyr68Cys [103], Arg79Gln [104], Gln100-
Arg [105] and Gly117Arg [65]. Another mutation involves
the Cys135 which is replaced by an Arg [73], and the last
missense mutation of the light chain associated with severe
bleeding diathesis is the Arg152 at the activation site which
is substituted by a Gln [104]. This last mutation is a type II
mutation, as well as the mutation Arg79Gln. The intra-chain
cysteine bonds located in the EGF1 domain are highly con-
served among the vitamin K-dependent coagulation serine
proteases. Therefore, the replacement of Cys61 by a Phe
disrupts a cysteine bond essential for the cohesion of the
protein and its functions, consistent with the observed clini-
cal phenotype [68]. The Arg79Gln and Gln100Arg mutations
have been studied by expression of recombinant proteins in
vitro. The Arg79Gln variant has reduced affinity for TF, and
the side chain of this residue was later shown to be critically
involved in the interactions with TF [106]. Hypothesis about
loss of functions in the case of the Asn57Ile mutant have
been extrapolated from expression studies performed with
the Asn57>Asp mutant [107], which demonstrated that this
mutation is likely to disrupt tertiary bonding structure be-
cause of the loss of an important intra-molecular hydrogen
bond between Asn57 and Cys63 [73].
The substitution of Gly117 by an Arg results in the re-
placement of a hydrogen atom with a large, positively
charged, side chain in the second EGF-like domain of FVII.
Molecular modelling revealed that any displacement of the
neighbouring Tyr118 residue would affect the loop Pro134-
Cys135-Gly136-Lys137. Amino acid sequence alignments of
all known mammalian FVII sequences reveals complete con-
servation of Gly at this position. Inspection of the haemo-
philia B mutation database identified several mutations af-
fecting the FIX equivalent residue Gly114: Gly114Glu,
Gly114Ala and Gly114Val. All these mutations are associ-
ated with severely reduced FIX activity and antigen levels.
Furthermore, Gly117 is conserved in all known vertebrate
Gla-EGF1-EGF2-serine proteases including birds and bony
fish. As chicken and the bony fish Fugu rubripes last shared
Fig. (7).  Molecular modeling of the mutations located in the Gla domain (extrapolated from the structure of prothrombin [131] associated
with severe bleeding diathesis. The residues likely to be involved in the binding to the membrane are indicated in blue. (a) mutations in the
FVII Gla domain are indicated in orange. (b) Mutated residues in the FX Gla domain are indicated in pink.
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a common ancestor with man 350 and 430 million years ago,
it suggests this residue is vital for maintenance of a correctly
folded structure [65]. In FVII, the Cys135 residue forms one
half of the disulphide bridge to Cys262 in the heavy chain,
enabling the formation of a disulphide-linked two-chain
FVIIa molecule after cleavage at Arg152. Therefore its sub-
stitution hinders the cohesion of the two chains after activa-
tion of FVII. Finally, the replacement or Arg152 by a Gln
hinders the activation of the zymogen form, explaining the
severity of the observed phenotype.
In the FX gene, only two mutations have been described
in this region of the protein which are associated with severe
bleeding diathesis: Cys109Tyr [81], and Gly133Arg [70].
The first mutation, which affects a highly conserved residue
and disrupts a disulphide bridge, is likely to affect protein
folding and stability, whereas the Gly133Arg mutation may
probably destabilize disulphide linkage between Cys132 and
Cys302 in the connecting region. The replacement of Gly
residue by Arg at position 133 allows additional hydrogen
bonds with Gln98, Ala112 and Phe392. The identification of
two corresponding mutations in FIX, i.e. a Gly133Arg and
Gly133Glu, causing haemophilia B suggests its importance
in the connecting region of FX.
Mutations Affecting the Catalytic Domain
In the FVII gene, only 15 different missense mutations
have been shown to be associated with severe hemorrhagic
Fig. (8).  Molecular modeling of the mutations located in the EGF domains of FVII and FX associated with severe bleeding diathesis. (a)
EGF1 domain of FVII. The mutated residues and the mutations are indicated in bold letters. (b) Molecular modeling of the EGF1 domain of
FVII. Cysteine residues involved in disulfide bridges are indicated in blue. The residues affected by mutations are indicated in orange. (c)
EGF2 domain of FX. The mutated residues and the mutations are indicated in bold letters. (d) Molecular modeling of the EGF2 domain of
FX. Cysteine residues involved in disulfide bridges are indicated in blue. The residues affected by mutations are indicated in pink.
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diathesis when present at the homozygous state or compound
heterozygous state: Asp242Asn [103], Arg247Cys [84],
Arg277Cys [84], Ser282Arg [84], Gly283Ser[108], Ala294-
Val [109], Pro303Thr [110], Cys310Phe [111], Phe328Ser
[112], Cys329Gly [68], Asp343Asn [73], His348Gln [113],
Thr359Met [114], Trp364Phe [84], and Gly375Glu [68]
(Fig. 9a).
The mutation Asp242Asn [103] affects one of the resi-
dues of the catalytic triad, which is an essential component
of the charge relay system required for serine protease
activity. The consequences of some others mutations are
explained by the recent data brought by crystallography. The
Arg247 residue has been shown to be involved in both TF
binding and catalytic activity. The introduction of a Cys
residue at this place may perturb any of the 12 Cys-Cys
bridges within FVII to affect correct folding of the whole
protein [84]. The Arg277, Ser282 and Gly283 residues be-
long to the A2 strand. The Ala294 residue belongs to the
loop 140s, and the Pro303 residue to the B2 strand. Since A2
and B2 strands and loop 140s are involved in the conforma-
tional changes of the zymogen and zymogen-like form into
the activated form [35, 36, 106], mutations located in these
regions or at their vicinity are likely to disturb the equilib-
rium existing between these forms. The study of the
Ala294Val mutation, which showed that the interaction of
this FVII variant with TF was altered, suggested that this
residue, and more likely loop 140s, plays a pivotal role not
only in the recognition of FX by the FVIIa-TF complex, but
also in the interaction of FVII with both its activators and
cofactor TF [115], supported this hypothesis. However,
whether this mutation disturbs the zymogen form, or the en-
zyme form, or the conversion between both forms remains to
be determined. The Cys310, Phe328 and Cys329 residues all
belong to the loop 170s or Met loop, the Cys310 and Cys329
residues being involved in a disulphide bond. Located at the
surface of the protein, this loop plays an essential role in the
catalyitc activity of the protein [116]. Therefore, the severe
clinical phenotype associated with mutations disturbing the
folding of this region is consistent with these data. The for-
mation of a salt bridge between Ile153 and Asp343 drives
the conversion of FVIIa from being zymogen-like to the ac-
tive form. Therefore, the replacement of this Asp by an Asn
hinders the proper formation of the active site. Expression
using in vitro systems of the His348Gln mutant suggests that
this mutation leads to FVII deficiency due to impaired secre-
tion of the molecule. In the case of the Thr359Met mutation,
expression studies demonstrated that the mutant protein ac-
cumulates intracellularly resulting in a severe secretion de-
fect [114]. The Trp364 residue is highly conserved in serine
proteases and occurs at the active site cleft. Its replacement is
likely to result in perturbation of the substrate binding site of
FVII [84]. The Gly375 residue is located in the substrate
binding pocket of the protease domain close to the active site
residues. Moreover, Gly375 directly abuts the scissile argin-
ine side-chain of the enzyme’s substrates. Substitution in this
region is likely to severely affect FVII enzymatic activity.
In the FX gene, only 13 different mutations located in the
catalytic domain have been shown to be associated with se-
vere hemorrhagic diathesis when present at the homozygous
state or compound heterozygous state: Gly204Glu and
Gly204Arg [32], Gly222Asp[32], Gly223Arg [70], Asp282-
Asn [81], Thr318Met [117], Arg347His [82], Cys350Phe
[118], Ser 354Arg [70], Gly366Ser [119], Gly380Arg [69],
Gly381Asp [120], and Pro382Leu [121] (Fig. 9b). The
Gly204 residue is located in a short loop formed by a disul-
phide bridge. Results of expression studies suggest that the
replacement of this residue by a bulkier one results in a se-
cretion defect or accelerated clearance of the mutant chain
[32]. The Gly222 residue is located in the core of the protein
at the vicinity of the catalytic triad. Molecular modelling of
the Gly222Asp mutation suggests that its replacement by an
hydrophilic residue will disrupt its correct folding [32]. The
Gly223 residue is conserved in 14 of 17 FX or related prote-
ases studied. Gly223 is a very small amino acid present in
beta-strand C in serine protease subdomain 1 [80], and in a
hydrophobic environment between Gly219 to Leu226. Its
replacement by Arg223 may cause the positive charge and
the larger side chain of arginine to impair the correct folding
of this protein or perturb the catalytic triad. Topologically
equivalent missense mutations causing FIX deficiency -
Gly208Asp, Gly208Val and Gly208Ser- suggest a critical
role of Gly223 for FX activity [70].
The Asp282Asn mutation is topologically equivalent
with the Asp242Asn mutation in the catalytic domain of
FVII [103], since it affects the Asp residue of the catalytic
triad, which is an essential component of the charge relay
system required for serine protease activity. To our knowl-
edge, neither in vitro expression nor modelling data are
available to explain the severe deficiency associated with
bleeding diathesis identified with the mutation of the Thr318
residue. However, molecular modelling suggested the in-
volvement of a H-bond between the side-chains of Ser343
and Thr318 as they occur in anti-parallel beta-pleated sheets
near the substrate-binding pocket of FX. The Ser354 residue
is inaccessible in between the alpha helix A2 (Arg347-
Ser353) and a bend (Ser355-Phe356) in serine protease sub-
domain 2 [80]. Replacement of Ser354 by Arg creates addi-
tional hydrogen bonds with Trp399, Tyr409 and Ile411.
Ser354 is close to Lys351. Lysine at codon 351 with Arg347
and Lys414 is likely to contribute to the core epitope of FXa
for binding to FVa. The mutation of a small-buried residue
by a large basic aminoacid is likely to have steric or electro-
static effects on this pocket. Identification of a Ser339Pro
equivalent mutation in FIX provides evidence that mutations
in this codon are severe enough to cause FX deficiency [70].
Expression studies about the Arg347His mutation showed
that FX molecules carrying the Arg347His mutation have
dramatically decreased activity [82].The Cys350 residue is
highly conserved among the coagulation serine proteases. It
is noteworthy that the Cys350Phe mutation is topologically
equivalent of the Cys310Phe mutation in FVII [111], which
is also associated with severe bleeding diathesis. This obser-
vation further supports the importance of this residue for the
structure and function of the proteins. Molecular modelling
of the Cys350Phe mutation confirms that this mutation leads
to the disruption of a disulfide bridge in the catalytic region
of FX [118]. The Gly366 residue is positioned at the primary
substrate binding pocket. Therefore, the replacement of Gly
with Ser would cause defective substrate binding, leading to
the loss of enzymatic activity [119]. For the Gly380Arg mu-
tation [69] no data are available. However, this residue is
located next to the Ser379 residue of the catalytic triad, and
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is located in a sequence (Gly-Asp-Ser-Gly-Gly-Pro) 100%
conserved in all mammalian serine proteases, which empha-
size the conservation of this region. Indeed, in vitro study of
the functional consequences of the Gly381Asp mutation re-
veals that the mutation significantly affects the activity of
FXa, possibly by impairing crucial interactions in the cata-
lytic cleft. These results are supported by the presence of
topologically equivalent mutations in FIX (Gly367Arg,
Gly367Glu, and Gly367Ala) responsible for severe haemo-
philia B[120]. The Pro382 residue is also located in this
highly conserved sequence, and molecular modelling showed
that this residue is important for the correct formation of the
catalytically active structure. The Pro side chain ring im-
poses constraints on the way a protein folds, and tends to be
conserved for this reason, and it was shown that the
Pro382Leu mutant affects FX activity and antigen levels as
the result of a disruption to its kinetic folding pathway
caused by the absence of the Pro residue [121].
COMBINED FVII AND FX DEFICIENCIES
Hereditary combined deficiency of FVII and FX defi-
ciencies have also been reported, although they constitute a
rare entity. Therefore, combined deficiencies occur more
often in countries with high rate of consanguinity. In an Ira-
nian family, of which the parents were second cousins, two
siblings had severe bleeding diathesis caused by a mild FX
deficiency due to an homozygous Ser3Cys mutation associ-
ated with severe FVII deficiency due to the presence of the
homozygous Cys310Phe mutation [122]. However, in an-
other case of combined FVII and FX deficiency diagnosed in
a 3 year-old boy born to consanguineous Moroccan parents,
the mutations were discovered fortuitously since the proband
was asymptomatic [123].
Combined FVII and FX deficiency can also rely upon
abnormalities in the number or in the structure of chromo-
some 13q34. For an example, blood clotting factors were
investigated in a patient with trisomy 8 mosaicism, a patient
with an r(13), and a patient with distal trisomy 13q. Results
were compatible with the assignment of the structural genes
of factors VII and X to 13q34 [124]. Scambler and William-
son described an individual monosomic for 13q34 chromo-
some carrying both FVII and FX gene, which was deficient
in levels of clotting factors VII and X, while her brother,
who is trisomic for 13q34, had elevated levels [125]. Several
other cases of combined FVII and FX deficiencies due to
chromosomal deletion have also been reported [126, 127].
CONCLUSIONS
FVII and FX deficiencies are rare bleeding disorders.
Individuals with undetectable levels of these proteins are at
risk of fatal hemorrhage. FVII gene mutations responsible
for FVII deficiency have been extensively studied, and a
large amount of mutations in FX gene have so far been re-
ported, allowing the collection of a large amount of data
concerning the functional consequences of the mutations. It
emerges from these studies that individuals with a severe
phenotype associated with severe bleeding diathesis are ho-
mozygous or double heterozygous for mutations disrupting
the expression of the protein. The identification of the dis-
ease-causing mutation allows a better management of the
carriers and renders it possible to perform pre-natal diagnosis
when necessary. Even if the majority of subjects with FVII
Fig. (9). Molecular modeling of the mutations located in the catalytic domain of FVII and FX associated with severe bleeding diathesis. (a)
Ribbon view of the catalytic domain of FVII. Residues of the catalytic triad are in red, residues affected by mutations are indicated in orange
spheres. In green, ribbon view of TF bound to FVIIa. (b) Ribbon view of the catalytic domain of FX. Residues of the catalytic triad are in
red, residues affected by mutations are indicated in pink spheres.
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and FX deficiencies are asymptomatic, the identification of a
very large number of naturally occurring mutations allowed
a better understanding of the structure-functions relation-
ships of vitamin K-dependent proteins. Based on these stud-
ies, protein engineering allows the development of recombi-
nant proteins with altered properties, which might be of
clinical interest in the near future.
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Splice site selection is a key element of pre-mRNA splicing. Although it is known to involve specific recognition of short
consensus sequences by the splicing machinery, the mechanisms by which 59 splice sites are accurately identified
remain controversial and incompletely resolved. The human F7 gene contains in its seventh intron (IVS7) a 37-bp VNTR
minisatellite whose first element spans the exon7–IVS7 boundary. As a consequence, the IVS7 authentic donor splice
site is followed by several cryptic splice sites identical in sequence, referred to as 59 pseudo-sites, which normally
remain silent. This region, therefore, provides a remarkable model to decipher the mechanism underlying 59 splice site
selection in mammals. We previously suggested a model for splice site selection that, in the presence of consecutive
splice consensus sequences, would stimulate exclusively the selection of the most upstream 59 splice site, rather than
repressing the 39 following pseudo-sites. In the present study, we provide experimental support to this hypothesis by
using a mutational approach involving a panel of 50 mutant and wild-type F7 constructs expressed in various cell
types. We demonstrate that the F7 IVS7 59 pseudo-sites are functional, but do not compete with the authentic donor
splice site. Moreover, we show that the selection of the 59 splice site follows a scanning-type mechanism, precluding
competition with other functional 59 pseudo-sites available on immediate sequence context downstream of the
activated one. In addition, 59 pseudo-sites with an increased complementarity to U1snRNA up to 91% do not compete
with the identified scanning mechanism. Altogether, these findings, which unveil a cell type–independent 5939-
oriented scanning process for accurate recognition of the authentic 59 splice site, reconciliate apparently contradictory
observations by establishing a hierarchy of competitiveness among the determinants involved in 59 splice site
selection.
Citation: Borensztajn K, Sobrier ML, Duquesnoy P, Fischer AM, Tapon-Bretaudie`re J, et al. (2006) Oriented scanning is the leading mechanism underlying 59 splice site
selection in mammals. PLoS Genet 2(9): e138. DOI: 10.1371/journal.pgen.0020138
Introduction
A problem in mammalian pre-mRNA splicing is decipher-
ing the mechanisms underlying the recognition of authentic
signals for proper splicing. The accurate recognition of exons
is a process that requires assembly of the major spliceosome,
a macromolecular machinery that involves the coordinated
action of small nuclear RNAs (snRNAs) and more than 100
polypeptides [1,2]. Any abnormality in that process will
generate aberrant mRNAs that are either unstable or code for
defective and/or deleterious protein isoforms [3]. As a
puzzling paradox, in higher eukaryotes, introns are essentially
deﬁned by three short and poorly conserved sequences: the 59
splice site, the branch point, and the 39 splice site [4,5].
Moreover, as splice site consensus motifs are degenerated,
within a typical mammalian transcript, several sequences, in
addition to the authentic splicing elements, referred to as
pseudo-sites, may match the consensus splice site signals, and
sometimes even better than the real splice sites. These
elements deﬁne a set of pseudo-exons that greatly outnumber
genuine exons, but that are normally not included in mature
mRNAs [6].
A number of structural features has been shown to play a
key role in 59 splice site selection [7]. One of them is the splice
site sequence itself. The 59 splice site consensus sequence
comprises nine partially conserved nucleotides at the exon–
intron boundary: MAG/guragu (with M and r standing for A
or C and a or g, respectively, and / denoting the cleavage site).
This consensus actually reﬂects the base pairing between the
donor splice sequence and the 59 terminus of the U1snRNA,
which is involved in the early steps of splicing [8]. For a given
splice site, the strength of this interaction is usually assessed
by its consensus value (CV) [4]. Besides this interaction,
different sets of auxiliary cis-regulatory elements, known as
splicing enhancers or silencers, contribute to the identiﬁca-
tion of authentic 59 splice sites [1].
The situation may be complicated by the presence, within
several genes, of minisatellites, with their ﬁrst monomer
element spanning an exon–intron boundary. As a conse-
quence, the exact sequence of the splice donor site is
reiterated in the following intron. Such minisatellites provide
an outstanding physiological model to study the mechanisms
underlying splice site selection. However, the resulting
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splicing pattern has been investigated in very few cases only,
and demonstrated the activation of only the most and
second-most upstream pseudo-sites. Such is the case for the
second intronic sequence of the human interferon-inducible
6–16 gene, in which the authentic splice donor site is followed
by 25 pseudo-sites, whereas transcript analysis demonstrated
the constitutive utilisation of the two most proximal pseudo-
sites in addition to the authentic one [9]. Two pseudo-sites
are also utilised in addition to the authentic splice donor site
in the human CBS gene, encoding the cystathionine beta-
synthase, that contains a minisatellite in intron (IVS) 13 with
1520 monomer repeats[10,11]. In the human LAMIN B2
gene, which contains a minisatellite consisting of 1015
repeats of a 100-bp monomer, only the authentic splice donor
site is used [12]; a similar situation has been observed in the
PDGF gene that contains 1618 repeats of an 81-bp monomer
element in intron 4 [13]. In all these cases, the mechanism
precluding the use of pseudo-sites has not been investigated.
Like the above-mentioned genes, the F7 gene (GENBANK
access: NM_000131), which encodes FVII (zymogen of a
blood coagulation serine protease), displays a peculiar
organization with a minisatellite located within IVS7 [14].
In IVS7, the ﬁrst 37-bp monomer element consists of the last
four bp of exon 7 and the ﬁrst 33 bp of IVS7 [15]. This
minisatellite is polymorphic, with at least ﬁve different alleles
containing ﬁve to nine repeats of this 37-bp monomer ([16–
19]). The IVS7 59 authentic donor splice site UGG/gugggu
(where / represents the cleavage site) is, therefore, followed by
four to eight copies of 59 pseudo-splice sites that are strictly
identical in sequence; however, strikingly, in physiological
conditions, only the most upstream 59 splice site is used [15].
The study of F7 pre-mRNA splicing thus provides an
opportunity to assess the mechanism underlying 59 splice
site selection for transcripts of particular clinical importance,
as judged by the potentially severe phenotype of patients with
inherited FVII deﬁciency [20].
In previous work, we investigated the functional conse-
quences of a transversion located within the authentic IVS7
splice donor site of the F7 gene from a patient with severe
FVII deﬁciency [21]. We showed that the mutation resulted in
the activation of a single cryptic site corresponding to the 59
pseudo-site located in the second IVS7 minisatellite mono-
mer repeat. This observation led us to propose the existence
of a physiological mechanism that, in the presence of
consecutive splice consensus sequences, would exclusively
stimulate and select the most upstream 59 splice site, rather
than repress the 39 following pseudo-site(s) [21]. This model
prompted us to investigate the mechanism underlying the
accurate selection and activation of one particular 59 splice
donor site among ﬁve identical sites. In the present study, we
address this issue using a mutational approach. Our ﬁndings
unveil a nuclear 5939-oriented scanning mechanism as the
leading part of the splicing machinery, which is not cell type–
dependent.
Results
F7 IVS7 59 Pseudo-Sites Are Potentially Functional, but Do
Not Compete with the Authentic Donor Splice Site:
Evidence for a Scanning Process in 59 Splice Site Selection
To test whether each of the ﬁve IVS7 59 pseudo-sites are
potentially functional, in addition to the mutant minigene
carrying the mutation identiﬁed in our patient with severe
FVII deﬁciency and the wild-type construct (pF7m and pF7wt,
Figures 1 and 2A), we generated ﬁve constructs (designated
pF7m1 to pF7m5, see Materials and Methods and Figure 2A),
with sequential inactivation of one to ﬁve pseudo-sites. RT-
PCR ampliﬁcation of F7 transcripts isolated from Chinese
hamster ovarian (CHO) cells transfected with the wild-type
minigene yielded a 842-bp amplicon resulting from normal
splicing of the entire IVS7 (Figure 2B, lane 1). This result,
Figure 1. Schematic Representation of the Human F7 Gene and Wild-
Type and Mutant F7 Minigenes Cloned into pTracer-CMV Vector
Sizes of exons (E, open boxes) and introns (I, horizontal lines) are
indicated. Primers Pa, Pb, Pe, Ph, and Pm are represented by horizontal
arrows indicating their respective positions in the minigene sequence.
Inset indicates the last three nucleotides of exon 7 (capital letters) and
the first ten nucleotides of IVS7 (in lowercase characters) of the wild-type
F7 gene. The invariant gt dinucleotide is indicated in underlined bold
letters. A vertical arrow indicates the nucleotide change in the mutant
sequence.
DOI: 10.1371/journal.pgen.0020138.g001
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Synopsis
Typically, mammalian genes contain coding sequences (exons)
separated by non-coding sequences (introns). Introns are removed
during pre-mRNA splicing. The accurate recognition of introns
during splicing is essential, as any abnormality in that process will
generate abnormal mRNAs that can cause diseases. Understanding
the mechanisms of accurate splice site selection is of prime interest
to life scientists. Exon–intron borders (splice sites) are defined by
short sequences that are poorly conserved. The strength of any
splice sequence can be assessed by its degree of homology with a
splice site consensus sequence. Within exons and introns, several
sequences can match with this consensus as well as or better than
the splice sites. Using a system in which a splice site sequence is
repeated several times in the intron, the authors showed that linear
5939 search is a leading mechanism underlying splice site selection.
This scanning mechanism is cell type–independent, and only the
most upstream splice site of all the series is selected, even if splice
sites with a better match to the consensus are in the vicinity. These
findings reconciliate contradictory observations and establish a
hierarchy among the determinants involved in splice site selection.
which was obtained with the use of primers Pe and Pm, was
reproduced with other primer sets that ﬂank IVS7 (unpub-
lished data).
By contrast, in similar assays performed with the mutant
constructs pF7m and pF7m1 to pF7m5 (Figure 2B, lanes 2–7),
no normal splicing could be detected. More precisely,
transient transfection of constructs pF7m1 to pF7m4 resulted
in the generation of two kinds of aberrantly spliced products
(Figure 2B, lanes 3–6), one of size that was always slightly
larger than expected. Sequencing of the corresponding RT-
PCR products demonstrated that sequential inactivation of
the 59 pseudo-sites led to the activation of the next, most
upstream functional IVS7 59 pseudo-site available. Such
activation of a cryptic site led to the retention of short
portions of IVS7 in the corresponding mutant cDNA between
exons 7 and 8, accounting for the slight size differences
between the resulting RT-PCR products (Figure 2B); sequenc-
ing of the second aberrantly spliced product, which was
smaller in size than expected, showed that it corresponds to a
unique molecular species lacking the entire exon 7 (exon
skipping), thereby demonstrating that, for those constructs,
the IVS6 donor splice site was utilized in combination with
the IVS7 acceptor splice site. Strikingly, the relative amount
of the two observed splicing products seemed to differ
according to the construct, as shown after ethidium bromide
staining (Figure 2B, lanes 3 to 6). Indeed, although our
approach was not quantitative, the intensity of the larger
products corresponding to the activation of each of the
cryptic sites clearly decreased according to the number of
inactivated pseudo-sites, while concurrently, the intensity of
the smaller product lacking exon 7 increased. In keeping with
these observations, in cells transfected with the pF7m5
construct, in which all pseudo-sites were inactivated, only
the product resulting from exon 7 skipping could be detected
(Figure 2B, lane 7), whereas in cells transfected with the pF7m
construct, in which only the ﬁrst 59 splice site was inactivated,
a single product was identiﬁed, resulting from the activation
of the 59 pseudo-site located in the second 37-bp monomer
element (Figure 2B, lane 2). For all transfection experiments,
examination of 50 additional clones obtained after subclon-
ing of non-puriﬁed RT-PCR products generated with primers
Pe and Pm failed to detect any other splice variants, thereby
indicating that such species, if they indeed exist, are
expressed at extremely low levels.
Altogether, these data show that the ﬁve IVS7 59 pseudo-
sites are potentially functional but do not compete for
splicing with the IVS7 authentic donor splice site. They also
reveal that when several adjacent pseudo-sites are inactivated,
only the most upstream functional IVS7 59 pseudo-site
available is used, suggesting the existence of an accurate
mechanism underlying the selection of the active 59 splice
site.
Selection of the 59 Splice Site Follows a Scanning-Type
Mechanism Precluding Competition with Other Most
Upstream Functional 59 Pseudo-Site Available on
Immediate Sequence Context
To gain insights into the mechanism underlying selection
of the donor splice site, we next generated F7 minigenes
containing functional 59 pseudo-sites, separated by one or
several inactivated 59 splice sites (Figure 3A). As shown in
Figure 3B, RT-PCR ampliﬁcation of the transcripts expressed
by CHO cells transfected with the mutant constructs pF7m6
to pF7m11—in which the ﬁrst pseudo-site was always
mutated—yielded a single band slightly larger in size than
the one obtained with the wild-type construct (lanes 2 to 7); as
shown after sequencing, this larger molecular species results
from activation of the next functional 59 pseudo-site.
To conﬁrm the hypothesis that the most upstream 59 splice
site is selected for splicing, we studied the F7 transcripts
generated from CHO cells transfected with three additional
constructs (pF7m12 to pF7m14) in which the ﬁrst, second,
and fourth pseudo-sites were inactivated in combination with
either the third or the sixth pseudo-site (Figure 3A). As shown
in Figure 3B, PCR ampliﬁcation of the corresponding cDNAs
resulted in the generation of two kinds of aberrantly spliced
products (lanes 8 to 10): one of size always slightly larger than
expected that resulted from the activation of the most
Figure 2. Assessment of the Ability of the IVS7 Pseudo-Sites to Be
Activated
(A) Schematic representation of the constructs used in this experiment.
Top: Organization of the wild-type F7 IVS7 proximal region (pF7wt);
exons and introns are represented by open boxes and thin lines,
respectively. The first 37-bp monomer, which spans the exon7–IVS7
boundary, is repeated within IVS7. The monomers are represented by a
thick grey line. Each pseudo-splice site is represented by a grey box, and
is separated from the next one by 28 bp. Bottom: Schematic
representation of the various F7 minigenes carrying a T-to-A transition
located at the main dinucleotide of the consensus donor splice site and
involving several consecutive 37-bp monomer elements found in IVS7.
Mutations are represented by a black cross.
(B) RT-PCR amplification of F7 transcripts isolated from CHO cells
transfected with the above-mentioned constructs. The products
corresponding to the different PCR fragments, as identified by
sequencing, are schematically represented on both sides of the figure.
DOI: 10.1371/journal.pgen.0020138.g002
PLoS Genetics | www.plosgenetics.org September 2006 | Volume 2 | Issue 9 | e1380003
Oriented Scanning for 59 Splice Site Selection
upstream functional IVS7 59 pseudo-site, and an additional
band, smaller in size, that corresponded to a species in which
exon 7 was skipped. Again, when two splice products were
observed, their relative proportions seemed to differ accord-
ing to the position of the available functional 59 pseudo-site.
Taken together, these results are consistent with a
scanning-type process of selection of the 59 splice site, which
precludes competition with other more downstream func-
tional 59 pseudo-sites. Indeed, other splicing mechanisms
would predict the use of the ﬁrst functional 59 pseudo-sites
downstream of the inactivated splice site, whereas such a
scanning model predicts predominant use of the ﬁrst
available 59 splice site.
The Identified Scanning Mechanism for 59 Splice Site
Selection Is Not Cell Type–Dependent
The above-described experiments were performed in CHO
cells. To test whether the identiﬁed scanning process is cell
type–dependent, we performed similar studies in COS-7 and
HeLa cells with F7 minigenes that, when transfected in CHO
cells, gave representative RT-PCR patterns: pF7m and
pF7m10 that were associated with the use of the most
upstream functional 59 pseudo-site available (Figure 2B, lane
2, and Figure 3B, lane 6); pF7m12, associated with the same
splicing event and exon skipping (Figure 3B, lane 8); and
pF7m5 that was associated with exon skipping only (Figure
2B, lane 7). As shown in Figure 4, transfection of these
minigenes in COS-7 and HeLa cells led to splicing patterns
similar to those observed in CHO cells. These results provide
evidence for a scanning mechanism that is not cell type–
dependent, and, therefore, strongly suggest that the machi-
nery involved in 59 splice site selection is ubiquitous.
59 Pseudo-Sites with a CV as High as 91 Do Not Compete
with the Identified Scanning Process
The wild-type 59 splice donor site sequence of IVS7 of the
human F7 gene (TGG/gtgggt), like each of the ﬁve 59 pseudo-
sites, offers a reasonable agreement with the consensus
sequence of the splice donor sites, with a CV of 74 (Figure
5A), as assessed according to Shapiro and Senapathy [4]. To
test whether 59 pseudo-sites with higher CVs could compete
with the identiﬁed scanning process, we transfected CHO
cells with a series of F7 minigenes carrying different
Figure 3. Splice Site Selection in the Context of Functional 59 Pseudo-
Sites, Separated by One or Several Inactivated 59 Splice Sites
(A) Schematic representation of the constructs used in this experiment
(see legend to Figure 2A for the meaning of each symbol).
(B) RT-PCR amplification of F7 transcripts isolated from CHO cells
transfected with the above-mentioned constructs. The products
corresponding to the different PCR fragments, as identified by
sequencing, are schematically represented on both sides of the figure.
DOI: 10.1371/journal.pgen.0020138.g003
Figure 4. The Identified Scanning Mechanism for Splice Site Selection Is
Not Cell Type–Dependent
(A) Schematic representation of the constructs used in this experiment
(see legend to Figure 2A for the meaning of each symbol).
(B) RT-PCR amplification of F7 transcripts isolated from COS-7 and HeLa
cells transfected with the above-mentioned constructs. The products
corresponding to the different PCR fragments, as identified by
sequencing, are schematically represented on both sides of the figure.
DOI: 10.1371/journal.pgen.0020138.g004
PLoS Genetics | www.plosgenetics.org September 2006 | Volume 2 | Issue 9 | e1380004
Oriented Scanning for 59 Splice Site Selection
combinations of 59 pseudo-sites with increased CV on a
pF7wt or a pF7m background (Figures 5 and 6). The following
mutations were introduced in order to increase the com-
plementarity of the resulting transcripts with the 59 end of
the U1snRNA sequence: a G-to-A transition at position2 or
þ3 of the TGG/gtgggt splice site (i.e., TAG/gtgggt or TGG/
gtaggt with a CV of 82.2 or 85, respectively; see Figure 5A,
top), and a G-to-A transition at positionþ4 of the TGG/gtgggt
splice site (i.e., TGG/gtgagt with a CV of 91; see Figure 5B,
top). As shown in Figure 5A and 5B (bottom), the PCR
products generated from each construct demonstrated the
exclusive use of the most upstream functional 59 site,
regardless of its CV (i.e., 74, 82.2, 85, or 91). These results
were conﬁrmed by subcloning and subsequent sequencing of
the non-puriﬁed RT-PCR products.
We next tested whether the most upstream functional 59
site is still used when it is followed by sequences matching a
perfect splice donor site. To this end, we designed mutant F7
minigenes carrying the following mutations that were
introduced in the splice site sequences in order to match
perfectly with the 59 end of the U1snRNA sequence, in the
context of pF7wt: a T-to-C transition at position3, a G-to-A
transition at position2, and a G-to-A transition at position
þ4 of the TGG/gtgggt splice site (i.e., CAG/gtgagt with a CV of
100; see Figure 6, top). As shown in Figure 6 (bottom), two
molecular species were generated from these latest con-
structs. Although noteworthy, with such constructs one would
expect the exclusive use of the perfect sites; this experiment
and the subsequent sequencing of those products showed that
the optimal splice sequences were used with an efﬁciency of
approximately 70% (pF7wt_100–1) and 90% (pF7wt_100–
2), thereby demonstrating that the most upstream 59 site is
always used, even in the presence of a perfect splice site.
Taken together, these results show ﬁrstly that, even when
the CV is as high as 91%, the 59 pseudo-sites do not compete
with the identiﬁed scanning process. Secondly, competition
occurs only when those sequences match a perfect consensus
(CV of 100), and even in that case, the scanning process is still
active, as demonstrated by the use of the most upstream
functional 59 site.
No Autonomous Regulating Element Lies in the
Neighbouring Intronic Sequence
Intronic splice enhancer sequences, when placed between
competing 59 splice sites, have been shown to favour the use
of the upstream, most distal, 59 splice site [22,23]; we,
therefore, hypothesized that an intronic regulatory element,
which could overlap one or several 37-bp monomer repeats,
may either prevent the use of pseudo-sites or stimulate the
use of the most upstream one. To test this hypothesis, we
performed sequential deletions of the 37-bp monomer
repeats of pF7wt and/or pF7m; the resulting constructs
carrying one to six monomer repeats are shown in Figure
7A (top). As shown in Figure 7A (bottom), such truncations
did not change the splicing pattern observed with the pF7wt-
and the pF7m-derived constructs, suggesting that the deleted
regions did not contain any regulatory element.
Similarly, we designed F7 expression plasmids with the
insertion, in pF7wt and/or pF7m, of several 37-bp monomer
elements; the resulting constructs carrying eight to 12
monomer repeats are shown in Figure 7B (top). As shown
in Figure 7B (bottom), the choice of the 59 site used for
Figure 5. Splicing of a Series of Mutants with Increased Complementarity
of the IVS7 59 Pseudo-Sites to U1snRNA
(A) Splicing of F7 transcripts generated from F7 minigenes with a CV of
85 or 82.2.
(B) Splicing of F7 transcripts generated from F7 minigenes with a CV of
91.
(A and B) Top: Wild-type (middle line in [A], lower line in [B]) and mutated
(lower and upper lines in [A], upper line in [B]) 59 pseudo-sites in the F7
minigene. Dots show the location of the introduced mutations. Suffixes
of the constructs’ names and the resulting CVs are indicated. Middle:
Schematic representation of the constructs transfected in CHO cells.
Improved splice sites are represented by a hatched square (see legend to
Figure 2A for the meaning of each symbol). Bottom: RT-PCR amplification
of F7 transcripts isolated from CHO cells transfected with the above-
mentioned constructs. The products corresponding to the different PCR
fragments, as identified by sequencing, are schematically represented on
both sides of the figure.
DOI: 10.1371/journal.pgen.0020138.g005
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splicing was not modiﬁed by the number of 37-bp monomer
repeats contained in those constructs; indeed, in all cases only
the most upstream functional site was activated. We therefore
concluded that the neighbouring intronic sequence does not
contain an overlapping regulatory element.
As for the 37-bp monomer repeats themselves, we noticed
that they contain two G triplets that are small sequence
elements known to modulate 59 splice site selection in
mammals [22,23] (see Figure 2A, in bold underlined letters).
To determine if these elements affect 59 splice site selection,
we modiﬁed their sequence, while keeping the CV of the
corresponding 59 splice sites at least equal to the CV of the
wild-type sequence (74): a G-to-T transversion was introduced
at position 2 or þ4 of the TGG/gtgggt splice site (i.e., TTG/
gtgggt or TGG/gtgtgt with a CV of 74.7 or 74.1, respectively;
see Figure 8, bottom and middle). As shown in Figure 8
(bottom), mutations of the identiﬁed G triplets did not
modify the splicing pattern, strongly arguing against their
involvement in the selection of the most upstream 59 splice
site.
The Scanning Process Initiates Downstream of Exonic
Cryptic Sites
The ‘‘exon deﬁnition’’ model—based on the fact that, in
vertebrates, exons are generally much smaller than introns—
assumes that pairing between the splice sites occurs across an
exon through the concerted recognition of the splice sites
ﬂanking this exon (reviewed in [5]). This model predicts that a
mutation involving a 59 splice site would prevent the
recognition of the upstream exon, leading to skipping of this
exon and/or activation of a cryptic site that lies in this exon.
To gain insight into the initiation step of the scanning
process, we ﬁrst looked for potential cryptic donor splice sites
within exon 7 of the F7 gene. As previously reported, a strong
exonic cryptic site is located at IVS7–115, with a CV of 72,
close to the CV of the authentic IVS7 59 splice site sequence
(CV of 74) [21]. We subsequently generated two constructs,
derived from pF7wt and pF7m, in which this exonic cryptic
site TTG/GTGAAT (CV of 72) was mutated toward TAG/
GTGAAT (CV of 85), so that its resulting CV is above that of
the 59 authentic splice site (Figure 9A, top and middle), and
tested whether this improved cryptic site could be selected
for splicing. As shown in Figure 9A (bottom), this point
mutation did not modify the splicing patterns, as compared
with those associated with pF7wt and pF7m, a result that was
conﬁrmed by sequence analysis of the corresponding RT-PCR
products. These results, therefore, support the hypothesis
that, in these experimental conditions, the search for the
active 59 site initiates downstream of this exonic cryptic site.
However, an alternative explanation is the decreased
splicing efﬁciency of unusually small exons: indeed, a 59 splice
site located too close to the 39 splice site may have been
ignored due to the excessively small size of the potential exon
[24]. To test this hypothesis, we chose to work on another
sequence located in exon 7 (CCGCGGC, with a CV of 28%)
that, if selected for splicing, would yield an exon of 70
nucleotides (versus 124 nucleotides in the normal situation).
This size seemed reasonable, since, as demonstrated recently,
the length of abnormal exons that result from cryptic 59 splice
site usage is comprised of between 50 and 250 nucleotides [25].
Wemodiﬁed this sequence in order to generate two additional
mutants harbouring the following potential splice sequences:
CCGGTCGGC, with a CV of 72, very close to the CV of the
authentic splice site (74), and CAGGTAGGC with a CV of 89,
above that of the authentic 59 splice site (Figure 9B, top and
middle). Again, the PCR products generated from all the
constructs and subsequent sequencing demonstrated the
exclusive use of the authentic 59 site (Figure 9B, bottom).
These data strongly argue against an excessively small size of
the potential exon as a structural feature precluding the use of
an exonic cryptic donor splice site. Taken together, these
results further strengthen the hypothesis that the scanning
process initiates downstream of exonic cryptic sites.
Discussion
The human F7 gene, which encodes an essential coagu-
lation factor, provides a remarkable model to decipher the
mechanism underlying 59 splice site selection in mammals.
The ﬁrst 37-bp monomer element of the polymorphic
minisatellite located in IVS7 contains the exon7–IVS7
junction. As a consequence, in the primary transcripts,
several IVS7 59 splice sites (ranging from ﬁve to nine),
identical in sequence, compete to join a single 39 acceptor
site. It is, however, noteworthy that physiologically, only the
most upstream 59 splice site is used, the unused 59 splice sites
being referred to as pseudo-sites. Therefore, IVS7 of the
human F7 gene must rely upon peculiar mechanisms to
accurately control splice site selection. We have previously
proposed a model imparting a strong preference for use of
the most upstream 59 pseudo-site, rather than some repres-
Figure 6. Splicing of a Series of Mutants with IVS7 59 Pseudo-Sites
Perfectly Matching U1snRNA
Top: Wild-type (lower line) and mutated (upper line) 59 pseudo-sites in
the F7 minigene. Dots show the location of the introduced mutations.
Suffix of the constructs’ names and the resulting CV of 100 are indicated.
Middle: Schematic representation of the constructs transfected in CHO
cells. Splice sites matching the consensus are represented by a hatched
square (see legend to Figure 2A for the meaning of each symbol).
Bottom: RT-PCR amplification of F7 transcripts isolated from CHO cells
transfected with the above-mentioned constructs. The products
corresponding to the different PCR fragments, as identified by
sequencing, are schematically represented on both sides of the figure.
DOI: 10.1371/journal.pgen.0020138.g006
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sion of the downstream following ones [21]. The results of the
present study lend strong support to this model. They also
provide several lines of evidence that favour an unbending
scanning model that, in the context of several functional 59
splice sites, would always select the most upstream 59 splice
site through a mechanism that precludes competition with
other functional 59 pseudo-sites.
This study was initiated to test whether the different 59
pseudo-sites located in IVS7 of the F7 gene are functional.
Indeed, although all these sites are identical in sequence to
the authentic one, one cannot exclude the possibility that
they are unused because of a particular sequence context that
could act through different means—such as, for instance, a
secondary structure-dependent mechanism that would mask
these pseudo-sites. We examined the possible secondary
structure elements using different prediction of secondary
structure tools, such as those at http://www.genebee.msu.su/
services/rna2_reduced.html and http://www.bioinfo.rpi.edu/
applications/mfold/rna/form1.cgi.
However, we did not show any arrangement speciﬁc to the
sequence surrounding the pseudo-sites, which could explain
the splicing phenotype observed in our study. Previous
studies suggested that the 59 splice sites whose activation
would lead to a premature stop codon are not used so that an
open reading frame is maintained [26,27]. Nevertheless, in
our system, such a mechanism would predict the alternative
use, in addition to the authentic 59 splice site, of the ﬁfth and
sixth 59 pseudo-sites that do not lead to a premature stop
codon (unpublished data); as shown here, however, this is not
the case. An alternative explanation accounting for the non-
utilisation of the 59 pseudo-sites is that, as suggested by others
[22,23,28], they reside in a sequence context that hampers
their utilisation. We could, however, exclude the involvement
of intronic cis-acting auxiliary sequences in the splice site
selection. Our data, which demonstrate that all 59 pseudo-
sites can be efﬁciently activated, argue against this hypothesis
and rather suggest that these sites, though functional, are
physiologically unused because of a competition-based
mechanism. As shown here, the major determinant of this
mechanism would be the location of these sites relative to
each other: the more upstream intronic functional donor
splice site is much more competitive and is actually the only
one to be selected for splicing. These results strongly suggest
a mechanism of oriented linear search for the selection of the
59 splice site, starting upstream of the intervening sequence.
Indeed, alternative modes of scanning processes would
predict the use of other 59 splice sites downstream.
The strength of this model is attested to by the fact that 59
pseudo-sites with a CV as high as 91 still do not compete with
the most upstream functional site, since they are not used for
splicing, even at low efﬁciency. And only 59 pseudo-sites with
a CV of 100, hence perfectly matching the consensus
sequence, can shift splicing toward their use, even though
they still do not preclude the use of the most upstream
functional site with a much lower CV. In this regard, it is
important to underline that the optimal splice sequences are
extremely rare in human genes. A compilation of authentic
Figure 7. Search for Putative Intronic Sequences Regulating Splice Site
Recognition
(A) Top: Schematic representation of the constructs used in this
experiment with deletions involving one or several 37-bp monomers in
the context of pF7wt or pF7m (see legend to Figure 2A for the meaning
of each symbol). Bottom: RT-PCR amplification of F7 transcripts isolated
from CHO cells transfected with the above-mentioned constructs. The
products corresponding to the different PCR fragments, as identified by
sequencing, are schematically represented on both sides of the figure.
(B) Top: Schematic representation of the constructs used in this
experiment with insertions of several 37-bp monomers in the context
of pF7wt or pF7m (see legend to Figure 2A for the meaning of each
symbol). Bottom: RT-PCR amplification of F7 transcripts isolated from
CHO cells transfected with the above-mentioned constructs. The
products corresponding to the different PCR fragments, as identified
by sequencing, are schematically represented on both sides of the figure.
DOI: 10.1371/journal.pgen.0020138.g007
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and cryptic donor splice sequences revealed that the average
CV of authentic splice sites was 82.96 6 6% [25], which is not
only far below the optimal homology (CV of 100%), but also
below the CV of pseudo-sites that we showed to be unable to
compete with the most upstream 59 splice. Moreover, a recent
comparative analysis of human donor splice sequences
showed that of 45,519 genes, only 2,360 contained a CV of
90% [29]. The low frequency of donor splice sequences
perfectly matching the consensus could be explained by the
fact that, as shown in Saccharomyces cerevisiae [30], hyper-
stabilization of the spliceosome (with more than seven
potential Watson–Crick base pairs to U1snRNA) would
inhibit the splicing process [31,32].
Our observations raise the larger question of the mecha-
nism by which the most upstream functional site is recognised
by the splicing machinery. In other words, what are the
determinants involved in the initial step of such an oriented
scanning process? This question is still open, although, in the
case of F7, we could show that the increase of the CV of the
exonic cryptic sites failed to induce their activation, thereby
implying that scanning initiates downstream of these sites.
Other data presented here, however, indicate that the extent
to which the orientated scanning process is activated is
distance-dependent: the further away the most upstream
Figure 9. Effect on the Splice Site Selection of Exon 7 Sequences with
Increased Complementarity to U1snRNA
(A) Splicing of F7 transcripts generated from F7 minigenes harbouring an
exonic cryptic site at 113 with a CV of 85.
(B) Splicing of F7 transcripts generated from F7 minigenes harbouring an
exonic cryptic site at 54 with a CV of 72 or 89.
(A and B) Top: Wild-type (lower line in [A], middle line in [B]) and mutated
(upper lines in [A], lower and upper line in [B]) 59 pseudo-sites in the F7
minigene. Dots show the location of the introduced mutations. Suffixes
of the constructs’ names and the resulting CVs are indicated. Middle:
Schematic representation of the constructs transfected in CHO cells.
Improved splice sites are represented by a hatched square (see legend to
Figure 2A for the meaning of each symbol). Bottom: RT-PCR amplification
of F7 transcripts isolated from CHO cells transfected with the above-
mentioned constructs. The products corresponding to the different PCR
fragments, as identified by sequencing, are schematically represented on
both sides of the figure.
DOI: 10.1371/journal.pgen.0020138.g009
Figure 8. Role of G Triplets in IVS7 Splice Site Recognition
Top: Wild-type (middle line) and mutated (lower and upper lines) 59
pseudo-sites in the F7 minigene. Dots show the location of the
introduced mutations. Suffixes of the constructs’ names and the
resulting CVs are indicated. Middle: Schematic representation of the
constructs transfected in CHO cells. Mutated splice sites are represented
by a hatched box (see legend to Figure 2A for the meaning of each
symbol). Bottom: RT-PCR amplification of F7 transcripts isolated from
CHO cells transfected with the above-mentioned constructs. The
products corresponding to the different PCR fragments, as identified
by sequencing, are schematically represented on both sides of the figure.
DOI: 10.1371/journal.pgen.0020138.g008
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functional 59 pseudo-site is from the authentic splice site, the
more the IVS6 donor splice site is activated, leading to exon 7
skipping. These data, therefore, suggest that the identiﬁed
oriented scanning process, even if predominant, is not
exclusive. In this regard, other mechanisms such as those
underlying exon deﬁnition [5], or those showing a decreased
splicing efﬁciency of exons that are unusually large [33] or
small [24], may also be involved in a balance that, in turn,
favors one or the other 59 splice site that ﬂanks the deﬁned
exon, according to the distance in between these two sites.
Although a scanning process is widely accepted as an
important mechanism for the selection of 39 splice sites [34–
39], none has gained general acceptance for the selection of
the 59 splice sites. Pioneering studies were performed using a
model in which tandem duplications of the donor or
acceptor RNA splice sites of the second intervening sequence
were introduced in the human G gamma-globin gene. The
transcript analysis demonstrated that splicing occurred only
at the proximal copy of the duplicated splice sites [40,41].
From these results, in the presence of only two competing
splice sites, a scanning model for splice site selection was
proposed, but this model was still a matter of debate because
a similar study performed by another group yielded opposite
results [42]. The exon deﬁnition model also involves a
scanning process; however, this one starts at the 39 end of
the upstream intron [5], and elements of the splicing complex
then progressively scan the sequence downstream through
the adjacent exon to locate a suitable 59 splice consensus
sequence. This model, therefore, predicts that a 59 splice site
mutation will lead either to the skipping of the exon
upstream of the mutated 59 splice site, or to activation of
an exonic cryptic splice site that corresponds to the ﬁrst
suitable 59 consensus sequence encountered by the spliceo-
some. Our data partly integrate the splicing patterns
predicted by the exon deﬁnition model: as predicted by this
model, we observed the skipping of exon 7 at different
efﬁciencies for the constructs carrying consecutive inactiva-
tions of the more upstream pseudo-sites. However, they also
diverge from this model in that activation of the strongest
exonic cryptic donor splice site—as predicted by the exon
deﬁnition model—was never observed, even when the CV of
this cryptic site was increased, bringing further complexity to
the characteristics of this mechanism. Finally, similar experi-
ments performed in cells originating from different types
and species, such as CHO, COS-7, and HeLa cells, gave rise to
the same splicing patterns, providing evidence that the
herein identiﬁed oriented scanning mechanism that occurs
within this unusually arranged region does not require any
cell-speciﬁc factor, but rather relies on the constitutive
splicing machinery.
In summary, our results strongly suggest that, in the
presence of consecutive potential splice sites in the neigh-
bouring sequence, unbending scanning will rule the selection
of the activated 59 splice site. In the absence of such
sequences, according to the above-mentioned studies, the
selection of the activated splice site seems to rely upon its
strength—i.e., its complementarity to U1snRNA. Taken
together, our data reconciliate apparently contradictory
observations in the mechanisms of 59 splice site recognition
in mammals by establishing a hierarchy of competitiveness
among the determinants involved in this process.
Materials and Methods
Plasmid constructs. A 3.5-kb F7 genomic region spanning intron 4
to exon 8 (nt7688–11188) was ampliﬁed from a normal individual and
from the FVII-deﬁcient patient identiﬁed previously who carried a
homozygous mutation (9726T.G) in IVS7 [21] The PCR ampliﬁcation
was performed with primers Pa and Pm (Figure 1) using the Expand
high-ﬁdelity PCR system (Boehringer Mannheim, Mannheim, Ger-
many) according to the manufacturer’s recommendations. Both the
wild-type and the mutant F7 allele carried the six repeats of the 37-bp
monomer element (b allele, unpublished data). The wild-type and
mutant PCR fragments were cloned into the cytomegalovirus (CMV)
promoter-based expression vector pTracer (Invitrogen, Carlsbad,
California, United States) using the T4 DNA ligase (Invitrogen)
according to standard procedures; the resulting constructs were
designated pF7wt and pF7m, respectively.
These two expression plasmids were used as templates to generate
48 different constructs by site-directed mutagenesis using the
QuickChange system (Stratagene, Amsterdam, Netherlands). The
characteristics of the resulting plasmids are: the ﬁrst series consists
of 14 constructs—designated pF7m1 to pF7m14 (Figures 2 and 3)—
carrying a T-to-A transition located at the main dinucleotide of the
consensus donor splice site and involving several of the 37-bp
monomer elements found in IVS7.
The second series of expression plasmids consists of 15 constructs:
pF7wt_2G.Am1 to pF7wt_2G.Am4, pF7wt_þ3G.Am1 and
pF7wt_þ3G.Am2, pF7wt_þ4G.Am1 and pF7wt_þ4G.Am2, and
pF7wt_CV100–1 and pF7wt_CV100–2, which have been designed in
order to improve the CV of one or several pseudo-sites in the context
of pF7wt; and pF7m_2G.Am5 and pF7m_2G.Am6, and
pF7m_þ3G.Am3 to pF7m_þ3G.Am5, which have been designed
in order to improve the CV of one or several pseudo-sites in the
context of pF7m (Figures 5 and 6).
The third series consists of 14 constructs (Figure 7): pF7wt_del1 to
pF7wt_del5, which have been generated from pF7wt and carry a
targeted deletion involving one to ﬁve of the 37-bp monomer
elements found in IVS7, respectively. Similar deletions involving
three or four of these monomer elements were generated from a
pF7m background, thereby resulting in two expression plasmids
designated pF7m_del3 and pF7m_del4. Constructs were also
generated with insertion of a variable number of the 37-bp monomer
element, either on a pF7wt background (i.e., pF7wt_ins2 to
pF7wt_ins5) or from pF7m (i.e., pF7mins3 and pF7mins5).
The fourth series consists of ﬁve expression plasmids, which were
designed to assess the functional importance of G triplets on splicing,
were generated from pF7wt or pF7m and (Figure 8): pF7wt_2G.T,
pF7wt_þ4G.Tm1, pF7wt_þ4G.Tm2, pF7m_–2G.T, and
pF7m_þ4G.T.
The two following site-directed mutageneses were generated on
pF7wt or pF7m in order to improve the CV (from 74 to 85) of a
cryptic donor splice site located within exon 7 at position113. The
resulting plasmids were named pF7wt_CV85 and pF7m_CV85. The
last two constructs, pF7wt_CV72 and pF7wt_CV89, have been
designed in order to create a donor splice consensus sequence
located within exon 7 at position54 (Figure 9).
All primers used in ampliﬁcation and mutagenesis steps are
available on request. All the constructs were checked by sequencing
the inserts and the vector ﬂanking regions.
Cell culture and transfections. CHO cells were grown in ISCOVE
medium (Invitrogen). HeLa cells and COS-7 cells were grown in
DMEM medium. Both media were supplemented with 10% fetal calf
serum (FCS) in a 5% carbon dioxide atmosphere at 37 8C.
Transfections were performed at 60% of conﬂuence by the Lip-
ofectamin method (Invitrogen) in OptiMEM medium with 2 lg of
each of the various constructs, according to the manufacturer’s
instructions. After 5 h, OptiMEM medium was removed and replaced
by the normal medium supplemented with 10% FCS. Each trans-
fection experiment was repeated at least twice.
RNA isolation and cDNA synthesis. Total RNA was extracted from
the cells 48 h after transfection by using RNAplusTM (Bioprobe
Systems, Montreuil-sous-bois, France) according to manufacturer’s
instructions. Following precipitation, RNA was treated with DNaseI
to remove any contaminating plasmid DNA. First-strand cDNA
synthesis was performed from 5 lg of total RNA, with random
hexamers as primers (Pharmacia) and Superscript II (Invitrogen).
One-tenth of each of the ﬁrst-strand synthesis reaction products was
used in each of the three subsequent PCR reactions with oligonu-
cleotides Pb (59 TCTGTGTGAACGAGAACGGC 39) and Pm to
amplify exons 5 to 8, Pe (59 AAGAAATGCCAGCAAACCCC 39) and
Pm to ampli fy exons 6 to 8 , and Ph (5 9 GGAGCT-
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CAGTTGTGTGGGGG 39) and Pm to amplify exons 7 to 8 (see Figure
1). PCR ampliﬁcations were carried out using Expand high-ﬁdelity
PCR systems (Boehringer-Mannheim) as described above.
Transcript analysis. The PCR-ampliﬁed cDNA fragments were
visualized after separation by electrophoresis on 1% agarose gel and
revelation by ethidium bromide staining. Non-puriﬁed PCR products
obtained in each reaction with the various constructs were subcloned
into the plasmid vector pTOPO-4 (TOPO TA-Cloning, Invitrogen).
For each subcloning experiment, at least 50 independent clones were
sequenced on both strands in order to characterize the transcripts.
CV analysis. The statistical rules from Shapiro and Senapathy [4]
were used to assign a score for the authentic and mutated IVS7 splice
sites and the modiﬁed pseudo-sites, as previously described [21].
Brieﬂy, these scores reﬂect the degree of conservation in different
positions resulting from the alignment of 1,446 59 splice sites of other
genes. The consensus 59 splice site sequence is MAG/guragu and spans
from the position 3 (the third nucleotide from the 39 end of the
upstream exon) toþ6 (the sixth nucleotide in the intron). A score of




The GenBank (http://www.ncbi.nlm.nih.gov/Genbank/index.html) ac-
cession number for the F7 gene is NM_000131.
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Summary. Background: Tissue factor (TF) and factor (F) VIIa
are the primary initiators of the coagulation cascade, but also
promote non-hemostatic events, such as angiogenesis and
tumor growth, via activation of protease activated receptor-2
(PAR2). Our previous ﬁndings indicated that the TF:FVIIa
complex activates signal transducer and activator of transcrip-
tion (STAT) signaling, leading to cell survival in TF-transfected
baby hamster kidney (BHK) cells. Methods: Using BHKTF,
keratinocytes (HaCaT) and human umbilical vein endothelial
cells (HUVEC),FVIIa-inducedphosphorylationandactivation
of the transcription factor cyclic AMP-responsive binding
protein (CREB) were tested and compared to that elicited by
thrombinandFXa. In addition, the eﬀect of these factors on cell
survival and expression of apoptosis-associated proteins was
monitored. Results: Factor VIIa led to a TF-dependent, but TF
cytoplasmic domain-independent phosphorylation and activa-
tion of CREB in BHKTF, HaCaT and HUVEC. CREB
activation was sensitive to blockade of the extracellular-signal
regulated kinase 1/2 pathway and PAR2. Surprisingly, FVIIa
decreased cell survival in HaCaT cells but not other cell types
and upregulated the pro-apoptotic proteins Bak and Puma in a
CREB-dependent manner. Factor Xa, but not FIIa, induced
phosphorylation of CREB, but did not have an eﬀect on
apoptosis. Conclusion: TF:FVIIa induces CREB phosphoryla-
tion and activation in several cell types, but TF:FVIIa induces
pro-apoptotic proteins and apoptosis only in selected cell
types.
Keywords: apoptosis, coagulation factors, protease activated
receptor, signal transduction.
Introduction
Tissue factor (TF) plays a pivotal role in physiological
events such as normal hemostasis and angiogenesis, but also
in pathological diseases such as sepsis and malignant
diseases. Especially, the role of TF in cancer has been the
subject of recent research. TF is an independent risk factor
for hepatic metastases in human colorectal carcinoma [1]
but TF has also been shown to regulate thrombin-depen-
dent metastasis TF [2]. TF expression correlates with the
grade of malignancy [3] and overexpression in ﬁbrosarcoma
[4], pancreatic cancer cells [5] and melanoma cells [6]
enhances tumor growth. Knock-down of TF by means of
small interfering RNA (siRNA) leads to a decrease in
tumor angiogenesis and subsequent tumor growth in a
murine coloncarcinoma model [7]. In contrast, TF-deﬁcient
cell lines established from mouse embryos by oncogene
transformation are not changed in their tumor growth
behavior upon re-expression of TF, although metastasis is
positively inﬂuenced [8]. These experiments suggest that the
mere presence of TF is not sufﬁcient and that the role of
TF in tumor growth is context-dependent.
One possible mechanism by which TF inﬂuences malignant
disease is through intracellular signaling. Binding of TF to
factor (F) VIIa, TFs natural ligand, proteolytically activates
the G-protein-coupled protease activated receptor-2 (PAR2)
[9]. TF:FVIIa downstream signaling includes activation of the
extracellular-signal regulated kinase (ERK) 1/2, p38 MAP
kinase and PI3-kinase/c-Akt pathways, as well as a number of
GTPases [10–12]. Importantly, activation of these pathways
promotes cell proliferation, gene expression, anti-apoptosis,
and cell migration [13–17], processes that are critical to the
development of cancer. TFs cytoplasmic tail negatively
regulates the a3b1 integrin function in keratinocytes, speciﬁcally
when grown on the matrix protein Laminin-5. Binding of
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FVIIa to TF may lead to TF tail phosphorylation and reversal
of this inhibition [18].
We have recently shown that TF:FVIIa signaling leads to
activation of the JAK2-STAT5 pathway, via the GTPases G12
and G13. Activation of the transcription factor STAT5 led to
inhibition of apoptosis via production of the anti-apoptotic
protein Bcl-XL [19]. We have also shown that the coagulation
factor FXa induces activation of another transcription factor,
cyclic AMP-responsive binding protein (CREB) [20]. In
contrast, FXa-induced activation of CREB promoted apopto-
sis in tumor cells via upregulation of the BH3-only pro-
apoptotic protein Bim, which led to caspase-3 cleavage, the
main hallmark of apoptosis.
Here, we show that the TF:FVIIa complex induces CREB
activation through PAR2 cleavage and activation of ERK1/2
in hamster kidney cells, keratinocytes and endothelial cells.
Nevertheless, FVIIa induces upregulation of the pro-apoptotic
proteins Bak and Puma as well as apoptosis only in keratino-
cytes. Therefore, TF in complex with FVIIa induces different
effects on cell survival in different cells.
Materials and methods
Materials
The antibodies raised against p-CREB (Ser133), p-STAT5
(Tyr694), Bak, and Puma were purchased from Cell Signaling
Technologies (Beverly, MA, USA). b-actin, Ga12 and Ga13
antibodies were from Santa Cruz (Santa Cruz, CA, USA).
Lysophosphatidic acid (LPA), Pertussis Toxin and 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT)
were from Sigma-Aldrich (Zwijndrecht, the Netherlands).
Recombinant FVIIa was purchased from Novo Nordisk
(Bagsvaerd, Denmark), hirudin was from Calbiochem
(EMD, Gibbstown, NJ, USA), and tick anticoagulant protein
(TAP) was a kind gift fromG. Vlasuk (Corvas Int., San Diego,
CA, USA). The dominant-negative CREB expression vectors
were from Clontech (Mountain View, CA, USA).
Cell culture, transfection and transduction
Baby hamster kidney (BHK) cells, stably transfected with full
length TF or with a TF cytoplasmic domain-deleted mutant
truncated at residue 247 (generous gifts from L. Petersen,
Novo Nordisk, Bagsvaerd, Denmark) and HaCaT keratino-
cytes were maintained in Dulbeccos Modiﬁed Eagles
Medium, supplemented with 10% fetal calf serum (FCS;
Fisher Scientiﬁc, Landsmeer, the Netherlands) under stan-
dard conditions. Inhibitors were added 30 min prior to the
experiment (with the exception of PTX; 6 h) in the following
concentrations: PD98059: 20 lM, LY294002: 10 lM,
SB203580: 10 lM, Hirudin: 25 U mL)1, TAP: 200 nM. Cells
were stimulated with 10 nM FVIIa unless stated differently.
Transient transfections with Ga12 and Ga13 dominant-nega-
tive constructs (G12G228A) and (G13G225A) (a gift from
S. Offermanns) were carried out using effectene reagent as
suggested by the supplier (Qiagen, Venlo, the Netherlands).
Transfections were carried out for 16 h. Using GFP-expres-
sion constructs, the transfection efﬁciency was determined to
be at least 75%. Human umbilical vein endothelial cells
(HUVEC) were obtained from Clonetics (San Diego, CA,
USA) and cultured in EGM medium containing 2% fetal
bovine serum, 1 mg mL)1 hydrocortisone, 10 lg mL)1 hu-
man epidermal growth factor, and 3 mg mL)1 bovine brain
extract. HUVEC were transduced for 4–6 h with TF and
PAR2 adenoviral constructs as described previously [21], and
cells were starved for 5 h M199 medium supplemented with
1.5 mM CaCl2 and 20 mM Hepes.
Western blotting
Cells were rapidly harvested by scraping in sample buffer. After
boiling at 95 C, the lysates were loaded onto sodium
dodecylsulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and subsequently transferred to a PVDF membrane.
The membranes were blocked and incubated with primary
antibody over night at 4 C, diluted 1:1000 in wash buffer
containing 2.5% BSA. Subsequently, the membranes were
incubated with a horseradish peroxidase-conjugated secondary
antibody in wash buffer, containing 2% low-fat milk powder.
The bands were visualized, using Lumilight plus ECL
substrate from Roche (Meidrecht, the Netherlands) and a
chemiluminescence detector with a cooled CCD-camera from
Syngene (Cambridge, UK).
Secreted alkaline phosphatase assay
Cells were grown in 24 wells and transfected with either the
cyclic AMP response-secreted alkaline phosphatase (CRE-
SEAP) construct or a SV40-driven SEAP construct for 16 h,
and serum starved for another 16 h. Subsequently, cells were
stimulated with FVIIa or forskolin for 4 h. Twenty-ﬁve
microliter medium was taken and cell debris was removed by
centrifugation at 1700 g. The supernatant was incubated for
15 min at 65 C to inactivate non-secreted alkaline phospha-
tases. Subsequently, 25 lL of 2· SEAP buffer [2 M Dietha-
nolamine (DEA) pH 9.8; 1 mM MgCl2; 20 mM L-
homoarginine] was added and incubated for 10 min at 37 C.
Then, 0.5 lL 10 mM MUP was diluted in 25 lL 1· SEAP
buffer and added to the sample. The samples were measured in
96-well plates in a ﬂuorimeter (Cytoﬂuor; PerSeptive Biosys-
tems, Framingham, MA, USA) with excitation 360 and
emission 450 nm.
Survival assay
Cell viability was assessed using an MTT reduction assay (a
colorimetric assay in which a tetrazolium compound is
bioreduced by cells into a colored formazan product in direct
proportion to the number of living cells in culture) in 96-well
plates. Shortly, cells were seeded at 70%conﬂuence and starved
for one day after which FVIIa, FXa or FIIa (thrombin) was
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added. Viability was measured at the times indicated in the
graphs. The control was set at 100%.
Statistical analysis and quantification of the Western blots
In all ﬁgures, means and standard errors of at least triplicates
are shown. Western blots represent at least three independent
experiments. Statistical signiﬁcance: * represents P < 0.05, **
represents P < 0.01 and *** represents P < 0.001.
Results
TF:FVIIa induces CREB activation in BHK cells
To investigate whether TF:FVIIa can activate the transcrip-
tion factor CREB, we stimulated TF-expressing BHK cells
with 10 nM FVIIa. A transient phosphorylation of CREB
that peaked at 10 min was observed after FVIIa stimulation
(Fig. 1A). TF:FVIIa-induced phosphorylation of CREB
occurred at concentrations as low as 3.1 nM FVIIa (Fig. 1B).
In contrast, STAT5 activation in the same cell type was
readily observed at 0.8 nM [19] (Fig. 1B), suggesting that
distinct TF:FVIIa-induced pathways showed different sensi-
tivities towards TF:FVIIa. Factor VIIa-induced CREB
phosphorylation was critically dependent on TF as BHK
cells that do not express TF did not show FVIIa-dependent
CREB phosphorylation (Fig. 1C). Factor VIIa-induced
CREB activation in cells expressing TF lacking its cytoplas-
mic tail demonstrated that this domain is not required for
this effect. This is consistent with previous reports obtained
in the same cell type [22]. An active site-blocked form of
FVIIa (FFR-FVIIa) had only a marginal effect on CREB
phosphorylation, demonstrating that FVIIa proteolytic activ-
ity is a major contributing factor to TF:FVIIa-dependent
CREB phosphorylation (Fig. 1D).
TF:FVIIa may proteolytically activate traces of FX or
prothrombin in the media, which then activate signal trans-
duction cascades independent from the FVIIa function.
Inclusion of the FXa inhibitor TAP or the thrombin inhibitor
hirudin did not inhibit FVIIa-induced CREB phosphorylation,
demonstrating that TF:FVIIa induces CREB phosphorylation
independent of FXa or thrombin action (Fig. 1E).
To determine whether CREB phosphorylation correlated
with activity, we performed a transactivation assay. BHKTF
cells were transfected with a CREB-responsive SEAP-express-
ing construct or a SV40-driven SEAP construct that expresses
SEAP in a CREB-independent manner. Ten nanomolar FVIIa
or 10 lM forskolin, a well-characterized inducer of CREB
activation, induced SEAP expression, whereas SV40-induced
SEAP expression was unaffected (Fig. 1F), demonstrating that
FVIIa speciﬁcally inducedCREBtranscriptionalactivity, rather
than total protein expression, in the time frame examined.
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Fig. 1. Tissue factor:factor VIIa (TF:FVIIa) signaling induces cyclic AMP-responsive binding protein (CREB) activation in baby hamster kidney (BHKTF)
cells. (A) Factor VIIa induces time-dependent CREB phosphorylation in BHKTF cells. Cells were serum starved and stimulated with 10 nM FVIIa at the
times indicated. Phosphorylated and total levels of CREB were detected on Western blot. (B) Dose-dependent CREB vs. STAT5 phosphorylation after
FVIIa stimulation in BHKTF cells. Cells were serum starved and stimulated with the FVIIa concentrations indicated. The graph shows quantiﬁed bands
of three independent experiments. (C) TF, but not its cytoplasmic tail, is required for FVIIa-dependent CREB phosphorylation. Wild-type BHK cells,
or cells stably transfected with a TFmutant lacking the cytoplasmic domain, were stimulated with FVIIa at the times indicated. (D) Factor VIIa proteolytic
activity is themajor determinant forCREBphosphorylation.BHKTF cellswere stimulatedwithFVIIaor active site-inhibitedFVIIa (FFR-VIIa) for 10 min.
The graph shows quantiﬁcations of three independent experiments. (E) Factor VIIa-dependent CREB phosphorylation is independent of FXa or thrombin
generation. BHKTF cells were pretreated mock, with 100 nM tick anticoagulant protein (TAP), or 25 U mL)1 hirudin, and subsequently stimulated with
FVIIa. (F) Factor VIIa induces CREB-dependent transcription. BHKTF cells were transfected with the indicated constructs and stimulated with 10 nM
FVIIa or forskolin. SV40- and CRE-dependent secreted alkaline phosphatase (SEAP) expression was assayed as described in the Methods section.
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TF:FVIIa-induced CREB activation is dependent on MEK, but
not on G12/G13 or Gi
We next determined pathways downstream of TF:FVIIa,
leading to CREB phosphorylation, using pharmacological
inhibitors. Factor VIIa-induced CREB phosphorylation was
sensitive to inhibitors to the ERK1/2 pathway, but not to p38
MAP kinase or PI3-kinase inhibitors (Fig. 2A). This shows
that ERK1/2 is critically required for phosphorylation of
CREB.
We have previously shown that TF:FVIIa-induced STAT5
activation requires functional G12/G13 a-subunits [19]. There-
fore, we transfected BHKTF cells with constructs expressing
inactive G12/G13 a-subunits and determined CREB phosphor-
ylation after FVIIa stimulation. Interestingly, whereas trans-
fection with inactive G12/G13 a-subunits inhibited FVIIa-
induced STAT5 phosphorylation, CREB activation was unaf-
fected (Fig. 2B). In addition, CREB phosphorylation was not
affected by the Gi-inhibitor pertussis toxin (Fig. 2C), although
it did inhibit signaling by LPA, which has been shown to be
sensitive to PTX in the literature [23].
TF:FVIIa-induced CREB activation is PAR2-dependent
Next, we intended to identify the functional receptor that
mediates TF:FVIIa-induced CREB phosphorylation. We used
the spontaneously immortalized human keratinocyte cell line
HaCaT, as tools to assess the role of protease-targeted
receptors are speciﬁc for human models and are not available
for hamster cells. We ﬁrst characterized CREB activation by
TF:FVIIa in HaCaT cells. CREB activation was induced by
FVIIa at concentrations as low as 3.1 nM (Fig. 3A) and CREB
phosphorylation persisted up to 80 min or longer (Fig. 3B).
Importantly, activation of the anti-apoptotic transcription
factor STAT5, which is activated in BHKTF by FVIIa, was not
observed in HaCaT cells. Similar to what was observed in
BHKTF cells, FVIIa-induced CREB phosphorylation was
sensitive to MEK inhibition, but not to PI3-kinase, p38
MAP kinase, FXa or thrombin inhibitors (Fig. 3C). We then
utilized an antibody raised against the cleavage site in PAR2,
thus inhibiting PAR2 activation by proteases. We found that
pre-incubation of HaCaT cells with 100 lg mL)1 anti-PAR2
efﬁciently blocked TF:FVIIa-induced CREB activation
(Fig. 3D). As a separate line of evidence for the involvement
of PAR2 in TF:FVIIa-induced CREB phosphorylation, we
adenovirally transduced HUVEC, which normally do not
express TF or PAR2, with human TF expression construct,
human PAR2 expression construct, or a combination thereof.
As expected, only the combined expression of TF and PAR2
led to FVIIa-induced CREB phosphorylation in HUVEC
(Fig. 3E).
CREB activation by TF:FVIIa results in upregulation of
pro-apoptotic proteins in HaCaT cells
TF:FVIIa signaling results in enhanced cell survival in BHKTF
cells via activation of the transcription factors STAT5.
Therefore, we determined whether TF:FVIIa also induced cell
survival in HaCaT cells. To our surprise, serum-starved
HaCaT cells showed a modest but signiﬁcant reduction in cell
survival upon incubation with FVIIa (Fig. 4A), which is in
contrast to our previous observations in BHKTF cells. We then
screened HaCaT cells for upregulated pro-apoptotic proteins
after FVIIa stimulation on a translational level. These exper-
iments revealed that the pro-apoptotic proteins Bak and Puma
were upregulated by FVIIa stimulation (Fig. 4B). Moreover,
inclusion of two different dominant-negative CREB mutants,
one lacking the activational phosphorylation site at serine 133
(S133A) and one lacking the DNA binding site (K-CREB), led
to an abolished Bak/Puma expression after FVIIa stimulation
(Fig. 4C). Moreover, basal levels of these proteins were also
affected by the presence of dominant-negative CREB proteins.
These results indicate that CREB activation, both under basal
conditions and after FVIIa stimulation, was required for
upregulation of Bak and Puma. Interestingly, FVIIa did not
lead to upregulation of Bak or Puma in BHKTF cells (results
not shown), nor did it induce apoptosis or pro-apoptotic
proteins in HUVEC transduced with adenoviral TF and PAR2
expression constructs. Rather, FVIIa induced cell survival and
inhibition of PUMA expression (Figs. 5A and B).
Thrombin and FXa-dependent signaling
It is currently unclear whether TF:FVIIa signaling constitutes a
































Fig. 2. Downstream pathways leading to factor (F) VII-induced cyclic
AMP-responsive binding protein (CREB) phosphorylation. (A) CREB
phosphorylation is dependent on the extracellular-signal regulated kinase
(ERK), but not PI3-kinase or p38 MAP kinase pathway. Baby hamster
kidney (BHKTF) cells were pretreated with inhibitors to the p38 MAP
kinase pathway (SB203580; SB, 10 lM), the PI3-kinase pathway
(LY294002; LY, 10 lM) or the ERK pathway (PD98059; PD, 20 lM).
Cells were stimulated with FVIIa, phosphorylated and total CREB was
determined onWestern blot. (B) CREB phosphorylation is not dependent
on G12 or G13. BHK
TF cells were transfected with constructs expressing
dominant-negative G12 or G13 a-subunits and subsequently stimulated
with FVIIa. CREB and STAT5 phosphorylation was assessed onWestern
blot. b-actin was used as a loading control; G12 and G13 a-subunit
expressions are shown in separate panels. (C) CREB phosphorylation is
not dependent on Gi. Cells were treated mock or with 200 ng mL
)1
Pertussis Toxin for 6 h, and stimulated with FVIIa.
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by other coagulation factors such as FXa and thrombin (FIIa).
We therefore assessed whether the coagulation factors throm-
bin and FXa also induce CREB signaling and apoptotic
features in BHKTF cells and HaCaT. Importantly, FXa, but
not thrombin, elicited CREB activation in both BHKTF and
HaCaT cells (Fig. 6A). Furthermore, whereas FXa induces cell
survival in BHKTF cells [24], it did not signiﬁcantly change
cell survival in HaCaT cells. Thrombin, which also induces cell
survival in BHKTF, led to cell survival in HaCaT cells as well
(Fig. 6B). Factor Xa did not signiﬁcantly upregulate or
downregulate Puma or Bak levels in either BHKTF or HaCaT
cells. Similarly, incubation of HaCaT with thrombin did not
alter Puma or Bak levels, but a trend towards lower Puma
levels was observed in BHKTF cells (Fig. 6C). In conclusion,
FVIIa appears to be unique in that it induces synthesis of pro-
apoptotic proteins and a modest apoptotic response in HaCaT
cells.
Discussion
Coagulation factors have attracted attention in the ﬁeld of
cancer. TF is an important determinant of metastasis and a risk
factor for hepatic metastasis in patients suffering from colon
carcinoma [1]. In addition, TF regulates primary tumor growth
in colon carcinoma [7]. TF:FVIIa signaling promotes IL-8
production and breast cancer cell migration [25], but also
stimulates anti-apoptotic signaling in TF-expressing BHK cells
[15,19]. Anti-apoptotic signaling results in the survival of cells
that were challenged with serum starvation or loss of adhesion
(anoikis). Here, we show that TF:FVIIa activates the tran-
scription factor CREB, which unexpectedly resulted in upreg-
ulation of pro-apoptotic proteins. Furthermore, FVIIa led to
impaired survival in HaCaT cells, possibly through CREB-
dependent upregulation of the pro-apoptotic proteins Bak and
Puma. Proteolytic activation of PAR2, but not TFs cytoplas-
mic domain, was required for TF:FVIIa-induced CREB
activation.
Although coagulation factor-induced apoptosis is in direct
contrast with our previous results that show that TF:FVIIa
promotes cell survival in BHKTF [17,19], a similar induction
of apoptosis was described for FXa-induced PAR1 activa-
tion in tumor cells from epithelial origin [20]. In contrast,
FXa promoted cell survival in ﬁbroblasts. This correlates
well with the role of the TF:FVIIa complex in (anti-
)apoptosis, as it stimulates survival in BHKTF cells and
endothelial cells that express TF and PAR2, but stimulates
apoptosis in HaCaT epithelial cells. The exact rationale for
these different effects on cell survival is not clear, but may
relate to the TF:FVIIa-induced activation of the transcrip-
tion factor STAT5 in non-epithelial cells. Therefore, it is
very plausible that TF:FVIIa-induced apoptosis in HaCaT
cells arises from a lack of STAT5 activation. Another
intriguing ﬁnding is the involvement of ERK1/2 in a pro-
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Fig. 3. Tissue factor:factor VIIa (TF:FVIIa) signaling is dependent on protease activated receptor-2 (PAR2). (A) Dose-dependent cyclic AMP-respon-
sive binding protein (CREB) phosphorylation after FVIIa stimulation in HaCaT cells. Cells were serum starved and stimulated with the FVIIa
concentrations indicated. CREB phosphorylation was veriﬁed on Western blot. (B) Time-dependent activation of CREB, but not STAT5 by FVIIa in
HaCaT cells. Cells were serum starved and stimulated with FVIIa for various time intervals. (C) Eﬀect of inhibitors on FVIIa-induced CREB
activation in HaCaT cells. Cells were pretreated with the inhibitors indicated, in the concentrations mentioned previously and stimulated with FVIIa
or FFR-FVIIa. (D) PAR2-blocking antibody inhibits FVIIa-induced CREB activation. HaCaT cells were treated with PAR2 antibody for 30 min
and stimulated with FVIIa. (E) Combined TF and PAR2 expression facilitates FVIIa-induced CREB activation. Human umbilical vein endothelial
cells (HUVEC) were transduced with TF and PAR2 adenovirus, as described in the Methods section, and stimulated with FVIIa. Expression of TF
and PAR2 was veriﬁed on Western blot. The PAR2 blot shows a multiple band pattern typically observed after PAR2 blotting.
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is generally associated with cell survival [26], the involve-
ment of ERK1/2 in apoptosis has been described previously
[27,28].
Our experiments indicate that TF:FVIIa-induced CREB
activation proceeds through activation of PAR2. Interestingly,
during the preparation of this paper, a recent report has been
published on PAR2-dependent CREB activation, supporting
the data presented here [29]. PAR2 couples to a heterotrimeric
G-protein and therefore we also investigated the nature of the
G-protein involved in TF:FVIIa-induced CREB phosphoryla-
tion. Despite the fact that inhibition of G12/G13 G-proteins
efﬁciently inhibited STAT5 activation by the TF:FVIIa
complex, inhibition of G12/G13 did not affect CREB phos-
phorylation. Similarly, inhibition of Gi by Pertussis Toxin did
not inhibit CREB phosphorylation. Consequently, the nature
of the G-protein involved is still unknown.
In both HaCaT and BHKTF cells, proteolytic activity of
FVIIa was the major determinant of CREB phosphorylation,



















































Fig. 4. Factor (F) VIIa stimulates cyclic AMP-responsive binding protein
(CREB)-dependent upregulation of the pro-apoptotic proteins Bak and
Puma. (A) Factor VIIa decreases cell survival in HaCaT. Cells were seeded
and stimulated with 10 nM FVIIa. Cell viability was assayed at t = 0, 1
and 2 days. Loss of viability was expressed as percentage of the unstim-
ulated control at day 0. (B) Factor VIIa upregulates Bak and Puma.
Cells were stimulated with 10 nM FVIIa for the times indicated. Bak and
Puma expression were detected on Western blot. The graph shows
quantiﬁed Western blots of three independent experiments. (C) Factor
VIIa-induced expression of Bak and Puma requires functional CREB.
HaCaT cells were transfected with CREB mutants (see text), serum
starved and stimulated mock or with FVIIa for 8 h. Bak and Puma levels
were detected on Western blot. b-actin is included as a loading control.
0












































Fig. 5. Factor (F) VIIa induces survival and diminished PUMA expres-
sion in human umbilical vein endothelial cells (HUVEC). (A) Factor VIIa
induces cell survival in HUVEC. HUVEC were transduced to express
tissue factor and protease activated receptor-2 (PAR2). Cells were starved
and incubated with FVIIa. Cell viability was assayed at t = 0, 1 and
2 days. (B) Eﬀect of FVIIa on PUMA and Bak levels. Cells were starved
and stimulated with 10 nM FVIIa. Puma and Bak levels were determined
on Western blot. The graph shows quantiﬁcations three independent
experiments.
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induced CREB phosphorylation was observed. It should be
noted that a recent study by Ott et al. [30] shows that high
concentrations of proteolytically inactive FVIIa can signal
through the TF cytoplasmic domain in bladder carcinoma
cells. Thus, inactive FVIIa may induce a modest form of
signaling, independent of PAR2 activation.
Factors Xa and IIa (thrombin) do not induce apoptosis in
the cell lines examined. Thrombin even appears to enhance cell
survival in HaCaT cells. This feature is combined with a lack of
thrombin-induced CREB activation in both BHKTF and
HaCaT cells. We do, at present, not have an explanation for
this, but differences in signaling after activation of the thrombin
receptor PAR1 vs. FVIIa-activated PAR2 may account for
this.
In conclusion, we show that TF:FVIIa-induced signaling
activates CREB via the ERK pathway. CREB activation leads
to upregulation of the pro-apoptotic proteins Puma and Bak
and leads to reduced cell survival in keratinocytes. These data
point out that the role of TF in cell survival is not as
straightforward as previously thought and suggest that the cell
type examined determines whether TF:FVIIa signaling is pro-
or anti-apoptotic.
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Activated factor Xa (FXa) is traditionally known as an
important player in the coagulation cascade responsible
for thrombin generation. Long considered a passive
bystander, it is now evident that FXa exerts direct effects
on a wide variety of cell types via activation of its two
main receptors, protease-activated receptor-1 (PAR-1)
and PAR-2. Recent findings suggest that PAR-2 plays a
crucial role in fibro-proliferative diseases such as fibro-
sis, tissue remodeling and cancer and point towards FXa
as the important mediator coordinating the interface
between coagulation and disease progression. Here,
we provide an overview of the FXa signaling pathways
that mediate its effects in pathophysiology and explore
the potential therapeutic implications of targeting FXa;
in terms of arresting disease progression, the modu-
lation of FXa activity might be more important than
the modulation of FVIIa or thrombin.
Non-hemostatic functions of FXa in health and disease:
old thoughts and new developments
Coagulation factor X (FX) is a vitamin-K-dependent
plasma protein that plays an important role in the regu-
lation of blood coagulation by converting prothrombin into
thrombin. As shown inBox 1, activated FX (FXa) occupies a
central position in the coagulation cascade as a conver-
gence point between intrinsic and extrinsic pathways.
Its crucial role in hemostasis is well-established and
demonstrated by the severe bleeding diathesis of patients
suffering from inherited FX deficiencies [1]. Recently, a
non-hemostatic role of FXa has been proposed [2], and
increasing evidence suggests that FXa elicits various
and complex signaling events on a wide range of cell types
by activating protease-activated receptor (PAR)-1 and
PAR-2 (which act as receptors for multiple coagulation
factors). The role of PAR-1, themain receptor for thrombin,
has been extensively studied in pathophysiology over
recent decades. FXa and thrombin share PAR-1 as a down-
stream cellular receptor [3], and this led to the assumption
that FXa signaling would be highly reminiscent of throm-
bin signaling. Therefore, the significance of FXa-induced
cellular responses remained largely underexplored, and
their contribution to pathophysiological processes was not
recognized.
Interest in FXa signaling was ignited after the realiz-
ation that PAR-2, rather than PAR-1, acts as a key player
in the progression of a wide pattern of pathologies at the
fibro-proliferative interface (among others) [4–7]. The
fibro-proliferative process (see Glossary) is intimately
linked to tissue remodeling, fibrosis and cancer. Because
coagulation cascade activation in general appears to be
closely linked to these processes, investigators started to
challenge the concept that the functional consequences of
FXa-induced signal transduction are simply redundant of
thrombin, dramatically boosting research linking coagu-
lation cascade activation to the progression of various
diseases. The results of these efforts have uncovered
FXa signaling as a cardinal player in fibro-proliferative
pathology and now have led to the realization that FXa is
situated on the crossroads between coagulation and sig-
naling and that this is of significance in pathophysiology.
Here, we review recent studies of the cellular processes
that FXa employs to perform this function and the implica-
tions for future therapy.
To this end, we first present an overview of the signaling
pathways induced by FXa in different cell types and sum-
marize the recent findings demonstrating the presence of
FXa in the extravascular compartment to allow a better
Review
Glossary
Angiogenesis: blood-vessel formation, which usually accompanies the growth
of malignant tissue.
Fibro-proliferative diseases: the formation of fibrous tissue in a repair or
reactive process, as opposed to formation of fibrous tissue as a normal part of
the tissue or organ.
Intima: the innermost layer of the arteries, which contains a layer of endothelial
cells that can be damaged in atherosclerosis.
Intracellular signal transduction: the transmission of signals from the
environment to the nucleus (where they ultimately affect protein synthesis)
or to the cytoskeleton (where they change cell shape and motility).
Low molecular weight heparin (LMWH): a form of heparin medication used to
prevent blood clots with less risk of hemorrhage (bleeding) than heparin with
greater molecular weight.
Mitogen: a substance, usually some form of a protein, that encourages a cell to
commence cell division, triggering mitosis.
Serine proteases: a class of protein-digesting enzymes that are characterized
by the presence of a serine residue in the active center of the enzyme.
Sphingosine 1-phosphate (S1P): a signaling molecule that, after binding to its
cell surface receptor, regulates a wide range of cellular events, including
endothelial barrier protection.
Tissue remodeling: modification of tissue shape, including reorganization of
connective tissue components (extracellular matrix and fibroblasts).
Zymogen: an inactive precursor of an enzyme secreted by living cells.
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understanding of the spatio-temporal regulation of FXa
signaling in different tissues. We next focus on the modu-
lation of PAR-2 expression in pathogenesis and the poten-
tial importance of FXa-induced signaling in the relevant
cell types. Finally, we explore the potential therapeutic
implications of targeting FXa signaling with pharmaco-
logical FXa inhibitors during pathology.
Coagulation factors are not just passive bystanders:
emergence of the signaling paradigm
In the late 1970s, during a program set to identify poten-
tial mitogenic components of serum, thrombin was shown
to be a powerful mitogen for fibroblasts and to induce
fibroblast migration in wound scratch assays via a direct
mechanism requiring thrombin’s catalytic activity and
involving receptor activation [8]. The quandary as to
how coagulation factors influenced cellular responses, a
connection that was suspected since Trousseau’s obser-
vations on the eponym syndrome (for a review about Prof.
Trousseau, see [9]), was elucidated by the identification of
the thrombin receptor PAR-1 in 1991. PAR-1 represented
a fundamentally unique subclass of the seven transmem-
brane domain protein superfamily because receptors in
the PAR subclass are activated by proteolytic cleavage
[8,10]. This mechanism is described and illustrated in Box
2. To date, four PARs (PAR-1 to -4) have been identified,
each with distinct N-terminal cleavage sites and tethered
ligand pharmacology, and thrombin signals through PAR-
1, -3 and -4, depending on the cell type and its concen-
tration [8].
The structural homology of tissue factor (TF) with the
class 2 cytokine receptor superfamily led to the hypothesis
that binding of FVIIa to TF would induce intracellular
signaling as well. Indeed, FVIIa binding to TF triggers
Box 1. Blood coagulation cascade
The blood coagulation cascade is regulated by a series of activation
reactions (Figure I). At each step a precursor protein is converted to an
active protease by cleavage of one or more peptide bonds in the
precursor molecule. Blood coagulation is triggered upon vascular
injury by exposure of the transmembrane receptor tissue factor (TF)
to factor (F)VII, which circulates mainly in its inactive zymogen form.
Small amounts of the active form of FVII (FVIIa) are also present in the
circulation. However, FVIIa displays only weak catalytic activity by
itself, and it only has full catalytic activity when in complex with TF on
a phospholipid surface. Complex formation between FVIIa and TF
results in the activation of FX either directly (extrinsic pathway) or via
activation of FIX (intrinsic pathway). FXa thus occupies a central
position in the coagulation cascade as a convergence point between
the intrinsic and extrinsic pathway. FXa subsequently converts
prothrombin to thrombin, thereby generating traces of thrombin.
These small amounts of thrombin are not sufficient to induce the
formation of a blood clot by the conversion of fibrinogen to fibrin but
do activate cofactors FV and FVIII by limited proteolysis. This
propagation step allows the generation of sufficient amounts of
thrombin, resulting in the generation of a fibrin clot.
Figure I. Schematic representation of the coagulation cascade. Tissue factor (TF) and activated FVII form a complex to activate FIX and FX. FXa converts prothrombin
(PT) into thrombin (T), which in turn cleaves fibrinogen into fibrin. In addition, thrombin also activates FVIII and FV, which are cofactors for FIXa and FXa, respectively,
and FXI, which activates FIX.
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signaling pathways (see [3] for an excellent review). The
interaction of FVIIa with TF is essential for signaling
because the binding induces a major structural change
in the serine protease domain, allowing its full activity.
Interestingly, TF–FVIIa signaling appears to be mediated
via PAR-2 activation [3]. FVII(a) also binds to endothelial
protein C receptor (EPCR), but the EPCR–FVIIa complex
neither activates PAR-1 or PAR-2 nor promotes FXa gener-
ation [11]. The functional significance and consequences of
this interaction thus remain to be defined.
Over the last decade, a plethora of studies established
the pleiotropic role of FVIIa and thrombin in health and
disease (e.g. inflammation, cancer and angiogenesis, but
also wound healing and bone development for thrombin
[3,10,12]). However, as an intermediate in the coagulation
cascade, FXa has long been considered a passive bystander
only, and consequently its role in cell biology remained
relatively unexplored. It is now clear that FXa plays a
crucial non-hemostatic role.
FXa activates both PAR-1 and PAR-2
An overwhelming amount of data suggests that FXa med-
iates intracellular signaling via activation of PAR-1 and/or
PAR-2 (dependent on cell type and concentration used;
Table 1). Strikingly, both these PARs are expressed in a
broad range of tissues: the airway, bone (osteoblasts), the
cardiovascular system (vascular smooth muscle cells
[VSMCs] and endothelium for both receptors and cardiac
myocytes for PAR-2 only), the epidermis, the immune
system, the intestine, the kidney, the nervous system
and the stomach; in addition, PAR-2 is expressed in the
pancreas and ureter [8].
Several studies determined the preferential receptor
thatmediates FXa-dependent signaling. A picture emerges
that FXa activates PAR-2 when engaged in the ternary
TF–FVIIa–FXa complex, whereas soluble FXa activates
both PAR-1 and PAR-2 (see Table 1) [13,14]. However,
the cell type and the receptor repertoire on individual cell
types is also of major importance for receptor selection by
FXa (see Table 1). Specifically, PAR activation is also
tightly regulated by heterologous receptor crosstalk. For
instance, during angiogenesis, TF exerts a negative regu-
latory control on PAR-2 signaling that is released by
phosphorylation of TF’s cytoplasmic domain [15,16]. More-
over, alternative receptors, for instance those of the sphin-
gosine 1-phosphate (S1P) receptor family, might also
modify FXa-dependent PAR activation [17].
Signaling pathways evoked by FXa: lessons from
in vitro studies
The FXa receptors PAR-1 and -2 are almost ubiquitously
expressed, and FXa signaling has been observed in many
cell types, including endothelial and epithelial cells, leu-
kocytes, fibroblasts and (V)SMCs, cancer cells, neurons
and tubular cells. The different organs and the constituting
cell types in which FXa signaling has been observed, the
receptor involved and the cellular effects are summarized
in Table 1.
Classically, after receptor activation, FXa induces phos-
phoinositides hydrolysis leading to calcium oscillation.
FXa also triggers the phosphorylation of mitogen-activated
protein kinases (MAPKs), specifically extracellular-signal
related kinase (ERK) and c-Jun N-terminal kinase (JNK)
pathways, leading to initiation of different transcriptional
Box 2. Mechanism of protease-activated receptor (PAR) activation
PAR-1 and PAR-2 are activated by proteolytic cleavage of theN-terminal
portion, which generates a new tethered ligand that binds to the second
extracellular loop of the receptor to induce transmembrane signaling to
G proteins (Figure I). ActivatedG proteins can in turn affect a substantial
network of signaling pathways, which trigger a cascade of downstream
events, thereby regulatingmany cellular functions such as cytoskeleton
reorganization and cell survival [98]. As a consequence of the
autocatalytic activation, a peptide sequence as short as six amino-acid
residues derived from the N terminus is able to activate the receptor in
the absence of protease-mediated cleavage of the N terminus. The
sequence of this agonist peptide is SFLLRN for PAR-1 and SLIGKV for
PAR-2 [8]. It is noteworthy that there are species-dependent differences
in structure and expression of PAR-1 and PAR-2. For instance, human
platelets express PAR-1 and PAR-4, whereas mouse platelets express
PAR-3 and PAR-4 but not PAR-1. Structural differences also exist
between species, especially in the sequence of the tethered ligand [98].
This is particularly relevant when comparing results obtained in animal
experiments using different species.
Figure I. Schematic representation of PAR activation. Proteolytic cleavage of the N-terminal extremity (a) generates a new tethered peptide that interacts with the
second extracellular loop of the receptor (b). (c) The agonist peptide (peptide sequence identical to the new tethered peptide; shown as gray rectangle) is able to activate
the receptor in the absence of protease-mediated cleavage of the N terminus.
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Table 1. Cellular effects of FXa signaling in various cell types
Cell type Origin FXa forma Effects Receptor
involved
Refs
Human artery endothelial cells Vessel wall Soluble Ca2+ mobilization; IL-6 release PAR-1 and PAR-2 [82]
HUVEC Vessel wall Soluble IL-6, IL-8 expression PAR-2 [83]
Coronary artery; HUVECs;
lung microvascular
Vessel wall Soluble In synergy with TNF: TF expression;
NF-kB activation; inhibition of IkBa;
phosphorylation of JNK, c-jun; inhibition




HUVEC Vessel wall Soluble IL-6, IL-8, MCP-1 production; E-selectin,
ICAM-1, VCAM-1 expression and
leucocyte adhesion
ND [84,85]
HUVEC Vessel wall Soluble and
in complex
Phosphoinositide hydrolysis PAR-2 [13]
Lung endothelial cells
derived from PAR-1/ mice






derived from PAR-1/ mice





HUVEC-C; EA.hy926 Vessel wall In complex MAPK phosphorylation; CTGF induction PAR-1 and
PAR-2
[13]
Monocytes Bloodstream ND TF expression ND [66]
Mononuclear leukocytes Bloodstream Soluble IL-6, IL-8, MCP-1 release PAR-1 [84]
Mononuclear Bloodstream Soluble CCR-2 expression; JNK phosphorylation ND [86]




Lung Soluble Ca2+ mobilization; procollagen production;
cell proliferation
PAR-1 [43]
Dermal fibroblasts Skin Soluble MCP-1, IL-6, IL-8 and VEGF expression ND [44]
Murine skin fibroblasts Skin Soluble Phosphoinositide hydrolysis PAR-1 [13]





Phosphoinositide hydrolysis; Egr-1 induction;





Muscle; skin Soluble ERK1/2 phosphorylation; fibronectin and TGF-b
production; IL-6 and MCP-1 release; SM-a-actin
and desmin expression; myofibroblast
differentiation; cell proliferation; cell migration
PAR-2 [7]
Saphenous vein SMCs Vessel wall Soluble ERK1/2 activation; MMP-2 release; cell migration;
cell proliferation
PAR-1 [55,56]
Human aortic SMCs Vessel wall Soluble ERK1/2 phosphorylation; cell proliferation PAR-2 [56]
Human coronary artery
SMCs; human aortic SMCs;
human adventitial fibroblasts





Human aortic SMCs Vessel wall Soluble bFGF release; cell proliferation PAR-1 [59]
Rabbit aortic SMCs Vessel wall Soluble Cell proliferation in synergy with serotonin GPCR [58]
Rat aortic SMCs Vessel wall Soluble NO release; relaxation PAR-2 [55,56]
Rabbit aortic SMCs Vessel wall ND Cell proliferation in synergy with epiregulin ND [57]
Human mesangial cells Kidney Soluble ERK1/2 phosphorylation; cell proliferation PAR-2 [88]





MAPK activation; cell proliferation
SaOS-2 Osteoblast In complex Ca2+ mobilization PAR-2 [90]
OVSAYO Ovarian carcinoma In complex Cell migration PAR-1 [24]
Adr-MCF-7; MDA-MB-231 Breast cancer In complex PI hydrolysis; MAPK phosphorylation;




Soluble MAPK phosphorylation; NF-kB activation;








Soluble MAPK phosphorylation; CREB activation;
Bim upregulation; cell apoptosis
PAR-1 [29]
Hippocampal neurons Central nervous
system
Soluble Protection against glutamate toxicity Other receptors
(remain to be defined)
[94,95]
Epithelial (MCDK) Kidney ND PI hydrolysis; Ca2+ mobilization PAR-2 [13]
HK-2 (human epithelial
kidney)
Kidney ND PAI-1 gene expression; Ca2+ mobilization;
TGF-b production
PAR-2 [5]
FHs 74 Int Small intestine Soluble Cell apoptosis ND [29]
Keratinocytes; HaCaT Skin Soluble and
in complex
PI hydrolysis; Egr-1 gene induction Partly PAR-2 [13]
H292 Airway (mucin-
producing cells)
Soluble Mucin and amphiregulin production Other
receptor(s)
[27]
Abbreviations: bFGF, basic endothelial growth factor; CREB, cAMP response element binding; Egr-1, early gene response-1; GPCR, G-protein-coupled receptor; ICAM-1,
intracellular adhesion molecule-1; MKP, MAPKinase phosphatase; ND, not determined; NF-kB, necrosis factor kB; PAI-1, plasminogen activator inhibitor-1; PDGF, platelet-
derived growth factor; PI, phosphatidyl inositol; TNF, tumor necrosis factor; VCAM, vascular cell adhesion molecule; VEGF, vascular endothelial growth factor.
aSoluble or in the ternary complex TF–FVIIa–FXa.
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programs (See Table 1 and Figure 1a). These programs
promote cell growth and differentiation, as well as
migration, and include the induction, among others, of
genes encoding cytokines (such as interleukin [IL]-6, IL-8
or monocyte chemotactic protein-1 [MCP-1]), receptors
(such as TF or intracellular adhesion molecule [ICAM])
and proteins of the extracellular matrix (ECM; such
as connective tissue growth factor [CTGF], collagen or
fibronectin) (Figure 1b and Table 1). However, as shown
in Figure 1b, it is noteworthy that FXa signaling is
highly specific according to the cell type. Hence, for
instance, FXa induces proliferation of fibroblasts,
VSMCs or mesangial cells but not of endothelial cells
or leukocytes.
Extravascular expression of FXa: linking in vitro
signaling data to in vivo relevance?
From the above, it is evident that FXa has significant
cellular effects in extravascular cells. However, in order
for these in vitro findings to be physiologically relevant,
FXa should be present within the tissues these cells reside
in. The most straightforward explanation for why FXa
might be present outside the bloodstream would be as
consequence of vascular injury. In this case, fibroblasts
and SMCs, which reside in the underlying ECM and con-
stitutively express TF, are exposed to circulating blood,
thereby triggering the coagulation cascade leading to the
formation of FXa and a blood clot. Strikingly, both throm-
bin and FXa are bound to, and enzymatically active in,
blood clots [2]. This is particularly relevant during coron-
ary interventions such as balloon angioplasty, stent
implantation and aortocoronary bypass, which all lead
to clot formation. FXa generated either by vascular leakage
or present and active in the clot is thus able to induce
signaling in cells of connective tissues.
Alternatively, FXa can be delivered locally by macro-
phages. As discussed in [2], these circulating white blood
cells express FXa receptors that allow them to bind FXa
generated intravascularly. After subsequent macrophage
diapedesis, FXa is released at the site of inflammation,
allowing direct signal transduction to occur [2].
A final mechanism explaining the presence of FXa away
from the bloodstream would be ectopic synthesis of FXa.
Indeed, ectopic expression of FX occurs physiologically in a
variety of tissues, including microglia, neurons, epithelial
cells of the nose, bronchus, duodenum, kidney, lung, heart
and macrophages [18–20]. During pathophysiology, FXa is
also synthesized ectopically, and this might be crucial for
the progression of disease. Duringmalignancy, extravascu-
lar blood coagulation is observed within tumor tissues in
laryngeal, colon, melanoma, renal, pancreatic and lung
carcinomas [21–23]. In agreement, ectopic expression of
FX by cancer cells was recently observed in ovarian cancer
cells [24]. This is in line with observations showing FX on
tumor cells in small lung cell carcinoma, renal cell carci-
noma and malignant melanoma [21]. Interestingly, ectopic
synthesis of FX during pathophysiology is not restricted to
cancer cells. For instance, in amurinemodel of Parkinson’s
disease [25], during experimental glomerulonephritis [26]
and in amurine model of asthma [27], ectopic expression of
FX has been observed.
Functional consequences of FXa signaling in
pathophysiology
The pleiotropic cellular effects induced by FXa suggest that
it might play a crucial role under normal circumstances as
well as during pathophysiology. Until recently, FXa’s role
remained largely unexplored. Indeed, the majority of stu-
dies aimed at elucidating the role of coagulation cascade
activation on disease progression focused on PAR-1.
Because PAR-1 was mainly recognized as a thrombin re-
ceptor, the obtained results were described to be mediated
by thrombin. It was commonly accepted that FXa-induced
PAR-1 activation would only elicit redundant effects of
thrombin.
The first recognition that FXa indeed is important
during physiology came from knockout animals showing
partial embryonic lethality. The existing view on FXa
signaling further changed when it was demonstrated that
activation of PAR-1 by different agonists triggered differ-
ential responses [28,29]. Moreover, recently PAR-2
emerged as a crucial player in tissue fibrosis and remodel-
ing. Overall, these findings led to the concept that FXa
elicits specific cellular effects that have a role in a diverse
range of pathophysiological processes.
FXa and development
Because the loss of thrombin is partially lethal in mice [30]
and because of the pleiotropic effects evoked by FXa-
induced intracellular signaling, one could speculate that
the absence of FX might be deleterious for normal de-
velopment. Indeed, homozygous FX-deficient embryos
are underrepresented among the offspring of heterozygous
breeding pairs. Only 15% of the neonates are FX-deficient,
but themajority of these neonates die within five days from
fatal bleeding. The remaining FX-deficient animals suc-
cumb shortly after birth owing to hemorrhage [31].
The phenotype of FX deficiency is similar to that of
prothrombin deficiency, whereas fibrinogen null mice do
not suffer from problems during mid-gestation, and there
is no evidence of fetal loss of these animals [31]. This
suggests that the lethality observed in thrombin- and
FXa-deficient mice is not due to insufficient coagulation
but rather to specific signaling properties. One could thus
speculate that FXa has a critical embryonic (non-hemo-
static) function at mid-gestation. If so, FXa-dependent
PAR activation might be crucial for vascular development
during embryogenesis. However, PAR-1-deficient mice are
born in the expected frequency (although suffering from
altered responses to arterial injury [32]). By contrast,
50% of PAR-2-deficient mice die either during gestation
or immediately after birth [4], suggesting that PAR-2
activation is important during vascular development.
Future studies specifically addressing the importance of
FXa-dependent PAR-2 signaling during embryogenesis
should clarify whether cellular effects of FXa are important
during normal development.
FXa in fibrosis
Over the last decade, the cellular responses induced by
coagulation factor signaling in wound healing and its
pathologic counterpart, tissue fibrosis, have attracted
growing interest. Indeed, many fibrotic disorders are
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Figure 1. The pleiotropic effects of FXa signaling in health and disease. (a) Schematic representation of FXa-mediated PAR-1 activation (soluble FXa) and/or PAR-2
activation (ternary complex). Unbroken arrows represent direct effects, whereas broken arrows show indirect effects mediated by activation of downstream mediators.
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associated with activation of the coagulation cascade. For
instance, in post-ischemic renal damage, persistent fibrin
deposition is observed [33]. Fibrin deposition accompanied
by increased thrombin and FX levels is also observed in
patients with lung fibrosis [34–36]. In keeping with these
observations, anticoagulant therapy was beneficial in a
murine model of bleomycin-induced lung fibrosis [37].
Furthermore, anticoagulant therapy (warfarin or low mol-
ecular weight heparin [LMWH]) in addition to predniso-
lone improved the survival of patients with idiopathic
pulmonary fibrosis (IPF) [38]. On a physiological level,
effects might well involve reduced activation of the
PAR–S1P receptor axis, which has very recently emerged
as a critical mediator in dendritic-cell-mediated inflam-
mation, as well as in reduced fibro-proliferative activity.
The relative inefficiency of anti-inflammatory drugs in
dealing with fibrosis suggests that the latter is especially
important.
At themolecular level, wound healing and fibrosis share
similar mechanisms, including fibroblast migration, pro-
liferation and subsequent differentiation into myofibro-
blasts that typically express a-smooth muscle (SM) actin
[39]. Next, these myofibroblasts, which show enhanced
metabolic activity compared to the activity of undifferen-
tiated fibroblasts, synthesize components of the new ECM,
thereby restoring the structure and function of injured
tissues [40] (Figure 2). During the pathogenesis of fibrosis,
these tightly regulated mechanisms escape self-limiting
control, and fibrosis is considered as an aberrant wound
healing response [34,40] (Figure 2). Exacerbation of fibro-
blast or SMC migration and proliferation and accumu-
lation of myofibroblasts, which are associated with
excessive ECM protein biosynthesis and organ-destructive
remodeling, all actively participate in the progression of
fibrotic lesions [39].
Recent data indicate that PAR-2 contributes to tissue
fibrosis. For instance, high expression of pulmonary PAR-2
is observed in acute and chronic lung injury, suggesting
that PAR-2 participates in inflammation and fibro-prolifer-
ation during lung fibrosis [41]. In renal interstitial fibrosis,
a-SM actin and PAR-2 expression is correlated [42],
whereas PAR-2 expression is increased in biopsies of
patients with IgA nephropathy [5]. Finally, both FXa
and PAR-2 are overexpressed in the kidney of rats sub-
jected to experimental glomerulonephritis. Importantly,
specific FXa inhibition is beneficial in rat models of mesan-
gioproliferative glomerulonephritis, partly because fibrin
deposition is reduced [26].
In vitro data support a crucial role for FXa-dependent
signaling in fibrosis via PAR-2 activation. As shown in
Table 1, FXa signals in cells of the connective tissuemainly
by PAR-2 activation. In pancreatic stellate cells, PAR-2
activation (by trypsin) increases proliferation and collagen
production, thereby contributing to fibrosis [6]. However,
the effect of FXa has not been determined on stellate cells.
Activation of proximal tubular cells by FXa leads to PAR-2-
dependent expression of PAI-1 and transforming growth
factor-b (TGF-b) [5]. FXa induces mitogenic response in
fibroblasts either via PAR-1 or PAR-2 [7,43]. Moreover,
FXa is, in a PAR-2-dependent manner, a powerful che-
moattractant for fibroblasts and contributes to fibroblast
differentiation into myofibroblasts [7]. Furthermore, FXa
enhances the production of IL-6, IL-8 and MCP-1 [7,44],
which are known chemoattractants [40] (Figure 2). FXa
(b) Effect of FXa-induced signaling in the indicated cell types on inflammation, receptor expression, cell function and extracellular matrix and growth factor production.
Next to the different cell types, the originating tissue and/or organ is indicated. The main cellular receptors involved in FXa-induced signal transduction are indicated for
each individual cell type. Abbreviations: CCR-2, chemokine (C-C) motif receptor 2; CTGF, connective tissue growth factor; FGF, fibroblast growth factor; ICAM, intracellular
adhesion molecule; IP3R, inositol-1,4,5 triphosphate receptor; JNK1/2, c-Jun N-terminal kinase 1/2; MAPK, mitogen-activated protein kinase; MCP-1, monocyte chemotactic
protein-1; PDGF, platelet-derived growth factor; PI, phosphatidyl inositol; PKC, protein kinase C; PLCb, phospholipase Cb; TGF-b, transforming growth factor-b; VCAM,
vascular cell adhesion molecule; VEGF, vascular endothelial growth factor.
Figure 2. Schematic overview on the role of FXa-induced signaling in tissue remodeling and fibrosis. Upon vascular injury (or during inflammation or fibrosis), activation of
the coagulation cascade leads to FXa generation. FXa acts as a chemoattractant for fibroblasts and/or smooth muscle cells. Subsequently, FXa induces proliferation,
extracellular matrix (ECM) metabolism, cytokine and growth factor production and differentiation of fibroblasts into myofibroblasts. Through its procoagulant effect, FXa
converts prothrombin into thrombin, which itself has fibro-proliferative effects.
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also induces the secretion of fibronectin, collagen and TGF-
b [7,43], the latter being the most potent pro-fibrotic
cytokine [45].
FXa in restenosis, intimal hyperplasia and
atherosclerosis
Vascular remodeling, during restenosis, intimal hyperpla-
sia, vein graft remodeling and atherogenesis, leads to
narrowing of the lumen and represents a common theme
of many cardiovascular abnormalities. Interestingly, it
shares many features with fibrosis, for instance cell inva-
sion, proliferation and exacerbated ECM deposition
(Figure 2). Moreover, accumulation of myofibroblasts has
a crucial role in vascular remodeling [46–48].
Another common feature of fibrosis is that activation of
the coagulation cascade is frequently observed in patients
suffering from vascular disease. For instance, fibrin depo-
sition is observed during different stages of atherosclerosis,
whereas restenosis after angioplasty occurs more fre-
quently in patients with thrombus formation (containing
active FXa [49]) at the site of angioplasty [50]. However,
reduction of thrombus formation without inhibiting coagu-
lation factors does not inhibit intimal hyperplasia after
balloon injury in pig coronary arteries [51,52], emphasizing
a potential non-hemostatic role for coagulation factors in
restenosis.
To date, the contribution of PAR-2 in vascular remodel-
ing remains elusive, but this role might well be important.
In a rat model of balloon-injured carotid artery, PAR-2 was
upregulated in medial SMCs, proliferating adventitial
myofibroblasts and SMCs of the neointima [4]. Moreover,
PAR-2 expression is enhanced in human coronary athero-
sclerotic lesions, suggesting that PAR-2-dependent cellu-
lar trafficking might be one of the regulatory signaling
responses to vascular injury [53]. Finally, in a murine
model of vascular injury, neointima formation was mark-
edly reduced in PAR-2-deficient mice [54]. Obviously,
further studies are warranted to explore this direction.
Several findings support the hypothesis that FXa-de-
pendent signaling is an important mediator in tissue
remodeling. FXa promotes SMC proliferation and
migration [55–59] and differentiation of fibroblasts into
myofibroblasts (as indicated before) [7]. Importantly, inhi-
bition of FXa reduces VSMC proliferation [56] and rest-
enosis after balloon angioplasty [56,60–63]. Interestingly,
FXa levels remain elevated at the site of injury for one
week in a pig model of overstretch-injured coronary
arteries [64], thereby allowing sustained PAR-2 activation.
In addition to FXa-dependent PAR activation, FXa de-
pendent TF expression by endothelial cells, as well as
SMCs and monocytes [65–68], might be deleterious in
the progression of vascular remodeling. Indeed, in athero-
sclerotic plaques TF levels are increased, leading to FXa
and thrombin formation but also to direct cellular effects
[69] such as SMC proliferation and subsequent athero-
sclerotic plaque growth.
FXa in airway remodeling
As a variation on the theme of FX contributing to tissue
remodeling, the architecture of the airway seems to be
under the control of FX. A recent landmark study showed
that FXa modulates airway remodeling in a murine model
of ovalbumin-induced asthma. FXa accumulated in the
lung of asthmatic mice, and fondaparinux treatment
(specifically targeting FXa) attenuated airway hyperre-
sponsiveness, decreased the thickness of the mucosal layer
and reduced collagen and a-SM actin deposition in the lung
[27]. Moreover, in vitro investigations indicated that FXa
enhanced mucin production. Hence, like in fibrosis and
vascular remodeling, an exaggerated cellular response
induced by FXa plays an important part in aberrant
morphogenesis.
FXa in angiogenesis
As already discussed, myofibroblasts are key cells during
tissue remodeling, but they also control angiogenesis
either during fibrosis or tumor growth [70–72]. During
pathological angiogenesis, activation of the coagulation
cascade is frequently observed [12,73]. FXa has no direct
effect on endothelial cell proliferation, migration or tube
formation, ruling out a direct role in angiogenesis [29,74].
However, several lines of evidence suggest that FXa has an
indirect role on angiogenesis during fibrosis and/or cancer.
FXa-stimulated fibroblasts secrete vascular endothelial
growth factor (VEGF) [44] and latent matrix metallopro-
teinases (MMPs). Furthermore, FXa activates these
MMPs, which might enhance tissue remodeling during
angiogenesis [75]. Finally, differentiation of fibroblasts
intomyofibroblasts induced by FXa [7]might also be highly
relevant in this setting. Overall, a picture emerges in
which FXa-dependent signaling in fibroblasts not only
affects fibrosis but might also be crucial for angiogenesis
in the context of both fibrotic disease and tumor pro-
gression.
FXa in cancer
In metastasis, FXa is most often characterized as a hemo-
static agent that induces formation of thrombin, the pro-
metastatic properties of which are well known [12]. In
addition to thrombin formation, FXa induces direct cellu-
lar effects in cancer cells (Table 1); however, the contri-
bution of FXa-induced signaling to tumor metastasis has
not yet been resolved. Interestingly, clinical trials in cancer
patients show that LMWH treatment (which preferen-
tially, although non-specifically, targets FXa activity) pro-
longs overall survival [76–78]. This provides strong
evidence that FXa has an essential role during tumor
growth and/or metastasis. However, future studies should
address whether FXa-induced signaling indeed plays a role
in cancer biology independently of thrombin generation.
Targeting FXa (Table 2)
From the above, it is evident that coagulation-factor-
induced signaling can contribute to vascular remodeling,
asthma, fibrosis and cancer. From a clinical perspective,
FXa seems to be an attractive therapeutic target based on
the knowledge gained so far on the amplified nature of
coagulation factor interactions and fibrin formation [79].
As a consequence, FXa inhibitors are more effective at
smaller doses than anticoagulants targeting thrombin.
Moreover, it is evident that blocking the coagulation cas-
cade upstream of thrombin formation is the most efficient
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method due to the incomplete suppression of thrombin
formation by direct thrombin inhibitors. Of the upstream
targets, FXa seems preferential because it is positioned at
the crossroad between intrinsic and extrinsic pathways of
the coagulation cascade.
The potential superiority of specific FXa inhibitors over
traditional, multi-targeted anticoagulants is underscored
by the fact that vitamin K antagonists do not prolong
survival in cancer patients [80]. Interestingly, clinical
trials have suggested a clinically relevant effect of LMWH,
which showed high anti-FXa activity but low anti-thrombin
activity [81]. Future clinical trials using specific FXa inhibi-
tors should prove or refute the concept that specific FXa
inhibitors are advantageous in this clinical setting. We
therefore eagerly await the results of ongoing clinical
trials in which fondaparinux (the first approved specific
FXa inhibitor) is used in non-small-cell lung cancer
patients (http://clinicaltrials.gov; identifier NCT00476216)
or patients with ovarian cancer (http://clinicaltrials.gov;
identifier NCT00659399). In agreement with these cancer
data, LMWH treatment of IPF patients improved survival
(as already indicated) [38].
Because the development of specific FXa inhibitors only
began recently (and only some have been approved for
clinical use), no clinical trials using such drugs have been
completed. In preclinical animal models, however, specific
FXa inhibitors have been used (Table 2). In animal models
of glomerulonephritis, restenosis, asthma, fibrosarcoma
and T-cell lymphoma, specific FXa inhibitors improved
the outcome of the disease, thereby further supporting a
role of FXa in pathogenesis.
There are currently several novel specific FXa inhibitors
in different phases of clinical testing for efficacy in cardi-
ovascular disease. If these compounds indeed prove effi-
cient, this would have therapeutic implications for diseases
in which progression is associated with activation of the
coagulation cascade.
Concluding remarks
Because of the pleiotropic cellular effects evoked by FXa in
both health and disease, it is evident that FXa is more than
a passive bystander in the coagulation cascade. In fact,
FXa might orchestrate crucial processes during tissue
remodeling, fibrosis, cancer and pathological angiogenesis.
Indeed, targeting FXa in animal models of restenosis,
asthma and cancer is beneficial, which underscores the
importance of FXa in pathology. However, it is difficult to
address the question of whether FXa inhibition is
beneficial due to inhibition of signaling or inhibition of
Table 2. Preclinical studies and clinical trials of FXa inhibitors
Disease Clinical trial or animal model FXa inhibitora Outcome Refs
Idiopathic pulmonary
fibrosis
Clinical trial LMWH (dalteparin) Reduced mortality [38]




Clinical trial LMWH (nadroparin) Reduced mortality [77]
Pancreatic cancer Clinical trialb LMWH (nadroparin) Reduced mortality [78]
Advanced malignancy Clinical trial LMWH (dalteparin) Reduced mortality [96]
Glomerulonephritis Rat model of mesangioproliferative DX-9065a Reduction of glomerular cell proliferation,





Rat model of injured vascular
endothelium
DX-9065a Decreased SMC proliferation [56]
Restenosis after balloon
angioplasty
Atherosclerotic rabbit model Recombinant tick
anticoagulant peptide;
recombinant antistasin
Inhibition of luminal diameter reduction [60]
Restenosis after balloon
angioplasty
Atherosclerotic rabbit model Recombinant tick
anticoagulant peptide;
Hirudin
Inhibition of luminal diameter reduction [61]
Asthma Murine ovalbumin model of asthma Fondaparinux Inhibition of airway hyperresponsiveness,
decreased the thickness of the mucosal





Murine model of T-cell lymphoma;
murine model of lung metastasis
of a human fibrosarcoma
WX-FX4 Reduction of metastasis [97]
aNote that LMWHs (as used in the clinical setting) are not specific FXa inhibitors because they also have a low thrombin inhibitory effect.
bThis study is a non-randomized study.
Box 3. Outstanding questions
 What determines whether FXa signals through PAR-1 and/or PAR-
2?
 Is FXa-dependent signal transduction important during embry-
ogenesis and does it explain the (partial) embryonic lethality of
FXa-deficient mice?
 What is the role of FXa-induced PAR-2 cleavage in fibrotic
disease?
 What is the relevance of FXa-induced signaling in cancer biology?
 Are the cellular effects of FXa in pathophysiology specific or
redundant to thrombin-induced signaling?
 Are effects of FXa in inflammatory processes (partially) dependent
on modulation of the PAR–S1P receptor axis?
 What is the mechanism that confers specificity to individual
coagulation factors?
 What is the role of receptor crosstalk in FXa-dependent signaling?
 Could specific FXa inhibitors have the potential to be clinically
superior to multitargeted anticoagulants in fibrosis, tissue remo-
deling and cancer?
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thrombin generation. Further understanding of the cellu-
lar program induced by FXa, the receptor(s) involved and
the consequences for pathophysiology is a major task lying
ahead of us. Indeed, even though recent observations have
highlighted the biological importance of FXa signaling in
health and disease, several outstanding issues remain
unresolved (Box 3). Most importantly, it is yet to be deter-
mined whether specific factors, such as FVIIa, FXa and
thrombin, fulfil specific or redundant roles in pathophy-
siology and what the mechanism that confers specificity
might be. Indeed, one could imagine the exploitation of
such effects for pharmacological intervention in specific
pathological contexts. Furthermore, the clinical relevance
of FXa inhibitors would need to be investigated in clinical
trials. Nevertheless, it is possible that when we have a
better understanding of the cellular effects induced by FXa
and the pathophysiological consequences, novel FXa
inhibitors specifically targeting its signaling properties
might emerge as therapeutic options in a broad range of
fatal diseases.
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Coagulation Factor (F)Xa is a serine protease that plays a crucial role during blood
coagulation by converting prothrombin into active thrombin. Recently, however, it emerged
that besides this role in coagulation, FXa induces intracellular signaling leading to different
cellular effects. Here, we show that coagulation factor (F)Xa drives tumor cells of epithelial
origin, but not endothelial cells or monocytes, into apoptosis, whereas it even enhances
fibroblast survival. FXa signals through the protease activated receptor (PAR)-1 to activate
extracellular-signal regulated kinase (ERK) 1/2 and p38. This activation is associated with
phosphorylation of th transcription factor CREB, and in tumor cells with up-regulation of
the BH3-only pro-apoptotic protein Bim, leading to caspase-3 cleavage, themain hallmark of
apoptosis. Transfection of tumor cells with dominant negative forms of CREB or siRNA for
either PAR-1, Bim, ERK1 and/or p38 inhibited the pro-apoptotic effect of FXa. In fibroblasts,
FXa-induced PAR-1 activation leads to down-regulation of Bim and pre-treatment with PAR-
1 or Bim siRNA abolishes proliferation. We thus provide evidence that beyond its role in
blood coagulation, FXa plays a key role in cellular processes in which Bim is the central
player in determining cell survival.








Coagulation factor (F)X is a vitamin-K-dependant plasma
protein that plays a key role in blood coagulation. Upon
vascular injury, FVII forms a 1:1 stoichiometric complex with
its cofactor, the cell surface receptor tissue factor (TF). After
autocatalytic activation, activated FVII (FVIIa) converts FX into
its active form, FXa. In the coagulation cascade, FXa occupies a
central position as a convergence point between the intrinsic
and extrinsic coagulation pathways, and converts prothrom-
bin into thrombin [1]. Beside its well known role as a co-
agulation factor, FXa, like the other serine-proteases FVIIa and
thrombin, induces intracellular signal transduction [2].
A family of G-protein-coupled receptors, the proteases-
activated receptors (PARs), that are activated by proteolytic
cleavage rather than ligand binding, has been identified in
recent years [3]. PARs are widely distributed in a variety of cell
types, including circulating blood cells, endothelial and
vascular smooth muscle cells, as well as in cells constituting
the nervous system, the gastrointestinal tract and the res-
piratory system. Among the 4 currently known PARs, PAR-1,-3
and-4 are cleaved by thrombin. PAR-2 is a target for cleavage
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by the TF/FVIIa complex, whereas FXa can activate both PAR-1
and PAR-2 [4,5]. Proteolytic cleavage of either receptor exposes
a new N-terminus that binds to the body of the receptor to
induce transmembrane signaling to G proteins. The activated
G proteins in turn impact on a substantial network of signaling
pathways, which trigger a cascade of downstream events,
thereby regulating many cellular functions like cytoskeleton
reorganization and cell survival [3]. For instance, in neuronal
and epithelial cells, as well as tumor cells, activation of PAR-1
induces apoptosis [6]. G-protein-dependent signaling path-
ways regulated through activation of PARs turn on the
migratory and invasive program in tumor cells [3,7], and
PAR-1 over-expression is correlated with the invasive proper-
ties of various human cancers [8]. Overall, these data provide
compelling evidence for a link between PAR-induced signaling
and cancer progression.
As FXa induces signal transduction through PARs, it is
commonly accepted that FXa might modulate tumor cell
growth, invasion and metastasis [9]. Indeed, FXa elicits
numerous cellular events, especially through activation of
PAR-1. FXa is mitogenic and induces proliferation of fibro-
blasts, smooth muscle cells and mesenchymal cells [10–12]. It
provokes expression of adhesion molecules on monocytes
[13], it induces NK-κB and Cyr61 gene expression in HeLa cells
and up-regulates the early growth response gene-1 in HaCaT
cells [4,5]. The contribution of these events to pathophysio-
logical processes has only just begun to unfold. For instance,
mitogenic effects exerted by FXa in aortic smoothmuscle cells
may contribute to intimal hyperplasia in arterial restenosis
[14].
A recent study using Baby Hamster Kidney (BHK) cells
transfected with TF showed that FXa induces prolonged
phosphorylation of p42/p44 MAPK and Phosphatidylinosi-
tide-3-(OH) kinase pathways thereby enhancing cell survival
suggesting that FXa facilitates metastasis [15]. However, as
BHK cells are fibroblasts which are not tumorigenic by
nature, extrapolation of these data to human tumor biology
in order to understand the mechanism of metastasis remains
speculative. Confirmation of the anti-apoptotic effect of FXa
in tumor cells and/or stromal cells surrounding tumors
seems essential for establishing the actual role of FXa in
tumor biology. Therefore, we determined the effect of FXa on
cell growth and survival using different human cancer cell
lines.
Material and methods
Cell culture and treatment
MDA-MB-231, MFC-7, SW-480, DLD-1, HT-29, A549, B16F10,
HL-60 and HEK293 cells were purchased from ATCC and
maintained in DMEM supplemented with 10% FCS. The
normal small intestine epithelial cell line FHs Int 74 was
purchased from ATCC and maintained in Hybri-Care medi-
um supplemented with 10% FCS and 30 ng/mL EGF
according to the manufacturer's recommendations. The
origin of the cancer cell lines used in this study, as well
as the genetic lesions, is indicated in Table 1. Human
monocytes and leukocytes were isolated from whole blood
using Ficoll reagent according to the manufacturer's recom-
mendations. Human Umbilical Vein Endothelial Cells
(HUVECs) were purchased from ATCC and maintained in
EBM-2 medium supplemented with 10% FCS and containing
VEGF, human fibroblast growth factor-B, human epidermal
growth factor, R3-insulin like growth factor-1, heparin,
hydrocortisone and ascorbate (EGM-2 SingleQuots, BioWhit-
taker Takara Shuzo).
Cell survival assay
Cells (104) plated onto 96-well plates in DMEM supplemented
with 1% FCSwere pretreated as indicated in the figure legends.
Cell survival was determined using MTT assays as described
previously [15].
Anoikis
To induce anoikis, cells were plated in DMEM supplemented
with 1% FCS on culture plates coated with polyHEMA (10 mg/
mL). At the indicated time points, cells were harvested and
viability was determined by MTT assay.
Immunoblotting
Cells were pre-treated for 60 min with either 20 μM PD98059,
20 μM SB203580 (both Promega, Madison), Hirudin (25 U/mL;
Calbiochem, Germany) or 200 nM TAP (kindly provided by Dr.
Vlasuk, Corvas International, San Diego, CA). If indicated, cells
Table 1 – Cell lines used in his study and their origin
Designation Organ Disease Genetic lesions according to ATCCa References
MCF-7 Mammary gland, breast Adenocarcinoma p53− [51]
MDA-MB-231 Mammary gland, breast Adenocarcinoma p53+ [52]
B16F10 Skin Melanoma p53+ [53]
HEK-293 Kidney N/A p53− [54]
SW-480 Colon Colo-rectal adenocarcinoma myc+; myb+; ras+; fos+; sis+; p53+; abl−; ros−; src− [55]
DLD-1 Colon Colo-rectal adenocarcinoma myc+; myb+; ras+; fos+; sis+; p53+; abl−; ros−; src− [56]
HT-29 Colon Colo-rectal adenocarcinoma myc+; ras+; myb+; fos+; sis+; p53+; abl−; ros−; src− [55]
A-549 Lung Carcinoma p53− [57]
HL-60 Peripheral blood Acute promyelocytic leukemia myc+ [58]
FHs 74 Int Small intestine N/A N/A [59]
a American Type Culture Collection.
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were pre-treated with 2 μg PAR-1 H-111 blocking antibody
(Santa Cruz Biotechnologies, CA) for 1 h. Next (unless stated
otherwise), cells were stimulated with 0.75 U/mL FXa (Kordia,
the Netherlands) or PBS. To determine the effect of receptor
desensitization on ERK1/2 phosphorylation, cells werewashed
twice with PBS, pretreated with FXa (0.75 U/mL) or Thrombin
(1U/mL; Kordia, the Netherlands) in serum-free conditions for
90 min. Phospho-ERK 1/2, phospho-p38, phospho-JNK, phos-
pho-CREB, Bim and cleaved-caspase 3 antibodies were from
Cell Signaling Technology (Beverly, MA); whereas β-actin and
PAR-1 antibodies were from Santa Cruz Biotechnologies. Cell
extracts were prepared and subjected toWestern blot analysis
as described previously [15].
DAPI staining
Cells at 20–30% of confluence, grown on coverslips and treated
with 0.75U FXa or PBS for 24 h, were washed with PBS, and
fixedwith 3.7% formaldehyde for 20min at room temperature.
After fixation, cells were permeabilized in PBS/0.1% Triton X-
100 (PBS-T) supplemented with 10% FCS for 1 h. Cell nuclei
were stainedwith DAPI (200 ng/mL; Roche) in PBS-T for 30min.
Next, cells were washed and mounted in Mowiol/DABCO
aqueous mounting medium (Vector Laboratories, Burlingame,
CA). Stained nuclei were visualized and photographed using
an epifluorescence microscope Leica DMRA (Wetzlar, Ger-
many). Images were captured on a cooled charge coupled
camera (KX Series, Apogee, Auburn, CA) operated by imagePro
Plus software (Media Cybernetics, Silver Spring, MD).
CREB vectors and siRNA
pCMV-CREB, pCMV-KCREB and pCMV-S133A expression
constructs were purchased from Clontech (BD Biosciences,
USA). Pre-designed human control (scrambled sequence not
leading to the specific degradation of any of our targets) and
p38-siRNA (signal silence pool siRNA kit) was purchased
from Cell Signaling. Pre-designed human ERK1, PAR-1
(reference ID #4377 and #158457) and PAR-2-siRNAs (refer-
ence #1960) were obtained from Ambion Inc (Austin, TX).
Pre-designed Bim siRNA was purchased from Santa Cruz
Biotechnologies.
Transfections
DNA transfections were performed using Effectene (Qiagen,
Hilden, Germany) according to the manufacturers' protocol.
For transfections in 6-wells plates, 2 μg DNA was used at a 1:6
ratio of DNA/Effectene. Cells were incubated with transfection
complexes for 16 h, after which fresh medium was added for
6 h preceding further experimentation. Transfections of pre-
designed siRNAs were performed using RNAiFect (Qiagen,
Hilden, Germany). For transfections in 6-wells plates, 0.6 μg
siRNA was used at a 1:3 ratio of RNA/RNAiFect.
RNA isolation and MLPA procedure
After 0–8 h of the indicated treatment, total RNA was isolated
using Trizol (Invitrogen, Carlsbad, CA) according to the
manufacturer's recommendation. Next, 100 ng total RNA
was used for theMLPA reaction as described previously [16,17].
Statistical analysis
The experiments were repeated independently as indicated in
the corresponding section. Statistical analysis was performed
with Graph Prism using two-tailed Student's t tests.
Results
MCF-7 and MDA-MB-231 human breast carcinoma cell lines
were incubated with different concentrations of FXa for 24 h.
Surprisingly, FXa inhibited cell survival (Fig. 1A), with optimal
inhibitionobservedat 0.75U/mL (inhibitionof survival by 38.3±
4% in MCF-7 (P<0.0001) and 45.6±3.8% in MDA-MB-231 cells
(P=0.0002). FXa-mediated inhibition of survival was specific
since Tick Anticoagulant Peptide (TAP; FXa inhibitor) but not
Hirudin (thrombin inhibitor) abolished the FXa effect (Fig. 1B).
To establishwhether FXa specifically inhibits survival of breast
cancer cells or whether FXa exerts its effect also in other tumor
cell lines, we selected colon tumor cell lines, HT-29, SW480 and
DLD-1, one lung tumor cell line A549, a murine melanoma cell
line B16F10 and the epithelial cell line HEK293. Indeed, FXa
impaired cell survival of all these cell lines to a similar extent as
it impaired survival of the breast cancer cell lines (Fig. 1C).
Inhibition of survivalwas dose-dependent and FXa-specific for
all cell lines (datanot shown). Primary tumor cells arenormally
outsideof the vasculatureunless they enter the bloodstreamat
the early stage of metastasis to travel to distant organs. To
confirm that FXa inhibits the growth and survival of circulating
tumor cells without affecting cells constitutively in contact
with blood (and thus FXa) under normal conditions or upon
vascular injury, the effect of FXa on monocytes, endothelial
cells and fibroblasts was assessed. As shown in Fig. 1C, FXa did
not impairmonocyte and/or endothelial cell survival and even
enhanced fibroblast survival suggesting that FXa specifically
inhibits tumor cell survival. Alternatively, based on the
epithelial origin of the selected tumor cells, one could argue
that FXa exerts a specific inhibitory effect on epithelial cells. To
prove or refute this hypothesis, non tumorigenic epithelial
cells fromnormal small intestine (FHs 74 Int)were treatedwith
FXa. Reciprocally, the same experiment was conducted using
HL-60 cells, which are non-epithelial promyelocytic cells
derived from acute promyelocytic leukemia (see Table 1). As
shown in Fig. 1C, FXa impaired the survival of the FHs 74 Int
cells to a similar extent as that observed for the tumor cells.
Furthermore, FXa had no effect on the survival of the non-
epithelial HL-60 cell line, suggesting that FXa indeed specifi-
cally targets epithelial (or epithelial-derived) cells.
Tumor cells lose matrix attachment during metastasis and
as a consequence undergo anoikis [18]. We therefore analyzed
the effect of FXa on the proliferation of cells grown in
suspension. As shown in Fig. 1D, FXa impaired cell survival
by approximately 35% (at t=24 h).
The morphological characteristics accompanying FXa-
mediated inhibition of survival, i.e. gradually rounding,
detachment and shrinkage of the cells (Fig. 1E), were sug-
gestive of apoptosis. These observations prompted us to
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Fig. 1 – FXa specifically impairs the growth of epithelial cells. (A) MCF-7 andMDA-MB-231 cells were incubated for 24 hwith the
indicated concentration of FXa, or with PBS (control). (B) FXa effects on MCF-7 cell survival were specific and did not rely upon
downstream thrombin formation, as the effect was almost completely abolished by TAP but not by Hirudin. (C) FXa (0.75 U/mL)
specifically inhibited the growth of normal (FHs 74 Int) and tumor cells with epithelial phenotype, but did not affect the growth
of monocytes and endothelial cells. In contrast, FXa enhanced the growth of fibroblasts. (D) FXa enhanced anoikis in
MDA-MB-231 and B16F10 cells. (E) Addition of FXa caused cells to become rounded, detached, shrunk in size and vesiculated,
which are hallmarks of apoptosis. Shown are untreated (control) and FXa-treated cells 24 h after the addition of FXa or PBS. Note
the difference in confluence between treated versus untreated cells, confirming impaired cell survival by FXa. The four panels
on the right show details (magnification 400×) of individual cells which allow a better appreciation of morphological changes
induced by FXa. Results of panels A to D represent the mean±SEM of experiments performed twice in octuplicate. ***P<0.0001,
**P<0.001.
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investigate the involvement of apoptosis in FXa-induced
inhibition of cell survival. To this end, MCF-7 and MDA-MB-
231 cells were treatedwith FXa to assess caspase-3 cleavage as
this is the central executioner caspase in apoptosis [19]. In both
cell lines, FXa treatment enhanced caspase-3 activation,which
was most prominent after 48 h treatment (Fig. 2A for MCF-7
cells, data for MDA-MB-231 not shown). To confirm the actual
involvement of apoptosis in FXa-induced inhibition of cell
survival, both cell lines were pre-treated with zVAD, a broad-
range peptide inhibitor of caspases, but a poor inhibitor of non-
caspase proteases, which completely abrogated the FXa effect
(Fig. 2B). Nuclear staining using the DNA-binding dye DAPI
showed that FXa inducedchromatin condensationandnuclear
fragmentationwhicharehallmarksof apoptosis [20] (Fig. 2C for
MCF-7, data not shown for MDA-MB-231). Similar experiments
performed in fibroblasts did not show differences between
control and FXa-treated cells (data not shown).
The cellular effects described for FXa, so far, are mediated
through the activation of PAR-1 or -2 [2,14]. To establish the
involvement of these PARs in FXa-induced apoptosis, MCF-7
and MDA-MB-231 cell were transfected with PAR-1 or PAR-2
siRNA. As shown in Fig. 3A, siRNA transfection was efficient
and specific. Knocking-down PAR-1 expression almost com-
pletely abolished FXa-induced apoptosis, whereas PAR-2
siRNA treatment had no effect (Fig. 3B for MCF-7, data not
shown for MDA-MB-231). These data indicate that FXa induces
apoptosis via PAR-1 cleavage and rule out the involvement of
PAR-2. To identify the intracellular pathway downstream of
PAR-1 underlying FXa-induced apoptosis, we analyzed phos-
phorylation of themajorMAPKinase proteins and showed that
FXa specifically leads to transient ERK1/2 and p38, but not
JNK1/2, phosphorylation (Fig. 3D forMCF-7, data not shown for
MDA-MB-231). FXa-induced phosphorylation of both kinases
was dose-dependent (data not shown) and specific (Fig. 3D) as
phosphorylation was blocked by TAP but not hirudin. Pre-
treatment with a PAR-1 blocking antibody reduced ERK1/2 and
p38 phosphorylation by nearly 70% (Fig. 3E). Similarly,
transfection with PAR-1 siRNA abolished phosphorylation of
these kinases (data not shown). Transfecting cells with ERK1
or p38 siRNA both partially inhibited FXa-induced apoptosis
(Fig. 3B for MCF-7, data not shown for MDA-MB-231), implying
the involvement of both these pathways in FXa-induced
apoptosis.
Following PAR-1 activation, thrombin is known to cause a
rapid and transient desensitization of PAR-1 signaling [21]. We
therefore evaluated FXa-induced ERK1/2 phosphorylation in
Fig. 2 – FXa induces apoptosis in tumor cells. (A) FXa induced caspase-3 cleavage, as determined on Western Blot. Equal
loading was verified using an β-actin antibody. Data are the mean±SEM (n=3). (B) FXa effects were abolished by pre-treatment
with zVADfmk. Depicted is the mean±SEM of experiments performed twice in octuplicate. (C) FXa induced chromatin
condensation as evident from enhanced fixation of DAPI in the nucleus of FXa-treated cells. The pictures were taken 24 h after
the addition of 0.75U FXa or PBS. ***P<0.0001.
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Fig. 3 – FXa-induced apoptosis involves PAR-1-mediated ERK- and p38-activation. (A) siRNA transfections efficiently
knock-down the targeted protein (top panels), whereas it did not affect the expression of non-targeted proteins (bottom
panel). (B) Involvement of PAR-1, ERK and p38 pathways in FXa-mediated apoptosis. FXa treatment of cells transfected with
control or PAR-2 siRNA induced apoptosis after 24 h, whereas in cells transfected with PAR-1-, p38- or ERK1-siRNA, the
effects of FXa were abolished. Depicted is the mean±SEM of experiments performed twice in octuplicate. (C) MCF-7 cells
were incubated for 0–48 h with the indicated concentration of thrombin, or with PBS (control). (D) FXa induced p38 and
ERK1/2 phosphorylation as shown by Western blot analysis using actin and total ERK1/2 as loading control (left panel).
FXa-induced phosphorylation is specific as it was reverted by TAP but not hirudin (right panel). The activity of the p38
(SB203580) and ERK1/2 (PD098059) inhibitors is indicated on the right part of this panel. (E ) Inhibition of PAR-1 activation
using a blocking antibody impaired FXa-induced phosphorylation of ERK1/2. (F) In cells pre-treated with Thrombin (1 U/mL)
or FXa (0.75 U/mL), the transient ERK1/2 phosphorylation induced by subsequent FXa treatment was abolished. Data shown
are phosphorylated ERK1/2 raw volumes divided by β-actin raw volumes (mean±SEM; n=3).
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thrombin-desensitized tumor cells. As shown in Fig. 3F for
MCF-7 cells, tumor cells pretreated with thrombin failed to
respond to FXa with respect to ERK1/2 phosphorylation.
Furthermore, FXa desensitized PAR-1 in amanner reminiscent
of thrombin. The fact that thrombin and FXa desensitization
of PAR-1 blocks FXa-induced phosphorylation of ERK1/2
confirms the involvement of PAR-1 in FXa-mediated signal
transduction.
To confirm that PAR-1 cleavage can drive cells into apop-
tosis, we incubated MCF-7 and MDA-MB-231 cells with 1 and
10 U/mL (10 and 100 nM) thrombin, a specific PAR-1 agonist
that cannot activate PAR-2 [22,23]). As shown in Fig. 3C for
MCF-7 cells, thrombin indeed impaired cell survival thereby
confirming previous data [24–26] showing the involvement of
PAR-1 in apoptosis.
CREB regulates the transcription of a range of pro-and/or
anti-apoptotic targeted genes [27] making it a likely candi-
date player in FXa-induced apoptosis. Indeed, FXa induced
CREB phosphorylation, and the effect was specific since
pretreatment with TAP but not hirudin prevented CREB
phosphorylation (Fig. 4A). Phosphorylation was partially
inhibited by pretreatment with U0126, an ERK-1 and ERK-2
inhibitor, PD098059, an inhibitor specific for MEK1/2 and
SB203580, which inhibits p38 phosphorylation, suggesting
that both pathways are involved in CREB phosphorylation
(the activity of these inhibitors was assessed using Western
blot analysis as indicted in Fig. 3D). To assess the relevance of
CREB phosphorylation for FXa induced-apoptosis, cells were
transfected with vectors either expressing wild-type CREB, or
expressing dominant negative mutants (KCREB or CREB
S133A). KCREB forms an inactive dimer with endogenous
CREB and blocks its ability to bind to its DNA binding
sequence, whereas CREB S133A contains a serine to alanine
mutation at position 133 that prevents its phosphorylation
and thus its ability to initiate target gene transcription. As
shown in Fig. 4B, cells over-expressing wild-type CREB are
driven into apoptosis by FXa. In contrast, cells transfected
with the dominant negative forms of CREB are (almost)
unresponsive to FXa. Thus, CREB plays an essential role in
FXa-induced cell apoptosis.
The phosphorylation of CREB by FXa indicates a direct
effect on gene transcription. Thr ugh expression profiling of
37 genes involved in apoptosis using multiplex ligation-
dependent probe amplification (MLPA) [17], we observed that
only two pro-apoptotic genes are induced by FXa (Table 2) of
which the induction of the BH3-only protein Bim could be
confirmed on the protein level (Fig. 5A for MCF-7, data not
shown for MDA-MB-231). Maximum FXa-induced Bim levels
were observed after 8 h (mRNA) or 24 h (protein). Based on
these expression profiling data, we hypothesized that Bim,
which is known to act as a death ligand that neutralizes
members of the pro-survival Bcl-2 subfamily [28], is a central
player in FXa-induced apoptosis. In keeping with this hypoth-
esis, Bim expression was up-regulated by FXa in non-
Fig. 4 – FXa-mediated apoptosis involves the phosphorylation of the transcription factor CREB via p38 and ERK1/2 MAP kinases.
(A) FXa inducedphosphorylationofCREB.TheWesternBlot (toppanel) is representativeof three independent experiments. Shown
in the bottom panel are density measurements of three independent Western blots (mean±SEM). FXa specifically induced CREB
phosphorylation, since its effects are reverted by TAP but not by Hirudin. Molecular mechanisms underlying CREB activation
involve ERK1/2 and p38MAPKinase, since CREB activationwas diminished by the use of U0126, PD098059 and SB203580. (B) CREB
activation is required for FXa-induced apoptosis as cells expressing the native form of CREB or the KCREB mutant but not cells
expressing the S133Amutant showed phosphorylated CREB after FXa treatment. Cells over-expressingwild-type CREB are driven
into apoptosis, whereas cells expressing the mutant CREB forms do not respond to FXa treatment. Depicted is the mean±SEM of
experiments performed in octuplicate. ***P<0.0001, *P<0.01.









l   
co
py
tumorigenic epithelial cells. To obtain support for this
hypothesis, Bim expression was transiently knocked down
in MCF-7 and MDA-MB-231 cells using Bim siRNA. Indeed,
FXa-induced apoptosis was completely abolished in both cell
lines (Fig. 5B for MCF-7, data not shown for MDA-MB-231)
establishing that FXa-induced apoptosis is dependent on Bim.
Table 2 – Transcriptional changes induced by FXa compared with untreated cells as determined by MLPA expression
profiling
Gene ID HUGO name Genbank Alias 0 h 2 h 4 h 8 h
APAF APAF1 AF149794 Apoptotic protease activating factor 1 1 1.01±0.01 0.98±0.03 1.03±0.01
APAF-XL APAF1 NM_013229 Apoptotic protease activating factor 1
(splice variant)
1 1.14±0.06 1.04±0.01 1.01±0.01
B2M B2M AB021288 Beta-2-microglobulin 1 1 1 1
BAD BAD AF021792 BCL2 antagonist of cell death; BCL2-binding
protein; BCL2L8
1 0.99±0.02 0.92±0.04 0.95±0.02
BAK BAK U16811 BCL2L7; BCL2 antagonist killer 1 1 1.04±0.04 0.97±0.03 1.06±0.02
BAX1 BAX L22473 BCL2-associated X protein 1 1.00±0.13 0.99±0.06 0.98±0.12
BAX2 BAX2 L22473 BCL2-associated X protein 1 1.06±0.01 0.97±0.02 0.98±0.01
PUMA BBC3 AF354654 Bcl-2 binding component 3; Bcl-2 binding
component 3
1 1.18±0.03 1.31±0.01 1.44±0.01
BCL2 BCL2 M14745 BCL2 1 1.19±0.02 1.03±0.01 1.09±0.02
A1 BCL2A1 U29680 BCL2-related protein A1; BFL1 ND ND ND ND
BCL-XL BCL2L1 Z231115 BCL2-like 1 1 1.06±0.03 1.16±0.1 1.10±0.02
BIM BCL2L11 AF032457.1 BCL2-like 11; BCL2-interacting protein Bim 1 1.20±0.03 1.48±0.08 1.59±0.05
BCL-W BCL2L2 D87461 BCL2-like 2 1 1.11±0.02 1.19±0.03 1.05±0.01
BCL-G BCL-G AF281254 Apoptosis regulator Bcl-G ND ND ND ND
BCL-RMB BCL-RAMBO AF325209 BCL-Rambo 1 1.05±0.04 0.98±0.02 0.99±0.02
BID BID AF042083 BH3-interacting domain death agonist 1 1.02±0.05 1.08±0.01 1.09±0.01
BIK BIK NM_001197 BCL2-interacting killer (apoptosis-inducing NBK 1 1.06±0.03 1.05±0.01 1.03±0.02
NIAP BIRC1 NM_004536 Baculoviral IAP repeat-containing protein 1 1 1.07±0.01 1.10±0.002 1.00±0.02
IAP2 BIRC2 U37547 Baculoviral IAP repeat-containing protein 2;
API1, HIAP2, CIAP1
ND ND ND ND
IAP1 BIRC3 NM_001165 Baculoviral IAP repeat-containing protein 3;
HIAP1; CIAP2
1 1.02±0.03 1.07±0.08 1.03±0.07
XIAP BIRC4 NM_001167 Baculoviral IAP repeat-containing protein 4;
API3; XIAP; ILP
1 1.05±0.04 0.99±0.04 1.05±0.01
SURVIVIN BIRC5 NM_001168 Baculoviral IAP repeat-containing 5, API4 1 1.01±0.05 0.98±0.002 0.98±0.01
APOLLON BIRC6 AF265555 Baculoviral IAP repeat-containing protein 6;
KIAA1289
1 1.14±0.06 1.07±0.03 1.12±0.04
LIVIN BIRC7 AF311388 Baculoviral IAP repeat-containing 7; MLIAP, KIAP ND ND ND ND
BMF BMF NM_033503 Bcl-2 modifying factor 1 1.16±0.03 0.98±0.01 1.10±0.01
NIP3 BNIP3 AF002697 BCL2/adenovirus E1B 19-kDa protein-interacting
protein 3
1 0.97±0.03 0.99±0.02 1.00±0.01
NIX BNIP3L AF067396 BCL2/adenovirus E1B 19-kDa protein-interacting
protein
3-Like
1 1.01±0.03 1.08±0.02 1.13±0.06
Flip CFLAR U97074 CASP8 and FADD-like apoptosis regulator, FLICE,
CASP8
1 1.02±0.01 1.10±0.01 1.18±0.03
FLT FLT M11147 Ferritin light chain 1 0.98±0.04 0.98±0.04 1.07±0.06
HRK HRK U76376 HARAKIRI;BCL2-interacting protein; DP5 1 0.97±0.03 1.01±0.02 1.01±0.01
MAP1 MAP1 AK024029 Modulator of apoptosis 1 1 1.06±0.05 0.96±0.04 1.10±0.01
MCL1-S MCL1 AF118124 Myeloid cell leukemia sequence 1 (BCL2-related),
short form
1 0.97±0.01 1.06±0.006 1.07±0.01
MCL1-L MCL1 AF118124 Myeloid cell leukemia sequence 1
(BCL2-related), long form
1 1.02±0.03 1.10±0.05 1.00±0.03
PARN PARN AJ005698 POLY(A)-specific ribonuclease; deadenylating
nuclease; DAN
1 1.10±0.04 1.04±0.005 1.07±0.03
AIF PDCD8 AF100928 Programmed cell death 8; apoptosis-inducing
factor; AIF
1 1.04±0.04 0.98±0.03 0.99±0.04
Noxa PMAIP1 D90070 Phorbol-12-myristate-13-acetate-induced
protein 1; APR
1 1.05±0.02 1.03±0.01 0.99±0.01
GUS SADS AK000602 Hypothetical protein FLJ20595 1 1.00±0.04 1.04±0.01 0.99±0.02
PI-9 SERPINB9 U71364 Serine (or cysteine) proteinase inhibitor, clade B,
member 9
1 1.11±0.06 1.10±0.03 1.03±0.04
DIABLO SMAC AK024768 Second mitochondria-derived activator of caspase 1 1.02±0.06 1.03±0.02 1.02±0.03
Expression values are normalized to B2M expression levels and fold induction compared to t=0 h is indicated (mean±SEM). Significant
up-regulation is highlighted by bold characters. ND: not detectable.
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The cell type-specific response to FXa made us speculate
about the underlying mechanism and the potential involve-
ment of Bim. To this end, we determined Bim expression in
fibroblasts treated with FXa. Unlike in epithelial cells (either
tumorigenic or not), FXa down-regulated Bim expression in
fibroblasts (Fig. 5C). PAR-1 but not PAR-2 siRNA pretreatment
abolished FXa-induced Bim down-regulation and reversed the
anti-apoptotic effect of FXa, suggesting that FXa acts via PAR-1
to prevent fibroblast apoptosis (Fig. 5D). Importantly, trans-
fection of fibroblasts with Bim siRNA blocked FXa-induced cell
survival, further demonstrating that the switch between pro-
and anti-apoptotic effects of FXa is controlled by Bim
regulation.
Discussion
Our results uncover several unexpected facets of coagulation
FXa in cell biology. First we show that FXa exerts a cell-type-
specific effect oncell survival. Indeed, FXa-induced intracellular
Fig. 5 – FXa-induced apoptosis is mediated through BH3-only Bim protein. (A) FXa treatment of MCF-7 cells induces Bim
expression at themRNA level as determined usingMLPA, and at the protein level as determined byWestern blotting. Shownon
top is a representative Western blot of Bim expression, whereas the bottom panel represents the MLPA data (mRNA) and
density measurements of Western blots (mean±SEM (n=3)). (B) Efficacy of Bim silencing is indicated in the anti-Bim Western
blot. The anti-actin Western blot is indicated as a loading control. In non-transfected cells and cells transfected with control
siRNA, FXa induced apoptosis as shown previously. In contrast, in cells transfected with Bim siRNA, the effect of FXa was
abolished. (C) In fibroblasts, FXa treatment down-regulates Bim protein expression. Shown on top is a representative Western
blot of Bim expression. (D) In non-transfected fibroblasts and fibroblasts transfected with control siRNA, FXa enhances cell
survival. In contrast, in cells transfected with Bim siRNA, the effect of FXa was abolished. Depicted is the mean±SEM of
experiments repeated twice performed in octuplicate; ***P<0.0001, **P<0.001, *P<0.01.
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signaling drives cells of epithelial origin (either tumorigenic or
not) into apoptosis, and enhances tumor cell anoikis, but has
no effect on endothelial cell or monocyte survival, whereas it
enhances fibroblast survival. This latter result supports
previous studies on an anti-apoptotic effect of FXa in
fibroblasts [12,15], smooth muscle cells [10,29,30] and mesan-
gial cells [11]. However, the finding of a pro-apoptotic effect of
FXa on tumor cells has not been reported previously, and
indicates that, aside from its well known effect on blood
coagulation and cell proliferation, FXa may also directly inhibit
the growth of cells.
Using a specific PAR-1 blocking antibody, we demonstrated
that FXa-induced signaling wasmediated by PAR-1 activation.
In accordance, desensitization of cells with thrombin, which
specifically cleaves PAR-1, but not by trypsin (unpublished
observations), which specifically activates PAR-2 [3], totally
inhibited FXa signaling. Although thrombin can also activate
PAR-3 and-4, it has been shown that these receptors are not
present on MCF-7 and MDA-MB-231 cells [25], further con-
firming that thrombin stimulation specifically desensitized
PAR-1 for further FXa activation. In addition, knocking-down
PAR-1, but not PAR-2 expression, abolished the effect of FXa on
cell survival. Taken together, our results establish that PAR-1
activation by FXa mediates apoptosis. At first, these results
might be surprising as several papers describe a crucial role for
PAR-1 in tumor cell growth and metastasis [7,31–34]. In
addition, thrombin is shown to act as a growth factor via
PAR-1 activation in a variety of cancer cell lines [34]. More
recently, however, PAR-1 activation has been shown to induce
apoptosis in different cell types [6,35,36]. For instance,
thrombin levels above 0.3 U/mL (3 nM) induced apoptosis via
PAR-1 in several tumor cell lines including MCF-7 and MDA-
MB-231 cells [24–26]. In this study, we confirmed the pro-
apoptotic effect of thrombin on the latter cell lines (Fig. 3C). In
addition, thrombin-induced PAR-1 activation also drives
primary cells (neurons [6,37] and epithelial cells [36,38]) into
apoptosis. Importantly, PAR-1 agonist peptides mimicked
thrombin effects on apoptosis though at much higher
concentrations (25–100 μM) due to different affinities. Thus,
PAR-1 activation might mediate tumor growth but might also
induce apoptosis indicating a pleiotropic role of this receptor
in tumor biology.
The effect of FXa on tumor cell apoptosis differs in at least
two ways from FXa-induced apoptosis. First, the effect of
thrombin on cell survival is shown to be biphasic as it induces
cell proliferation at low concentrations [23] but (as indicated
above) induces apoptosis at higher concentrations [24–26]. In
the present study, we show the absence of such a biphasic
effect for FXa as the induction of apoptosis was directly
correlated with increasing FXa levels. Second, thrombin
induces apoptosis of HL-60 cells (this study, data not shown
and [26]) and its effect is thus not restricted to epithelial cells,
whereas FXa has no effect on HL-60 cell survival (Fig. 1C). The
underlying mechanism for these differential effects of throm-
bin and FXa is not yet resolved. However, it is well-established
that by signaling through the same receptor different PAR-1
agonists can exert distinct biological effects. For instance, it
has already been shown that PAR-1 agonists were not able to
mimic thrombin-induced PAR-1 cleavage in fibroblasts, or
endothelial cells [39–41]. Also activated protein C-dependent
PAR-1 cleavage triggers signaling pathways which differ from
that induced by thrombin-mediated PAR-1 cleavage [42].
Interestingly, FXa induced apoptosis of all epithelial cells to
a similar extent despite the fact that PAR-1 expression levels
differ between the different cells. For instance, MDA-MB-231
cells are known to express high levels of PAR-1, whereas MCF-
7 cells express low levels of this receptor [24,25,43]. All other
tumor cell-lines express intermediate levels of PAR-1 (data not
shown). This suggests that PAR-1 levels in these cell lines are
not rate-limiting in FXa-induced apoptosis.
A recent study reported that the TF–FVIIa–FXa complex
prevented apoptosis in MCF-7Adr cells, which are MCF-7 cells
transfected with TF to allow FVII activation and ternary
complex formation [44]. Unfortunately, however, the effect
of FXa alone on apoptosiswas not determined in this study. As
the TF-FVIIa-FXa also activates PAR-2 it is attractive to
hypothesize that direct cleavage of PAR-1 by FXa induces
apoptosis whereas incorporation of FXa in the ternary
complex switches the affinity towards PAR-2 thereby inducing
cell survival. However, the receptor involved in the prevention
of apoptosis in the abovementioned study [44] has not been
investigated.
Strikingly, we established that the pro- (epithelial cells) or
anti-apoptotic (fibroblasts) effect exerted by FXa seems to be
regulated by Bim, a well-known key factor in the regulation of
apoptosis [45]. In the absence of death signals, Bim is
sequestered away from its site of action at the mitochondrial
outer membrane through interactions with the micro tubular
dynein motor [46]. Death signals trigger its release and rapid
translocation to the mitochondrial surface, where it neutra-
lizes the pro-survival activity of Bcl-2 family members,
inducing cell death [47]. In accordance with our results
thrombin down-regulates Bim expression in fibroblasts,
thereby preventing apoptosis [39]. The underlyingmechanism
by which FXa-induced PAR-1 activation leads to Bim up-
regulation in epithelial cells but to Bim down-regulation in
fibroblasts is currently not known. The rationale behind this
important dilemma of how PAR-cleavage induces different
cellular responses dependent on either ligand or cell type is
currently subject to an intense research effort.
The present study is the first report showing FXa-induced
apoptosis of tumor cells together with fibroblast survival via
the modulation of Bim. These data strongly suggest that,
beyond its role in blood coagulation, FXamight play a key role
in maintaining organ homeostasis or in pathological pro-
cesses. Especially a role in metastasis could be hypothesized
as many carcinomas shed epithelial cells into the circulation.
An increase of up to 100-fold of circulating neoplasic
epithelial cells is observed in patients with organ-confined
carcinoma, nodal involvement and/or distant metastases
[48,49]. Therefore, it is tempting to speculate that direct FXa-
induced signaling might limit the survival of circulating
epithelial cells. Further studies to investigate whether FXa
can mediate these anti-tumor effects in vivo would be highly
desirable, as pharmacological interference with FXa-depen-
dent thrombin generation without affecting FXa-induced
signal transduction, as it has been done for activated protein
C [50], might have interesting therapeutic implications not
only in cancer biology but also in other diseases where
activated coagulation factors play a key role.
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 Cell migration is critically important in (patho)physiological processes. The 
metastatic potential of cancer cells partly depends on activation of the 
coagulation cascade. Here, we show that activated coagulation factor X (FXa), 
which plays a central role in blood coagulation by mediating thrombin 
formation, inhibits migration of breast, lung and colon cancer cells. FXa acts via 
protease-activated receptor (PAR)-1-dependent signaling, and knocking-down 
PAR-1 expression abolishes these FXa effects. Both the Rho/ROCK and 
Src/FAK/paxillin pathways are required for FXa-mediated inhibition of cell 
migration. FXa induced pronounced stress fiber formation that is partially 
inhibited by pre-treatment with specific ROCK or Src inhibitors. Downstream of 
Rho/ROCK and Src/FAK/paxillin, FXa induces myosin light chain 
phosphorylation and LIMK1 activation resulting in cofilin inactivation. 
Knocking-down LIMK1 expression abolished FXa-induced inhibition of cell 
invasion. Our results reveal that FXa-mediated sustained cofilin inactivation 
leads to stabilization of actin filaments incompatible with migration. Thus, 
beyond its role in blood coagulation, FXa plays a key role in cell migration and 
we unravel a new mechanism of PAR-1-mediated inhibition of migration via Rho 





Coagulation factor (F)X is a vitamin-K dependent plasma protein that plays a key 
role in blood coagulation. Upon vascular injury, FVII forms a 1:1 stoichiometric 
complex with its cofactor, the cell surface receptor tissue factor (TF). After 
autocatalytic activation, activated FVII (FVIIa) converts FX into its active form, FXa. 
In the coagulation cascade, FXa occupies a central position as a convergence point 
between the intrinsic and extrinsic coagulation pathways, and converts prothrombin 
into thrombin, thereby regulating the generation of this vital procoagulant protein [1]. 
 Beside these well known effects in haemostasis, emergent data support the 
hypothesis that FXa elicits numerous cellular events by direct actions on a wide 
variety of cell types. FXa interacts with the protease-activated receptors PAR-1 and -2 
[2, 3]. Proteolytic cleavage of either receptor exposes a new N-terminus that binds to 
the body of the receptor thereby inducing signal transduction [4]. Activated PAR-1 is 
coupled via the heterotrimeric G-protein family members to a substantial network of 
signaling pathways [5, 6] accounting for the pleiotropic actions of PAR ligands [5, 7].  
 The contribution of the signaling pathways induced by FXa to pathophysiological 
processes has just begun to unfold. On endothelial cells, a synergistic induction of TF 
by FXa and TNF results in inhibition of negative regulatory signaling, which accounts 
for the amplification of cytokine-induced endothelial cell activation by FXa [8]. In 
fibroblasts and smooth muscle cells, FXa acts as a potent mitogen and stimulates 
proliferation [9-12]. FXa induces expression of adhesion molecules on monocytes 
[13], whereas in HeLa cells it leads to NF-κB and Cyr61 gene expression and up-
regulation of Egr-1 transcription [2, 3]. However, the functional consequence of FXa-
induced signal transduction in cancer cells remains more elusive, but it is generally 
accepted that FXa might also modulate tumor cell growth, invasion and metastasis 
[14]. 
Cell motility influences a number of critical physiological and pathological 
processes. For instance, wound healing requires the migration of fibroblasts and 
epithelial cells, whereas cancer cell metastasis, the major contributor to the lethality of 
cancer, is also highly dependent on cell migration. For cell motility to occur, two 
processes are important. Chemokinesis is the induction of random, non directional 
motility in response to a ligand without any orientational cues and chemotaxis 
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represents a directional response of cells toward a gradient of ligand [15]. Whereas a 
chemokinetic effect can occur without a chemotactic effect, no agonist has been 
described which solely influences chemotaxis without an influence on chemokinesis 
[16]. 
For cellular locomotion to occur, cells must be able to protrude, form and break 
adhesion sites between the cells and the substratum, and move the cell mass. These 
processes depend on the assembly of focal adhesions, structures that link actin 
filaments and integrin associated points of attachment with the extracellular matrix 
[17, 18], the concomitant formation of actin stress fibers and other cytoskeletal 
proteins [19]. Increased tyrosine phosphorylation of several proteins which are 
associated with focal adhesions are also implicated in cell migration. Among them, 
focal adhesion kinase (FAK) is a widely expressed and highly conserved non-receptor 
protein tyrosine kinase which is involved in the formation of actin stress fibers [20] 
and the regulation of motility. FAK, in turn, phosphorylates and/or associates with 
other cytoskeletal components, including Src and paxillin. Another major pathway 
involved in actin-containing cytoskeletal rearrangement engages the Rho family of 
small GTP-binding proteins, which contains three members, Rho, Rac and cdc42. In 
their active, GTP-bound form, Rho, Rac and cdc42 induce a wide range of biological 
actions [17, 18, 21, 22]. In addition, the Rho kinase ROCK, the downstream substrate 
of activated GTP-bound Rho, phosphorylates a number of substrates involved in 
actin-filament assembly and contractility [23]. 
Rho/ROCK pathway activation and subsequent stress fiber formation is known to 
be triggered by PAR-1 [24, 25], and a recent study showed PAR-1 mediated Src 
activation [26]. Since FXa is able to specifically activate PAR-1, in the present study, 
we investigated whether FXa modulates adhesion, motility and invasion of different 
cancer cells lines. We show that FXa activates Rho and Src pathways leading to the 
assembly of actin stress fibers and ultimately inhibition of cell migration. 
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Materials and Methods 
 
Cell culture. The breast cancer cell lines MDA-MB-231 and MFC-7, colon cancer 
cell lines SW-480, DLD-1, HCT-116, and HT-29, lung cancer cell line A549, as well 
as the C3H/10T1/2 fibroblasts were purchased from ATCC and maintained in DMEM 
supplemented with 10% Fetal Calf Serum (FCS).  
 
Reagents. Human FXa and thrombin were obtained from Kordia (Leiden, the 
Netherlands). Recombinant FVIIa was from NovoNordisk (Bagsvaerd, Denmark). 
Tick Anticoagulant Peptide (TAP) was kindly provided by Dr Georges Vlasuk 
(Corvas International Inc, San Diego, CA). Hirudin was purchased from Calbiochem 
(San Diego, CA). Unless otherwise specified, the concentrations of these reagents 
were 0.75 U/mL FXa, 1 U/mL thrombin, 25 U/mL hirudin, 100 nM FVIIa, 100 nM 
trypsin, 200 nM TAP. Pertussis toxin (100 ng/mL), phalloidin-FITC and phalloidin-
TRITC were purchased from Sigma (St-Louis, MO). Cell tracker green CMFDA (5-
chloromethylfluorescein diacetate) was obtained from Molecular Probes (Eugene, 
OR). PP1 (used at 10 µM) was from Biomol (Plymouth Meeting, PA), and Y-27632 
(used at 10 µM) was from Calbiochem (San Diego, CA). Control (scrambled 
sequence that does not lead to the specific degradation of any targets) and pre-
designed human PAR-1 (reference ID #4377) and PAR-2 (reference #1960) siRNA 
was obtained from Ambion Inc (Austin, TX), whereas LIMK1 siRNA was obtained 
from Santa Cruz (Santa Cruz, CA).  
 
Transfection. Transient transfections of MCF-7 and MDA-MB-231 cells (seeded at 
3*105 cells/well) with the different siRNAs were performed at 70% confluence using 
the RNAifect method (Qiagen, Hilden, Germany) according to the manufacturers 
recommendation. In all cases, cells were incubated with transfection complexes for 
16h, after which fresh medium was added as previously described [12]. For 
transfections in 6-well plates, 0.6 µg siRNA was used at a 1:3 ratio of RNA/ 
RNAiFect. 
 
Migration assays. Cells were grown to 70% confluence in 6-well plates and 
subsequently labeled for 1 hour with 10 µM CellTracker Green fluorescent dye in 
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serum-free medium prior to the migration assay as described previously [27]. Briefly, 
the fluorescent dye was incubated with the cells for 30 minutes at 37°C. Cells were 
washed once in medium to remove excessive soluble dye, then incubated for 1 hour at 
37°C in medium without dye. Subsequently, cells were washed and detached with 
2mM ethylenediaminetetraacetic acid (EDTA) in PBS. After complete detachment, 
cells (1*106) were resuspended in serum-free medium, pipetted through a 40 µM cell 
strainer (BD Falcon, Franklin Lakes, NJ) and transferred to 8 µM pore size HTS 
FluoroBlok Cell Culture Inserts which were inserted in fitting 24-well plates. Two 
types of assays were performed (fig. S1). For chemotaxis assays, cells were allowed 
to migrate toward the indicated agonists added to the bottom well. For chemokinesis 
assays, the different agonists were added to the top well or in both upper and lower 
well for the control checkboard assay as described previously [16]. Promptly, 
fluorescence values representing the number of cells on the bottom side of the insert 
were read during 30 cycles (each cycle comprising 4 readings spanning 2 minutes) at 
37°C on a Series 4000 CytoFluor Multi-Well Plate Reader (Perseptive Biosystems, 
Framingham, MA). Migration was allowed to proceed for 60 minutes as previously 
described for this real-time migration assay [27]. The raw fluorescence data were 
corrected for background fluorescence of serum-free medium and fading of the 
fluorophore, and then the data were plotted with GraphPad Prism 4.  
 
Invasion assays. Invasion assays through Matrigel were performed essentially as the 
migration assays above, except that inserts were coated with Matrigel (40µg), which 
was allowed to polymerize at 37°C for 2h. Fluorescent values were read during 200 
cycles (each cycle comprising 4 readings spanning 6 minutes) at 37°C as indicated 
above.  
 
Adhesion assay. As for the migration assay, cells were grown, labeled and when 
indicated pre-treated for 3h with 20% FCS, 0.75 U/mL FXa or PBS. Cells 
resuspended in serum-free medium were transferred to a tissue culture-treated 24-well 
plate, if indicated coated with IV collagen, fibronectin or gelatin (Gibco BRL, Grand 
Island, NY; respectively 5 and 20 µg/ml or 0.1%) in the presence of the indicated 
agonists and allowed to attach for 45 minutes. After this, a series of washes was 
performed with PBS with 45 minutes time intervals in which the cells were in 
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medium with the original compounds. Total fluorescence was read on the CytoFluor 
Multi-Well Plate Reader and analysed as indicated above for the migration assay.  
 
Receptor desensitization. To determine the effect of receptor desensitization on 
ERK1/2 phosphorylation, tumor cells were serum starved for 16h, then washed twice 
with PBS, pretreated with trypsin (100 nM) or thrombin (1 U/mL) in serum-free 
conditions for 90 minutes. Cells were subsequently stimulated for another 30 minutes 
with the indicated concentration of FXa, and the phosphorylation of ERK1/2 in the 
different conditions was assessed by immunoblotting.  
 
Immunoblotting and antibodies. Stimulated cells were washed twice with ice-cold 
PBS prior to lysis in Laemmli lysis buffer, incubated for 5 minutes at 95°C, and 
subjected to SDS-PAGE. After electrophoresis, the proteins were blotted to an 
immobilon-P PVDF membrane (Millipore, Billerica, MA), washed and blocked with 
2% Protifar Plus (Nutricia, Zoetermeer, Netherlands) in TBS with 0.1% Tween (TBS-
T). Blots were incubated with primary antibodies to actin (Santa Cruz, CA), phospho-
Rac/cdc42, phospho-FAK, phospho-paxillin, phospho-Src or phospho-LIMK1/2 (all 
Cell Signaling Technology, Beverly, MA), in 1% BSA TBS-T. All secondary 
antibodies were HRP-conjugated from DakoCytomation (Glostrup, Denmark). Blots 
were imaged using Lumilight Plus ECL substrate from Roche (Basel, Switzerland) on 
a GeneGnome imager (Syngene, Cambridge, UK).  
 
Immunofluorescence. Cells were grown on coverslips at 20-30% confluence. After 
stimulation with 0.75U/mL FXa or PBS (or solvent if indicated), for 10 minutes, cells 
were washed with PBS and fixed with 3.7% formaldehyde for 20 min at room 
temperature. Fixed cells were permeabilized and blocked in PBS/0.1% Triton X-100 
(PBS-T) supplemented with 10% FCS for 1 hour. Cell nuclei were stained with DAPI 
(200 ng/mL; Roche) in PBS-T for 30 min. The actin cytoskeleton was stained with 10 
µg/ml phalloidin-TRITC, or phalloidin-FITC for the study of stress fibers formation, 
in PBS-T supplemented with 1% BSA. For imaging FAK, paxillin, or Src 
phosphorylation, cells were blocked as for phalloidin staining, but subsequently 
incubated with the appropriate antibody and subsequent FITC-conjugated secondary 
antibody (both in 3% BSA/PBS-T). After staining, the cells were washed and 
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mounted in Mowiol/DABCO aqueous mounting medium (Vector Laboratories, 
Burlingame, CA). Images were visualized using an epifluorescence microscope 
(Leica DMRA, Wetzlar, Germany). Images were captured on a cooled charge coupled 
camera (KX Series, Apogee, Auburn CA) operated by ImagePro Plus software 
(Media Cybernetics, Silver Spring, MD). 
 
Statistical analysis 
All experiments were repeated at least 3 times (exact numbers are indicated in the 
corresponding result section). Statistical analysis was performed with Graph Prism 
using Mann-Whitney analysis. 
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Differential effects of FXa on cancer cell migration and motility.  
 In order to determine the effect of coagulation FXa on human cancer cell 
migration, we first determined the chemotactic response of two breast cancer cell 
lines towards FXa. As shown in figure 1A, FXa as a chemoattractant had no effect on 
migration of the highly metastatic MDA-MB-231 cell line, whereas it significantly 
inhibited migration of the poorly invasive MCF-7 breast cancer cell line. Next, we 
determined the effect of FXa on chemokinesis. As shown in figure 1A, FXa inhibited 
chemokinesis of both cancer cell lines, either highly metastatic or not, as compared to 
the controls. As control experiment, FXa was added to both the upper and lower well 
to preclude the formation of a FXa gradient which resulted in a similar inhibition of 
chemokinesis (data not shown). 
Figure 1. Effect of FXa on cell migration. 
(A) Chemotaxis and chemokinesis of 
MCF-7 and MDA-MB-231 breast cancer 
cells in the absence (control) or presence of 
0.75 U/mL FXa. (B) Dose response curve 
of FXa-induced inhibition of cell 
migration. (C) Specificity of FXa-induced 
(0.75 U/mL) inhibition of chemokinesis of 
MCF-7 and MDA-MB-231 cells. 
Pretreatment with TAP (200 nM; a specific 
FXa inhibitor), but not with hirudin (hir; 25 
U/mL; a specific thrombin inhibitor) 
abolished the FXa effect on chemokinesis. 
(D) Effect of FVIIa and thrombin on 
chemotaxis of MCF-7 and MDA-MB-231 
cells. The ability of MCF-7 and MDA-MB-
231 cells to migrate toward FVIIa (100 
nM) or thrombin (1 U/mL) was determined 
as described previously. (E) Chemotaxis 
and chemokinesis of different lung and 
colon cancer cell lines in the absence 
(control) or presence of 0.75 U/mL FXa. 
(F) Chemotaxis and chemokinesis of 
fibroblasts in the absence (control) or 
presence of 0.75 U/mL FXa. For all panels: 
results represent the mean (± SEM) number of cells migrated as percentage of the control, determined 
from five independent experiments. *P<0.05; **P<0.01; ***P<0.001. NS, non significant. 
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We examined the dose responsiveness of FXa-induced inhibition of chemokinesis 
in MDA-MB-231 and MCF-7 cells. For both cell lines, FXa concentrations as low as 
0.25 U/mL already blocked cell migration with maximal inhibition reached at 0.75 
U/mL (fig. 1B). To verify the specificity of the FXa effect on chemokinesis, cells 
were pre-treated with TAP, a specific FXa inhibitor, or with hirudin, a specific 
thrombin inhibitor. As shown in figure 1C, TAP but not hirudin abolished FXa-
mediated inhibition of chemokinesis. Similar results (specificity and dose-
responsiveness) were observed for FXa-mediated inhibition of chemotaxis on MCF-7 
cells (data not shown).  
As a control for our experimental setup, we established the chemotactic response 
towards thrombin (which has been shown to inhibit chemotaxis of both cell lines) and 
FVIIa, (which has been reported to enhance chemotaxis of MDA-MB-231 cells only) 
[28, 29]. Indeed, as shown in figure 1D, thrombin inhibits chemotaxis of both cell 
lines, whereas FVIIa only enhanced chemotaxis of the TF expressing MDA-MB-231 
cells but not of TF-negative MCF-7 cells. 
To establish whether FXa also inhibits the motility of other cancer cell lines or is 
breast cancer cell specific, we selected four colon cancer cell lines, HT-29, HCT-116, 
SW480, and DLD-1, and one lung cancer cell line A549. As shown in figure 1E, FXa 
slightly inhibited chemotaxis of A549 and DLD-1 cells, whereas it has a strong effect 
on HCT-116 cells. No significantly affect of FXa was observed on chemotaxis of 
SW480 and HT-29 cells, although a trend towards inhibition was observed. In 
contrast, FXa inhibited chemokinesis of all tested cell lines although to a somewhat 
different extent (fig. 1E). 
Primary tumour cells are normally outside the bloodstream and thus outside the 
reach of FXa, unless they enter the bloodstream at the early stage of hematogeneous 
metastasis to travel to distant organs. To determine whether FXa specifically targets 
cancer cells or acts in a more general manner, we next determined the effect of FXa 
on the motility of fibroblasts. As shown in figure 1F, FXa strongly enhanced 
chemotaxis and chemokinesis of fibroblasts (of respectively 76%±20 and 57±13%).  
 
Effect of FXa on cancer cell adhesion 
The observed effect of FXa on cell migration might be (at least partly) dependent 
on enhanced cell adhesion. To test this hypothesis, MCF-7 and MDA-MB-231 cells 
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were pretreated with FXa for different time periods (30 minutes to 3h) and adherence 
to tissue culture plates was determined. As expected, incubation of the cells with 20% 
FCS strongly enhanced adhesion compared to solvent control treatment (fig. 2). At a 
concentration that strongly inhibited cell migration (0.75 U/mL), FXa had no 
significant effect on cell adhesion (fig. 2A 
shows the results of MCF-7 cells after 3h FXa 
treatment, data not shown for other time points 
and/or MDA-MB-231 cells). To assess 
whether the effect of FXa on cell adhesion 
could differ according to extracellular matrix 
components, we also determined adhesion to 
plates coated with gelatin, type IV collagen or 
fibronectin. Again, these experimental 
conditions did not unveil an effect of FXa on 









Figure 2. Effect of FXa on adhesion of MCF-7 
cells. Fluorescently labeled cells were seeded in 6 well 
plates and subsequently pre-treated for 3h with 20% 
FCS (positive control), PBS (negative control) or 0.75 
U/mL FXa in serum free medium. Fluorescence in the 
wells was determined after subsequent washes 
representing the number of cells attached. (A) “empty” 
tissue culture well, (B) well coated with gelatin, (C) 
well coated with collagen and (D) well coated with 
fibronectin. For all panels: results represent the mean (± 
SEM) number of cells attached as percentage of the 
PBS control at wash 0, determined in three different 
experiments. ***P<0.001. NS, non significant 
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FXa inhibits cell migration via PAR-1 activation  
The cellular effects described for FXa, so far, are mediated through the activation 
of PAR-1 or -2 [14, 30, 31]. To establish the involvement of these PARs in FXa-
induced inhibition of chemokinesis, we transfected MDA-MB-231 and MCF-7 cells 
with siRNA specifically knocking-down the expression of either PAR-1 or -2. As 
shown in figure 3A for MCF-7 cells, transfection with control siRNA did not modify 
the inhibitory effect of FXa. In contrast, knocking-down PAR-1 expression abolished 
FXa-induced inhibition of cell migration, whereas silencing PAR-2 expression did not 
significantly alter this effect of FXa. The same results were obtained with MDA-MB-












Figure 3. FXa-mediated inhibition of MCF-7 cell involves PAR-1 activation but not Gαi. (A) siRNA 
transfection specifically and efficiently silence the targeted protein (top panel). Par-1 siRNA 
diminished PAR-1 expression but not PAR-2 expression, whereas PAR-2 siRNA inhibits PAR-2 but 
not PAR-1 expression. Transfection with control siRNA had no effect on FXa-mediated inhibition of 
cell migration, whereas PAR-1 siRNA completely abrogates the FXA effect. PAR-2 siRNA 
transfection did not modify the FXA effect on cell migration. Results represent the number of cells 
migrated determined in three independent experiments as percentage of control siRNA transfected 
cells, and are shown as mean ± SEM. ***P<0.001, *P<0.1; NS, non significant differences. (B) 
Desensitization of PAR-1 by thrombin (90 minutes with 1 U/mL), but not PAR-2 by trypsine (90 
minutes with 100 nM) impairs subsequent FXa-induced signal transduction as determined by Western 
blot analysis of phosphorylated ERK1/2. Total ERK1/2 is indicated as loading control. The blots 
represent stimulations with FXa for 30 minutes either with (two right panels) or without (left panel) 
desensitization. (C) Cells were treated for 30 minutes with PTX (100 ng/mL) before migration was 
assayed in the absence or presence of FXa (0.75 U/mL) as described in Materials and methods. Results 
are represented as for (A).   
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To confirm the involvement of PAR-1 in FXa-mediated inhibition of 
chemokinesis, receptor desensitization experiments were performed. To this end, 
FXa-induced phosphorylation of one of the major MAPkinase pathways, ERK1/2 was 
assessed. As shown in figure 3B, stimulation of the MCF-7 cells with 0.25 U/mL of 
FXa already triggers ERK1/2 phosphorylation, which peaks at a concentration of 0.75 
and 1 U/mL. FXa-induced ERK1/2 phosphorylation was significantly reduced by 
PAR-1 desensitization caused by pre-treating the cells with thrombin. In contrast, 
PAR-2 desensitization by trypsin pretreatment did not reduce ERK1/2 
phosphorylation. Together with the siRNA data, these data strongly suggest that FXa 
signal transduction is mediated via PAR-1 in these breast cancer cell lines.  
As different studies indicate that PAR-1-dependent Gαi activation inhibits cancer 
cell migration [28, 32, 33], we next addressed the potential involvement of this 
downstream G protein in the FXa effects. As shown in figure 3C for MCF-7 cells, 
pretreatment with Pertussis toxin (PTX), a known inhibitor of Gαi-linked pathways, 
inhibited cell migration. However, the pre-treatment of the cells with PTX did not 
block FXa-mediated inhibition of chemokinesis. Thus, the Gαi pathway is not 
involved in FXa-induced inhibition of cell migration. 
 
Requirement of Rho/ROCK and FAK/paxillin/Src pathways in FXa-mediated 
inhibition of chemokinesis 
As PAR-1 cleavage can trigger Rho and ROCK, as well as FAK and members of 
the Src family of proteins, we determined the effect of a specific ROCK or Src 
inhibitor (respectively Y-27632 and PP1) on FXa-mediated inhibition of 
chemokinesis. As shown in figure 4A, pretreatment of the cells for 30 minutes with 
either inhibitor did not modify cell migration. Both inhibitors however partially 
abrogated the effect of FXa on chemokinesis.  
To further confirm the involvement of these pathways, cells were stimulated with 
FXa for 0 to 15 minutes and lysates were analyzed by SDS-PAGE followed by 
immunoblotting with specific antibodies. As shown in figure 4B for MCF-7 cells, 
FXa rapidly induced phosphorylation at Tyr 576/577 with maximal phosphorylation 
at 1-2 minutes. In addition, FXa induced a rapid and robust phosphorylation of Src 
and of the adaptor molecule paxillin (already after 2 minute stimulation). Taken 
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together, these data suggest that FXa mediates its effect on cell migration via both the 
Src and Rho pathways.  
 
Figure 4. Rho/ROCK and Src pathway activation mediate FXa-induced inhibition of cell migration. 
(A) Pre-treatment of MDA-MB-231 and MCF-7 cells for 30 minutes with Y-27632 (10 µM; 
Rho/ROCK inhibitor) or PP1 (10 µM; Src kinase inhibitor) partly abolishes FXa-induced inhibition of 
cell migration. Results represent the mean (± SEM) number of cells migrated as percentage of the 
control, determined by three experiments. *P<0.05; **P<0.01; ***P<0.001. (B) FXa induces 
phosphorylation of FAK, paxillin and Src in MCF-7 cells as shown by Western blot analysis. Actin 
serves as loading control. The blots are representative of three independent experiments.  
 
FXa mediates cytoskeletal reorganization and stress fiber formation 
To confirm the activation of the FAK/paxillin/Src pathway, we used fluorescent 
microscopy on MCF-7 cells stimulated with FXa. As shown in figure 5A, after 10 
minutes of stimulation, spikes representing either phosphorylated FAK, paxillin or 
Src, could be observed at the cell membrane. Concomitant with the activation of these 
kinases, FXa induced actin cytoskeletal reorganization with a dramatic increase in 
stress fiber formation from less than 1% of the cells (n=300) showing stress fibers in 
the control situation to 64% (n=300) of the cells after FXa treatment (figure 5B). 
To further confirm the involvement of FXa-induced Rho/ROCK and/or 
FAK/paxillin/Src in stress fiber formation, cells were pretreated for 30 minutes with 
either Y-27632 or PP1 and subsequently stimulated with FXa. As shown in figure 5B, 
Y-27632 pretreatment substantially reduced the percentage of cells exhibiting stress 
fibers (21% compared to 64% of cells treated with FXa alone; n=300). Pretreatment 
with PP1 also significantly reduced the amount of cells with stress fibers (18%). 
Overall these data confirm the involvement of both the Rho/ROCK and/or 
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FAK/paxillin/Src pathways in FXa-mediated cytoskeletal reorganization leading to 




















Figure 5. Fluorescent microscopy of FXa stimulated MCF-7 cells. (A) Cells are stimulated for 10 
minutes with PBS (control) or FXa (0.75 U/mL) and subsequently fixed in formaldehyde. Incubation 
with phospho-antibodies (green) against of FAK, paxillin and Src followed by DAPi (nucleus; blue) 
and phalloidin (actin; red) was performed as described in materials and methods. (B) FXa treatment for 
10 minutes induces stress fiber formation, as compared to control (PBS stimulated cells), depicted by 
actin staining (phalloidin; green). Pre-treatment of the cells with either PP1 (10 µM; Src inhibitor) or 
Y-27632 (10 µM; ROCK inhibitor) partially abolished FXa-mediated stress fiber formation. 
Experiments were done four times with similar results.  
 
Downstream effects of Rho/ROCK and FAK/paxillin/Src pathway activation 
The observation that FXa-mediated inhibition of chemokinesis involves 
Rho/ROCK and FAK/paxillin/Src prompted us to determine the downstream signal 
transduction pathways leading to stress fiber formation and thus inhibiting 
chemokinesis. As in other models showing Rho/ROCK mediated inhibition of cell 
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migration, a concomitant inhibition of Rac/cdc42 phosphorylation had been observed, 
we hypothesized that such a mechanism accounts for the observed FXa effects. 
Alternatively, the activation of LIMK1/2, which inactivates cofilin and leads to 
inhibition of actin depolymerization, might be responsible for the observed inhibition 
of FXa-mediated chemokinesis. LIMK1/2 might be activated subsequently to 
Src/FAK/paxillin via Crk phosphorylation, an adaptor molecule which binds to 
phosphorylated paxillin, or directly by ROCK. Finally, Rho/ROCK activation leading 
to myosin light chain phosphorylation and actin stress fiber stabilization might 
explain the FXa effect on migration. Therefore, we determined whether FXa leads to 
phosphorylation of these downstream effectors. Cells were stimulated for the 
indicated times, and lysates were analyzed by SDS-PAGE followed by 
immunoblotting with specific antibodies. As shown in figure 6A for MCF-7 cells, 
FXa induced sustained phosphorylation of myosin light chain. Phosphorylation of Crk 
was observed after 5 minutes, peaked after 10 minutes and did not return to the basal 
level after 30 minutes of FXa stimulation. Concomitantly, FXa treatment led to a 
robust and sustained phosphorylation of LIMK1/2 and cofilin, in the same time frame. 
Surprisingly, FXa stimulation induced a dramatic activation of Rac/cdc42 peaking 
after 2 minutes (Figure 6B). The same experiments were conducted using MDA-MB-
231 cells and we observed similar results (data not shown). 
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 Figure 6. FXa inhibits 
cell migration and 
invasion via LIMK1-
mediated cofilin 
inactivation. (A) FXa 
induces phosphorylation 
of Crk, LIMK1/2, myosin 
light chain (indicated as 
myosin) and cofilin as 
demonstrated using 
Western blot analysis 
with specific antibodies. 
Equal loading is shown 
by the actin blot. 
Pretreatment of cells with 
PP1 (10 µM) or Y-27632 
(10 µM) for 30 minutes 
diminishes 
phosphorylation of all 
indicated kinases 
(although to a different 
extent). The blots are 
representative of three experiments. (B) Rac/cdc42 phophorylation after FXa treatment for the 
indicated time-points. Actin serves as loading control. (C) The invasive capacity of MDA-MB-231 
cells was assessed by a migration assay. Cells were seeded (in the presence of PBS (control), FXa (0.75 
U/mL) or thrombin (1 U/mL)) in inserts coated with Matrigel (40 µg). (D) Specific silencing LIMK1 
expression by siRNA transfection of MDA-MB-231 cells abolishes FXa-induced inhibition of cell 
invasion. siRNA transfection efficiently silence LIMK1 expression (top panel). Transfection with 
control siRNA had no effect on FXa-mediated inhibition of cell invasion, whereas LIMK1 siRNA 
completely abrogates the FXA effect. Results represent the number of cells migrated determined in 
three independent experiments as percentage of control siRNA transfected cells, and are shown as 








FXa inhibits cancer cell invasion via LIMK1 activation 
To assess the relevance of our data for pathophysiology, we determined the effect 
of FXa on the invasion of MDA-MB-231 cells in an in vitro invasion assay. As shown 
in figure 6C, both FXa and thrombin (known to inhibit invasion in this system) 
significantly inhibited invasion by approximately 30% (left panel). Subsequently, we 
performed the same assay using cells transfected with siRNA specifically knocking-
down the expression of LIMK1. As shown in figure 6C (right panel), transfection of 
the cells with control siRNA did not affect the inhibitory action of FXa on cell 
invasion. As previously reported[34], specific silencing of LIMK1 expression 
strongly reduced the basal invasion properties of MDA-MB-231 cells. However, FXa 
did not longer inhibit invasion in the absence of LIMK1 (figure 6C, right panel), 
confirming that FXa exerts its inhibitory effects on cell migration/invasion via 
LIMK1 activation. Taken together, these results suggest that FXa inhibits 
chemokinesis by stabilizing stress fibers via both LIMK1/2 and subsequent cofilin 
inactivation, and myosin light chain phosphorylation, whereas it is independent of 
Rho-dependent Rac/cdc42 inactivation. 
 
Discussion 
Regulation of cell migration is critically important in diverse biological processes 
such as organogenesis, neuronal axon pathfinding, wound healing, inflammatory 
responses, vascular remodeling and cancer cell dissemination. The underlying 
processes ruling either chemoattraction or chemorepulsion are tightly regulated. 
Numerous chemokines, growth factors, cytokines and other inflammatory mediators 
stimulating cell migration have been described, whereas the number of biological 
mediators that inhibit cell motility is more limited. The latter include metastin [35], 
several neurotransmitters like Slit, semaphorins, ephrins [36] or GABA[37-41], 
cannabinoids [42, 43] and sphingosine-1-phosphate [44]. In the present study, we 
identified coagulation FXa as a novel inhibitor of cancer cell migration. Specifically, 
FXa inhibited chemokinesis of all cancer cell lines tested, whereas it inhibited 
chemotaxis of MCF-7, A549, DLD-1 and HCT-116 cells but not HT-29, SW-480 and 
MDA-MB-231 cells. Inhibition of chemokinesis was not due to enhanced adhesive 
properties of the cells and prevented cancer cell invasion in an in vitro metastasis 
model.  
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 To explore the mechanism of FXa-mediated inhibition of cell migration, siRNA 
treatment of MCF-7 and MDA-MB-231 cells specifically knocking-down PAR-1 
expression showed that FXa mediates its inhibitory effect via PAR-1 activation (a 
notion confirmed by receptor desensitization). This observation might seem a bit 
surprising since PAR-1 is well known to play a crucial role in pathological invasion of 
many cancers. PAR-1 expression in cancer cells correlates with their metastatic 
potential [45] and it was recently shown to be a matrix metalloprotease receptor that 
promotes invasion of breast cancer cells [46]. However, thrombin activation of PAR1 
is known to have bimodal effects on tumor cell motility. Whereas weak activation of 
PAR-1 [46] promotes tumor cell motility, strong activation of PAR1 has already been 
shown to inhibit tumor cell motility [28, 32, 47]. Unlike the above-mentioned studies, 
FXa did not exert a bimodal effect both on inhibition of cell migration as well as on 
PAR-1-dependent signal transduction. This discrepancy underlines that different 
PAR-1 agonists trigger different cellular responses. The rationale behind this 
important dilemma of how PAR-cleavage induces different cellular responses 
dependent on the ligand is currently subject to an intense research effort.  
 FXa is also a PAR-2 agonist [30] and PAR-2 activation has been linked with 
enhanced cell motility [29, 48, 49]. However, both siRNA as well as desensitization 
studies allowed us to rule out a role for PAR-2 in FXa-mediated inhibition of 
chemokinesis. Contradictory to our results, it was recently shown that 0.3 U/mL FXa 
significantly enhanced chemotaxis of MDA-MB-231 cells via PAR-2 [49] but 
unfortunately the authors did not study chemokinesis. Moreover, the data of this study 
are not supported by the finding of Hjortoe and colleagues [29] showing that FXa has 
no effect on chemotaxis. A puzzling dilemma is that in all three studies MDA-MB-
231 cells were used and at this moment we do not have a proper explanation for the 
different results. 
  We showed that both Rho and Src pathways are required for FXa-mediated 
effects as confocal microscopy of actin-stained MCF-7 cells showed a dramatic effect 
of FXa on stress fiber formation, which was abolished by specific inhibitors of Rho 
and Src. Importantly, the Rho and Src inhibitors not only prevented stress fiber 
formation but also the subsequent inhibition of cell migration. The involvement of the 
Rho and Src pathways is intriguing, as activation of these protein kinases is normally 
associated with increased migration. However, several studies show that excessive 
Rho activity inhibits actin polarization and migration[50-52]. Similarly, Rac-
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dependent stress fiber formation induced by phosphorylation of FAK, paxillin and 
Src, also has been shown to inhibit of migration [20, 50, 53, 54]. Interestingly, studies 
aiming at the mechanism by which sphingosine-1-phosphate inhibits cell migration, 
point to a model in which Rho activation leads to Rac inactivation thereby impeding 
lamellipodia formation [55, 56]. Alternatively, the inhibition of S1P dependent 
migration might rely on the G-protein coupled receptor S1P2 and involves activation 
of FAK and Rho/ROCK without Rac inactivation [50, 51]. Our results are in 
agreement with the latter model as FXa induced a transient but strong phosphorylation 
of Rac and, in keeping with this observation, random membrane protrusions (figure 5) 
rather than lamellipodia.  
 In our study, we also showed the crucial involvement of LIMK1 activation and 
sustained cofilin phosphorylation. LIMK1 plays a crucial role in lamellipodium 
formation, which provides the driving force for cell movement during the initial stage 
of migration [57]. However, the activity of LIMK1 requires tight regulation: 
overexpression of constitutively active LIMK1 impairs the formation of polarized cell 
morphology and directional cell migration. In such cells, the single polarized 
lamellipodium required for cell migration is replaced by multiple non-polarized 
lamellipodia in random directions [58]. Taken together, these results suggest that 
excessive phosphorylation of cofilin (and thus inactivation) by LIMK1 results in the 
loss of cell polarity, thereby inhibiting cell migration, because cofilin is a potent 
regulator of actin filament dynamics [59, 60] and is a key player in maintaining and 
extending lamellipodial protrusions at the leading edge of migrating cells [58, 61]. 
Sustained phosphorylation of LIMK1 and cofilin induced by FXa was 
accompanied by prolonged myosin light chain phosphorylation. 
Hyperphosphorylation of myosin light chain induces aggregation of thick actin 
bundles in HeLa [62] and mesangial cells [63]. An attractive hypothesis, therefore, is 
that FXa-mediates stress fiber formation through a phosphorylation cascade beginning 
with Rho/ROCK and Src, leading to sustained LIMK1 phosphorylation and ultimately 
impeding both cofilin activity and myosin light chain dephosphorylation. This 
cascade stabilizes actin filaments and hinders cell migration by impeding the 
formation of a single polarized lamellipodium but actually inducing the formation of 
random protrusions (figure 7).  
Overall our data, linking FXa-induced signal transduction to cytoskeletal 
rearrangement, establish that beyond its role in blood coagulation, FXa is likely to 
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play a key role in maintaining organ homeostasis or in pathological processes such as 
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Background: Apart from mediating fibrin deposition, the activated coagulation 
factors(F) VIIa, Xa and thrombin share the common ability to activate protease-
activated receptors (PARs), which are generally assumed to mediate critical 
functions in angiogenesis and smooth and cardiac muscle physiology. The 
common ability of coagulation factors to activate the same PARs gives rise to the 
question as to the specificity of coagulation FVIIa, activated FX (FXa) and 
thrombin-induced engagement of PARs on target cell physiology. Methods and 
Results: We generated comprehensive descriptions of coagulation factor signal 
transduction employing peptide-arrays containing 1024 spatially-addressed 
mammalian kinase substrates. The results clearly define coagulation factor-
specific signalling for FVIIa, FXa, and thrombin, in addition to a set of signal 
transduction pathways common to these coagulation factors. Differences 
between coagulation factors are especially pronounced in cell cycle regulating 
pathways. Conclusions: Thus despite the common ability to engage PARs 




The extrinsic coagulation pathway is initiated by the binding of factor (F) 
VII/VIIa factor VII to tissue factor (TF), followed by activation of FX, thrombin and 
further haemostasis (reviewed in 1). For decades it had been thought that coagulation 
factors represented a group of relative passive mediators involved in the linear 
transduction of the coagulation cascade. Scientific progress in the last decade has 
taught us, however, that these factors actively engage target cells to induce signal 
transduction and thus fulfill critical functions in a wide variety of pathophysiological 
phenomena 2. The most prominent example is the interaction between factor VIIa and 
tissue factor, which is critical for blood vessel development, and tissue factor-
deficient mice die as a consequence of abnormalities in this development 3-5. 
Furthermore, tissue factor regulates inflammation, because inhibition of TF / FVIIa 
complex assembly dramatically enhanced survival of baboons to LD100 infusion with 
Escherichia coli 6 and monocyte diapedesis may involve tissue factor 7. Finally TF 
appears to be important in tumor progression, although this effect may well be 
dependent on the vasculogenic properties of the molecule 8. The molecular 
mechanisms, however, by which TF / FVIIa interactions exert these effects, remain 
poorly defined. Analogously FXa and thrombin (FIIa) also exert coagulation- 
independent effects. In murine models genetic ablation of the FX gene is incompatible 
with normal development, animals displaying partial embryonic lethality and 
substantial tissue necrosis suggesting developmental defects in histogenesis 9, while 
prothrombin gene ablation is responsible for embryonic lethality 10,11.  It is now 
generally recognised that thrombin is pivotal regulator of angiogenesis 12, bone 
formation 13 and has a coordinating role in inflammatory reactions 14. Factor X is not 
required for normal development and in contrast to FVIIa and thrombin does not seem 
to be involved in angiogenesis 15, but is a critical regulator of tissue repair following 
trauma 16,17. All three vitamin K-dependent coagulation factors seem, however, to be 
potent mitogens for fibroblasts 16,18-22. Thus, coagulation factors fulfil important 
functions in physiology and although cleary sharing common functions in physiology 
important specific differences as to their action in physiology. 
Signalling via coagulation factors proceeds via a family of G-protein-coupled 
receptors, the proteases-activated receptors (PARs), that are activated by proteolytic 
cleavage rather than ligand binding 23. PARs are widely distributed in a variety of cell 
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types, including circulating blood cells, endothelial and vascular smooth muscle cells, 
as well as in cells constituting the nervous system, the gastrointestinal tract and the 
respiratory system. Among the 4 currently known PARs, PAR-1, -3 and -4 are 
cleaved by thrombin. PAR-2 is a target for cleavage by the TF/FVIIa complex, 
whereas FXa can activate both PAR-1 and PAR-224,25 (figure1a). Proteolytic cleavage 
of either receptor exposes a new N-terminus that binds to the body of the receptor to 
induce transmembrane signalling to G proteins. The activated G proteins in turn 
impact on a substantial network of signalling pathways, which trigger a cascade of 
downstream events, thereby regulating many cellular functions like cytoskeleton 
reorganization and cell survival23.  
The common ability of  FVII, FX and thrombin to activate identical and highly 
similar PARs (see figure 1a) raises two main questions: firstly, do different 
coagulation factors exert specific effects on cellular signaling or are their differences 
in physiological function of the different coagulation factors not reflected in 
downstream signal transduction? Secondly, although the structural similarity between 
PAR1 and PAR2 is very high 26-28, some physiological data suggests that these 
receptors maybe coupled to different signal transduction pathways29,30. Thus, to what 
extend are pathways downstream of PAR1 and PAR2 common and divergent? The 
importance of answering these questions is further increased by the large 
amplification of the coagulation signal due the large differences in plasma 
concentration (plasma levels: 0.5 ug/ml FVII, 10 ug/ml FX and 100 ug/ml thrombin) 
31. Elucidating the specific effects of coagulation factors on cellular physiology is 
hampered by a lack of a priori knowledge as to the signaling pathways which 
possibly mediate such coagulation factor-specific effects. Hence, this problem is best 
approached in an unbiased comprehensive fashion. Over the last 3 years array and 
mass spectrometry technologies have enabled analysis of the transcriptome and 
proteome of biological systems. Although this information will be of significant value 
to the elucidation of molecular mechanisms that govern cellular effects induced by 
coagulation factors, an equally, if not more important goal, is to define the kinase 
pathways, or phosphoproteome, that participate in coagulation factor signaling, as 
these enzymes play a critical role in the signaling cascades that determine cell cycle 
entry, survival and the migration fate of cells in the mammalian body (for review, see 
for instance 32,33). Although, traditional genetic and biochemical approaches can 
certainly provide some of these answers; however, for technical and practical reasons 
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these are typically pursued one gene or pathway at a time. Excitingly, however, 
comprehensive description of mammalian kinase cascades is possible through the 
sequential spotting of kinase substrates on a carrier. When such peptide arrays are 
incubated with cellular lysates and radio active ATP, comprehensive descriptions of 
cellular signaling may be generated. Recently, important successes with this 
methodology were obtained including the description of lipopolysaccharide signaling 
in human peripheral blood monocytes 34, the identification of Fyn and Lck as early 
targets in glucocorticoid signaling 35 and the identification of the signaling pathways 
specifically active in Barrett’s oesophagus as compared to the surrounding normal 
epithelium 36. Hence, kinome profiling using peptide arrays offers the tantalizing 
possibility to study cellular signal transduction in a more or less comprehensive 
fashion. 
In the present study, we have applied this technology for studying the specific 
effects of coagulation factor VIIa, Xa, and thrombin (IIa) on cellular physiology. To 
answer the important question as to protease activated receptor(s) engagement and 
functional consequences has differential effects on cellular physiology, we used as a 
cell model system the highly metastatic breast carcinoma cell line MDA-MB-231, as 
it constitutively expresses Tissue Factor, PAR-1 and PAR-2. Remarkably, we find 
that the coagulation factors –apart from activating a set of common signal 





Human FXa and thrombin were obtained from Kordia (Leiden, the Netherlands). 
Recombinant FVIIa was from NovoNordisk (Bagsvaerd, Denmark). Unless otherwise 
specified, the concentrations of these reagents were 100 nM FVIIa, 0.75 U/mL FXa 
(130.5 nM), 1 U/mL thrombin (10 nM).  
 
Cell Culture and Treatment 
MDA-MB-231 cells were purchased from ATTC and maintained in L-15 Leibovitz 
medium supplemented with 10% Fetal Calf Serum (FCS) and 100IU/mL penicillin 
and 100IU/mL streptomycin. For the stimulation experiments, cells were seeded in 6-
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wells dishes to 70% confluence, washed twice with serum-free medium and serum-
starved overnight prior to 10 minutes stimulation by the above indicated agonists.  
 
Peptide arraying 
The production of the array and the protocol of the kinome array have been described 
in detail earlier 34. In short, cells were washed in PBS and lysed in a non-denaturing 
complete lysis buffer. The peptide arrays (Pepscan, Lelystad, the Netherlands), 
containing up to 1024 different kinase substrates in duplo, were incubated with cell 
lysates for 2 hours in a humidified stove at 37C°. Subsequently, the arrays were 
washed in 2M NaCl, 1% triton-x-100, PBS, 0.1% tween and H2O, where after slides 
were exposed to a phospho-imaging screen for 72 hours and scanned on a phospho-
imager (Fuji, Stamford, USA).   The density of the spots was measured and analyzed 
with array software. 
 
Data Analysis of Peptide Array 
For the analysis clustering using the spearman correlation coefficient was calculated 
for each combination of sets and clustering was performed using Johnston 
hierarchical clustering schemes. T-tests were also performed on each set of values to 




Generation of phosphoproteome profiles 
For our experiments we employed MDAMB231 breast cancer cells, which highly 
express tissue factor (data not shown). We established that under our experimental 
conditions, these cells do not endogenously release either FVIIa, FXa or thrombin 
(not shown). Cells were incubated with either 100 nM FVIIa, 0.75 U/ml (130.5 nM) 
FXa, 1 U/ml (10 nM) of thrombin or with vehicle control for 10 min (figure 1b). 
Using ERK phosphorylation as a read out, concentration curves and time curves 
displayed that these concentrations and time points are appropriate for efficient 
induction of PAR signaling (data not shown). After the 10 min incubation cells were 
lysed and the cell lysates were employed for in vitro phosphorylation of peptide 
arrays using 33P-γ-ATP. Arrays consisted of 1024 different nonapeptides, providing 
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kinase substrate consensus sequences across the entire mammalian kinome. On each 
separate carrier, the array was spotted two times, to allow assessment of possible 
variability in substrate phosphorylation. The final physical dimensions of the array 
were 25 x 75 mm, each peptide spot having a diameter of approximately 250 µm, and 
peptide spots being 620 µm apart. As a control for the specificity of the reaction 33P- 
γ-ATP was used; no incorporation of radioactivity was seen.  
On figure 1c representative phospho-imager scans of MDA-MB-231 cells before and 
after stimulation with the different coagulation factors are shown.  We then calculated 
the mean phosphorylation level for all substrates before and after the treatment (total 
number of data points is 9 for each group). The technical quality of the profiles was 
good, and we only allowed experiments in which the Pearson product moment 
correlation coefficient was 
more as 0.95 for the technical 
replicas. We decided to use 
these data for analysis as to 
determine specific and 
divergent phosphorylation 
following stimulation with 
different coagulation factors. 
Figure 1 (A) Schematic 
representation of the coagulation 
cascade and the sequential activation 
of coagulation factors (black arrows), 
and the Protease-Activated Receptors 
activated by the different factors (red 
lines). (B) Experimental set-up of the 
study. The TF-expressing breast 
cancer cells MDA-MB-231 were 
exposed for 10 minutes to vehicle 
control, 100nM FVII, 130.5 nM FXa 
or 10 nM thrombin, and subsequently 
lysated. Cell lysates were assayed on 
PepChip to obtain specific kinome 
profilings. (C) phospho-imagers scans 
of 1024 spot PepChipTM performed in 




Phosphoproteome profiles reveal common and divergent coagulation factor-
dependent kinase activity 
In Figure 2a we show the different coagulation factors vs vehicle on global 
phosphorylation patterns in MDAMB231 cells scatter plot where each dot represents 
the normalized mean phosphorylation level for each of the 1024 substrates arrayed 
(see 34). The scatter plot illustrates the relative degree of similarity and divergence of 
















Figure 2 Comparison of the phosphoproteomes of cells stimulated with vehicle control, FVIIa, FXa or 
thrombin for 10 minutes. (A) Scatter plot showing the mean amount of phosphorylation detected by 
PepChipTM for all 1024 substrated in respectively FVIIa (y axis) vs vehicle (x axis) treated cells (left 
panel), FXa (y axis) vs vehicle (x axis) treated cells (middle panel), thrombin (y axis) vs vehicle (x 
axis) treated cells (right panel). (B) Scatter plot showing the mean amount of phosphorylation detected 
by PepChipTM for all 1024 substrated in FXa (y axis) vs FVIIa (x axis) treated cells(left panel), 
thrombin (y axis) vs FVIIa (x axis) treated cells (middle panel),  and thrombin (y axis) vs FXa (x axis) 
treated cells (right panel). (C) Hierarchical clustering (according to Johnson 54 of the phosphorylated 
motifs among the lysates tested. 
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Strikingly, we observed that the similarity was the greatest between thrombin and 
vehicle (R2=0.8535), while it was less with FXa (R2=0.7925) and that the more 
important divergence was reached between FVIIa and vehicle phosphoproteome. 
These observations were even more obvious when we compared the phosphorylation 
patterns after FVIIa vs FXa(R2=0.7173), thrombin vs FVIIa(R2=0.7713) and thrombin 
vs FXa (R2=0.8121) (see figures 2a and 2b). These comparisons showed a distinct 
subset of substrates that fall off the diagonal towards the FVIIa axis (kinase activity 
stimulated by FVIIa). Representation of these results is displayed on figures 2b. We 
further clustered these results according to Johnson. This representation, which is 
shown on figure 2c, further confirm very distinct signalling patterns induced by each 
coagulation factor as compared to the control. Importantly, the observation that FVIIa, 
Xa, and thrombin-induced phosphoproteome profiles each preferentially cluster with 
vehicle control and not with other coagulation factors demonstrates that despite 
targeting the same receptors (PARs) each factor induces highly specific effects on the 
cellular kinome.   
 
Effect of FVIIa on cellular signalling as deduced from the phosphoproteome profile  
The results obtained were used to construct provisional signal transduction schemes 
showing the differences in cellular signalling induced by each coagulation factor as 
compared to vehicle.  We found that phosphorylation of 98 substrates on the 1024 
array differs significantly between the FVIIa vs vehicle data sets (supplemental Table 
I), yielding only 25 significantly different activated kinases (figure 3a). Some of the 
signalling cascades induced by FVIIa have already been described before albeit in 
other experimental systems (e.g. activation of Jak/STAT5, activation MAPK cassette 
and a JNK cassette [although more upstream activators are now identified as 
compared to earlier studies] and the PI3 kinase/PKB pathway, which seems to have a 
strong negative action on GSK3-β in this experimental system). But also new 
signalling events become apparent from this analysis.  A highly prominent 
characteristic, immediately emerging from visual inspection of the list of changed 
kinase activities in coagulation factor-stimulated cells, is the down regulation of cell 
cycle kinases, in particular of the G1 to S phase kinase Cdk2. Further analysis (see 
provisional signal transduction scheme) reveals that this inhibition is probably 
mediated via the sequential action of the protein kinase Cζ and p53 proteins. Also, a 
negative action of TGF-β signalling (a negative regulator of immune responses) is 
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observed, which may be involved in some pro-inflammatory actions of FVIIa.  In 
addition many peptides derived from cytoskeleton-regulating proteins are influenced, 
suggesting dynamic regulation of the cytoskeleton, which may be in agreement with 
the effects of FVIIa on migration, for instance a clear activation of the p21Rac 
effector PAK1 is seen and further dowmstream signalling towards p38 MAP kinase 
(MAPK14), which is important for inflammatory signalling 37. Other important effects 
concern upregulation of VEGF receptor activity and diminished CK2 activity. Very 
novel, the AMPK pathway is targeted by FVIIa at the level of LKB and thus FVIIa 
inhibits cellular responses to unfavourable metabolic conditions. 
 
Effect of FXa on cellular signalling as deduced from the phosphoproteome profile  
Signal transduction downstream of FXa has been much less extensively investigated 
as FVIIa and FXa for its effects on cellular signal transduction. From the provisional 
signal transduction scheme based on the changes in the phosphoproteome (See 
Supplemental Table II and figure 3b) , it appears that several pathways are in common 
with factor VIIa signalling (see figure 3d), in particular a pathway involving 
activation of PKB, leading to inhibition of GSK3-β in turn leading to diminished β-
catenin phosphorylation. Also, like FVIIa, FXa leads to dimished Cdk2 activity and 
Polo-like kinase activity, and thus FXa appears to inhibit the progression of the cell 
cycle. Furthermore, the upregulation VEGF receptor activity seen with FVIIa is also 
seen with FXa, as is diminished CK activity following coagulation factor treatment. 
Also, important differences, however, appear (Figures 3b and d). Whereas FVIIa 
activates PAK1 enzymatic activity, FXa stimulation down regulates activity of this 
kinase.  Again connections to pro-inflammatory MAP kinases are seen, e.g. JNK 
which is well-established to be involved in inflammatory responses (e.g. 38). A variety 
of peptides acting as substrates to the classical calcium and diacylglycerol responsive 
PKC is less phosphorylated after FXa treatment of the cells suggesting that these 
kinases are under negative regulation of FXa. Modulation of receptor protein kinases 
is complex, EGF receptor activity is down, but insulin receptor-dependent peptide 
phosphorylation is up, indicating that this receptor may be employed in cellular 






Figure 3 Schematic 
representation of the common 
and unique signaling pathways 
deduced from kinome profiling 
analysis induced by 
coagulation FVIIa (A), FXa 
(B) and thrombin (C). A-C: 
green line: kinase activation; 
red lines: kinases repression. 
(D) Schematic representation 
of pepchip array results 
comparing kinases pathways 
activated by FVIIa, FXa and 
Thrombin. The peptide 
numbers refer to the 
corresponding peptide 
numbers in supplemental table 


















Effect of thrombin on cellular signalling as deduced from the phosphoproteome 
profile  
Thrombin signalling is more reminiscent to FVIIa signalling as compared to FX 
signalling (See Supplemental Table III, Figures 3c and d), in the latter case for 
instance the negative regulation of TGF-β signalling is not observed but it is observed 
for both thrombin and FVIIa. Also down regulation of the nutrient sensing AMPK 
pathway was not seen with FXa, but is prominently seen after both FVIIa stimulation 
and thrombin stimulation. Like FXa signalling and FVIIa signalling strong activation 
of PKB pathway and subsequent inhibition of GSK-3-β (although the increased β-
catenin phosphorylation is only seen with FVIIa and not with FXa or thrombin). Also 
diminished CK2 activities have lysates from thrombin stimulated cells in common 
with the lysates from cells stimulated with the other two coagulation factors. 
Furthermore, like FVIIa and FXa, thrombin results in a downregulation of Cdk2 
activity (as well as diminished Polo-like kinase activity, in common with FXa), 
apparently resulting from increased Chk2 stimulation and thus probably the result of 
stimulation of the p53 pathway 39. The inhibition of the cell cycle was especially 
evident from co-inhibtition seen of Cdk5.  Striking is the relative small impact 
thrombin makes on cytoskeleton regulating kinases (but in fact inhibition of cell 
migration with thrombin has been described).  Again, VEGF receptor activity was 
upregulated, which was also seen with the two other coagulation factors. Thrombin 




Physiological data indicate that the different vitamin K-dependent coagulation 
factors exert factor-specific effects, but molecular data indicate that these factors 
activate the same receptors. In the present study we characterized the 
phosphoproteome induced by the individual factors and provided for the first time a 
comprehensive description of changes in kinase activity evoked by either FVIIa, FXa 
and thrombin. The results indicate a high level of a coagulation factor-specific kinome 
changes, but also show common signal transduction pathways downstream of these 
receptors. 
The kinome signatures obtained after stimulation of cells with vehicle control, 
FVIIa, FXa, and thrombin were markedly unique. Striking is the observation that the 
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kinome signatures  of the individual coagulation factors resembled more the vehicle 
control as compared to the kinome signatures generated by the other coagulation 
factors. This observation is striking for two reasons, on a structural level and on the 
level of genomic organisation, FVIIa and Xa are quite homologous, whereas thrombin 
is clearly different. Nevertheless, the similarity in structure is not reflected in more 
homology at the level of phosphoproteome, cluster analysis revealing that the 
phosphoproteome after Xa stimulation more resembles the phosphoproteome induced 
by thrombin as compared to that induced by FVIIa. In this context it is important to 
note that this analysis was performed on the entire body information available from 
the phosphoproteome analysis. The provisional signal transduction schemes are based 
on the peptides which actually show statistically significant differences (p<0.05) 
between the different conditions, When these schemes are compared (although these 
supervised provisional signal transduction schemes do not lend themselves to 
statistically rigorous testing of covariation), it would appear that FVIIa is more similar 
to thrombin-induced signalling events. However, in any case it is evident that the 
expected similarity between the FVIIa- and FXa-evoked kinomes is not evident, 
highlighting the unique effects on cellular kinase activity each of these coagulation 
factors exerts. 
These unique actions are remarkable in view of the biology of the PAR 
activation. Our results reveal that several signaling pathways regulated by FVIIa are 
also subject to control by FXa and thrombin (Figure 3d) as would be the a priori 
assumption from the targeting of similar receptors by these coagulation factors.    
Consistent with the notion that FXa is able to activate both PAR-1 and PAR-2, our 
results show that FXa shares common activated pathways with FVIIa, suggesting that 
these pathways arise from PAR-2 activation, and a common set of pathways with 
thrombin, which is likely to be a result of PAR-1 activation. More striking is the fact 
that thrombin shares with FVIIa for instance the activation of TGF-β receptor (Figure 
3d), as these coagulation factors do not share activation of an identical PAR family 
member. These results would be in line with the recently proposed  cross activation of 
by heterologous PARs following clustering of different PAR family members as was 
discussed in 40,41. Reciprocally, we determined that coagulation factors - although 
activating the same receptors - can trigger distinct and specific signalling pathways. 
For instance, GPCR activation downstream of FXa stimulation is linked to the 
activation of GRK7, while thrombin activates GRK5 specifically. The activation of 
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PARs entails the proteolytic release of a N-terminal fragment that subsequently act as 
a auto-ligand for the receptor23. There is no evidence that different coagulation factor 
lead to the hydrolytic release of different fragment, hence differences in signalling 
caused by different coagulation factors must be based on other molecular 
mechanisms. A possibility is that different factors cause conformational changes in 
the interacting PARs causing changes in the subsequent signal transduction. Proof for 
such a notion might be found in the observations that both APC and thrombin have 
the capacity to proteolytically activate PAR1 but –as shown by elegant gene 
expression analysis by Ruf cum suis- both interactions cause remarkably different 
effects on cellular gene expression 40,41. In this context it is important to note that APC 
is more homologous with FXa and FVIIa as compared to thrombin. Alternatively, it is 
possible that the differences in relative activation of the various PARs induce highly 
coagulation factor-specific kinomics changes. In any case, however,  the specificity of 
the effects evoked by the various coagulation factors acting via the same receptors on 
the phosphoproteome reveal a highly unique situation in mammalian biology and may 
reflect an evolutionary ancient system controlling tissue remodelling after trauma. 
Besides providing new insights about the role of PARs in coagulation factors 
signalling, the signalling systems identified using the kinomics analysis reveal 
important new aspects of coagulation factor biology. Genetic, biochemical and 
cellular studies have highlighted the importance of coagulation factors in 
morphogenesis of the circulatory system 9,42-44. The observation that VEGF receptor-
dependent kinase activity is upregulated by all three of the vitamin K-dependent 
coagulation factors fits well in this concept and may provide mechanistic clues 
explaining the action of coagulation factors on blood vessel formation. Activation of 
this receptor in our experimental system is almost certainly dependent on scaffold 
type activation via an intracellular non-receptor tyrosine kinase analogous to that 
described for G protein coupled receptors by Ulrich cum suis for the EGF receptor45. 
This idea is supported by the observation that the MTRDIYETDYY peptide appears 
to be hyperphosphorylated after coagulation factor stimulation, and this peptide has 
been described as scaffold phosphorylation acceptor in T cell signalling. Scaffold use 
of receptor tyrosine kinase seems not to be limited to the VEGF receptor, as the 
insulin receptor seems to be used by coagulation factors to stimulate PI3 kinase 
dependent signalling, but nevertheless specific as down regulation of PDGF receptor 
and EGF receptor kinase activities is observed. Strikingly, recently the transcriptome 
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induced by 100nM FVIIa (the concentration used in our study) in the same cell line 
(MDA-MB-231 breast carcinoma cells) has come available 41. The authors 
demonstrated that, after 6h stimulation, FVIIa is able to induce the expression of 
different genes such as IL-8, CXCL1, CSF1 and 2 and VEGFc which are all related to 
angiogenesis, with CSF1 46 and VEGFc 47,48 directly promoting angiogenesis, which 
supports the concept emerging from the kinomic data that a pro-angiogenic program 
is induced by FVIIa. It is of course tempting to speculate on the role of VEFG 
receptor transactivation by coagulation factors in the tissue remodelling following 
ischemic attack and possibly cancerous processes, but elucidation of this role awaits 
experiments in animal models employing VEGF receptor kinase inhibitors. 
Another important finding in the kinome profiles is the negative action 
induced by FVIIa and thrombin on TGF-β signalling (a negative regulator of immune 
responses) which may be involved in mediating the pro-inflammatory reaction 
following coagulation. Again, Albrektsen and colleagues observed in their study on 
the transcriptome that after 6h stimulation, 100 nM FVIIa induced the expression of a 
set of genes such as CXCL1 and IL-8 which, in addition to be involved in 
angiogenesis, are also potent pro-inflammatory markers. Overall, our study 
establishing a comprehensive kinomics profiling is supported by the study on 
Albrektsen et al, by determining the mechanisms underlying FVIIa-induced 
angiogenesis and inflammation which might open new therapeutical avenues.  
In the present study, a common theme in coagulation factor signalling is the 
downregulation of the cell cycle, probably via the p53/Chk2 pathway. At first this 
observation puzzled us because of the well documented stimulation of cancer cell 
proliferation by coagulation factors. It is, however, important to note that this 
observation may provide a molecular explanation for earlier observations that at the 
concentrations employed in this study, both thrombin and FXa induces tumor cell 
apoptosis rather as tumor growth 18,49-52, which requires higher local concentrations of 
these coagulation factor and probably stimulate the anti-apototic PKB pathway to 
such an extend that the CDK inhibition is negated. In this context it is important to 
note that also the downregulation of the LKB/AMPK cassette will also provide an 
anti-apoptotic signal (although it may increase necrosis). Thus a picture emerges from 
our studies in which coagulation factors modulate the growth status of the cell in a 
highly complex fashion, the exact outcome being dependent on the relative strength of 
the signals involved. In this respect it is interesting to see that the pathways common 
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to the various coagulation factors a highly reminiscent of those induced by interferon 
signalling which also has complex effects on cancer cell survival. This is the more 
striking in view of the evolutionary relationship between cytokine signalling and 
coagulation factor signalling 53. As coagulation factor signalling has been established 
earlier in vertebrate evolution than cytokine signalling, it may even be tempting to 
speculate that the highly coagulation factor specific effects observed in the present 
were originally not only acquired for their role in tissue repair following trauma but 
also served to coordinate the host response in infection. Later in evolution the latter 
function was probably taken over by cytokines, and coagulation factor signalling in 
the human now mainly serves to direct repair after vascular trauma and drive new 
vessel formation. Thus the kinomic profiles generated in the present study may well 
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Coagulation proteases have been suggested to play a
role in the pathogenesis of tissue remodeling and
fibrosis. We therefore assessed the proinflammatory
and fibroproliferative effects of coagulation protease
factor (F)Xa. We show that FXa elicits a signaling
response in C2C12 and NIH3T3 fibroblasts. FXa-in-
duced ERK1/2 phosphorylation was dependent on
protease-activated receptor (PAR)-2 cleavage because
desensitization with a PAR-2 agonist (trypsin) but not
a PAR-1 agonist (thrombin) abolished FXa-induced sig-
nal transduction and PAR-2 siRNA abolished FXa-in-
duced ERK1/2 phosphorylation. The PAR-2-dependent
cellular effects of FXa led to fibroblast proliferation,
migration, and differentiation into myofibroblasts, as
demonstrated by the expression of -smooth muscle
actin and desmin, followed by the secretion of the cy-
tokines monocyte chemotactic protein-1 and interleu-
kin-6 as well as the expression of the fibrogenic pro-
teins transforming growth factor- and fibronectin. To
assess the relevance of FXa-induced proliferation and
cell migration, we examined the effect of FXa in a
wound scratch assay. Indeed, FXa facilitated wound
healing in a PAR-2- and ERK1/2-dependent manner.
Taken together, these results support the notion that,
beyond its role in coagulation, FXa-dependent PAR-2
cleavage might play a role in the progression of tissue
fibrosis and remodeling. (Am J Pathol 2008, 172:309–320;
DOI: 10.2353/ajpath.2008.070347)
Fibroblasts comprise the most abundant cell type in con-
nective tissues and are central players in organ ho-
meostasis. Their main function is to maintain the struc-
tural integrity of connective tissue by secreting collagen
and fibronectin, which are principal components of the ex-
tracellular matrix (ECM). On injury, the fibrotic response
orchestrated by fibroblasts is a critical component of tissue
restoration and wound healing. Fibroblasts are frequently
exposed to coagulation proteases after vascular damage.
As fibroblasts constitutively express tissue factor, vascular
injury exposes tissue factor to circulating factor (F)VII.1 After
activation, FVIIa converts FX into its active form, FXa, which
subsequently converts prothrombin into thrombin leading to
the formation of a fibrin clot.
On the action of cytokines and growth factors secreted
by monocytes, fibroblasts migrate into the wound and
subsequently proliferate and concomitantly differentiate
into myofibroblasts2,3 that develop ultrastructural and
phenotypic characteristics of smooth muscle (SM) cells.
The neoexpression of -SM actin (-SMA), typical of SM
cells located in the vessel wall, is the hallmark of myofi-
broblastic cells.4 Myofibroblasts, which have enhanced
metabolic activity as compared to undifferentiated fibro-
blasts, synthesize components of the new ECM, thereby
restoring the structure and function of the injured tissue.
In addition, myofibroblasts amplify the healing process
by secreting inflammatory mediators.5
Fibroblast migration, proliferation, and differentiation in
combination with enhanced ECM synthesis require tight
regulation. The escape to self-limiting control results in a
broad range of pathologies characterized by fibrotic dis-
orders attributable to excessive fibroblast proliferation
and deregulated ECM deposition.5,6 Eventually, the ac-
cumulation of connective tissue compromises organ
function and often leads to premature death. Additionally,
vascular remodeling, which is characterized by deregu-
lated fibroproliferative responses represents a common
theme of many cardiovascular abnormalities. Mechanis-
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tic studies suggest that transforming growth factor
(TGF)- is the most potent cytokine inducing ECM syn-
thesis by myofibroblasts.7
Strikingly, many of the tissue fibrosis and remodeling
disorders are associated with activation of the coagula-
tion cascade. Persistent fibrin deposition has been ob-
served in renal fibrotic disease.8 In lung fibrosis patients,
thrombin levels but also zymogen FX levels are increased
together with enhanced fibrin deposition.9 Abundant fi-
brin deposition is also observed in atherosclerosis,10 and
patients with a thrombus after coronary angioplasty
(which is known to contain thrombin and FXa11) at the site
of vascular injury are at higher risk of restenosis.12
The identification of protease-activated receptors
(PARs), a family of G-protein-coupled receptors, consti-
tutes a potential link between activation of the coagula-
tion cascade and the progression of tissue remodeling or
fibrotic disease. Indeed, besides its properties in blood
coagulation, FXa and thrombin induce intracellular sig-
naling via proteolytic cleavage of PARs. PAR-1, -3, and -4
are cleaved by thrombin,13 whereas FXa can activate
both PAR-1 and PAR-2.14
Although the role of thrombin-induced PAR-1 activa-
tion in tissue repair has been well documented,15,16 less
is known about the contribution of FXa. In addition, the
involvement of PAR-2 in wound healing and fibrotic dis-
ease has only recently begun to unfold. For instance,
-SMA and PAR-2 expression are correlated in a renal
interstitial fibrosis model.17 Pulmonary PAR-2 is highly
expressed in acute and chronic lung injury, which sug-
gests that PAR-2 may participate in inflammation and
fibroproliferation.18 PAR-2 furthermore maintains pancre-
atic fibrosis through increased proliferation and collagen
production in pancreatic stellate cells.19 Finally, IgA ne-
phropathy biopsies revealed the presence of PAR-2.20
Interestingly, FXa triggers signaling pathways involved
in the regulation of cell growth and ECM deposition: it
stimulates proliferation of fibroblasts and SM cells21–24
and induces the expression of interleukin (IL)-6, IL-8,
monocyte chemotactic protein (MCP-1),25 and TGF-.20
Moreover, FXa induces ERK1/2 phosphorylation in several
cell lines, both murine and human, such as SM cells,26,27
cancer cells,14,21,28 endothelial cells,29 mesangial cells,30
and fibroblasts.22,31 The phosphorylation of ERK1/2 is
widely used as a surrogate marker for PAR-1 and PAR-2
activation.32 Moreover, the activation of ERK1/2 has been
closely associated with cellular proliferation,33,34 protein
synthesis,35 and more recently wound healing.36 Taken
together, these data support the hypothesis that FXa is
involved in the pathogenesis of tissue fibrosis and
remodeling. Therefore, we studied FXa-induced intra-
cellular signaling and determined the potential conse-
quence on proinflammatory and profibrotic responses.
Materials and Methods
Cell Culture
Growth-arrested fibroblasts NIH3T3 (CRL-1658) and
myoblasts C2C12 (CRL-1772) were purchased from
American Type Culture Collection (Manassas, VA), and
human dermal fibroblasts were obtained from Promocell
(Heidelberg, Germany). Cells were maintained in Dulbec-
co’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal calf serum (FCS). Unless stated otherwise,
cells were washed twice with phosphate-buffered saline
(PBS), serum-starved for 4 hours, and subsequently stim-
ulated as described.
Antibodies
Primary antibodies against -actin, -actin, desmin,
TGF-, fibronectin, PAR-1 (H-111), and PAR-2 (SAM11)
were from Santa Cruz Biotechnology, Santa Cruz, CA.
Phospho-FAK, phospho-p42/p44 MAP kinase, and phos-
pho-Src antibodies were purchased from Cell Signaling
Technology (Beverly, MA).
Reagents
Human FXa and thrombin were obtained from Kordia
(Leiden, the Netherlands). Tick anticoagulant peptide
(TAP) was kindly provided by Dr. Georges Vlasuk (Cor-
vas International Inc., San Diego, CA). Hirudin was pur-
chased from Calbiochem (San Diego, CA). All experi-
ments involving 24-hour incubation with FXa included
hirudin to block any thrombin signaling as described.14
Control experiments demonstrated that hirudin alone had
no effect in our assays. ERK1/2 inhibitor U0126 was
purchased from Cell Signaling Technology. Phalloidin-
fluorescein isothiocyanate and phalloidin-tetramethyl-
rhodamine isothiocyanate were purchased from Sigma
(St. Louis, MO). Cell tracker green CMFDA (5-chlorom-
ethylfluorescein diacetate) was obtained from Molecular
Probes (Eugene, OR). PP1 was from Biomol (Plymouth
Meeting, PA). PAR-1 cleavage-blocking monoclonal an-
tibody ATAP2 was obtained from Santa Cruz Biotechnol-
ogy and used as previously reported.37 Predesigned
PAR-2 (no. 158457) and control siRNA (no. 4611) was
obtained from Ambion Inc. (Austin, TX). One U/ml FXa
corresponds to 174 nmol/L.
Western Blot
Cells were lysed in Laemmli lysis buffer and incubated for
5 minutes at 95°C, and whole cell lysates were separated
by 10% sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis. After electrophoresis, proteins were trans-
ferred to an immobilon-P polyvinylidene difluoride mem-
brane (Millipore, Billerica, MA). Membranes were incubated
overnight at 4°C with primary antibodies. All secondary
antibodies were horseradish peroxidase-conjugated from
DakoCytomation (Glostrup, Denmark). Blots were imaged
using Lumilight Plus ECL substrate fromRoche (Basel, Swit-
zerland) on a GeneGnome imager (Syngene, Cambridge,
UK). Densitometry was performed in Photoshop 7.0 (Adobe
Systems, San Jose, CA) using the histogram function in a
selected area of constant size for each band. Background
was subtracted and values for the protein of interest were
corrected for those of -actin.
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Immunofluorescence
Cells were grown on coverslips at 20 to 30% confluence.
After pretreatment (when indicated), and subsequent
stimulation with 0.75 U/ml FXa or PBS for the indicated
time periods, cells were washed with PBS and fixed with
3.7% formaldehyde for 20 minutes at room temperature.
Fixed cells were permeabilized and blocked in PBS/0.1%
Triton X-100 (PBS-T) supplemented with 10% FCS for 1
hour. Cell nuclei were stained with 4,6-diamidino-2-phe-
nylindole (200 ng/ml, Roche) in PBS-T for 30 minutes. The
actin cytoskeleton was stained with 10 g/ml of phalloi-
din-tetramethyl-rhodamine isothiocyanate in PBS-T sup-
plemented with 1% bovine serum albumin. For imaging
FAK or Src phosphorylation, cells were blocked as for
phalloidin staining but subsequently incubated with the
appropriate antibody and subsequent fluorescein isothio-
cyanate-conjugated secondary antibody (both in 3% bo-
vine serum albumin/PBS-T). After staining, the cells were
washed and mounted in Mowiol/DABCO aqueous mount-
ing medium (Vector Laboratories, Burlingame, CA). Im-
ages were visualized using an epifluorescence micro-
scope (Leica DMRA, Wetzlar, Germany) and captured on
a cooled charge-coupled camera (KX Series; Apogee,
Auburn, CA) operated by ImagePro Plus software (Media
Cybernetics, Silver Spring, MD).
Proliferation Assay (MTT)
Cells seeded at a density of 104/cm2 in 96-well plates in
DMEM supplemented with 1% FCS, were (if indicated)
pretreated with TAP (200 nmol/L), hirudin (100 nmol/L), or
the ERK1/2 inhibitor U0126 (10 mol/L), after which they
were stimulated with FXa (1 U/ml) or PBS as a control.
Cell survival was determined at the indicated intervals
using a MTT assay as described before.38
Transfections
Transfections of predesigned siRNAs were performed us-
ing HiPerfect kit (Qiagen, Hilden, Germany) according to
the manufacturer’s protocol. For transfections in six-well
plates, 75 ng of siRNA was used at a 1:3 ratio of RNA/
HiPerfect reagent. Cells were incubated with transfection
complexes for 16 hours, after which fresh medium was
added for 6 hours preceding further experimentation.
Cell Migration Assay
Cells were grown to 70% confluence in six-well plates
and before experimentation labeled for 1 hour with 10
mol/L CellTracker Green in serum-free medium. The
dye was fixed by a 1-hour incubation in medium with 10%
FCS. Subsequently, cells were washed and detached
with 2 mmol/L ethylenediaminetetraacetic acid in PBS.
Next, cells were resuspended in serum-free medium and
transferred to 8-m pore size HTS FluoroBlok cell culture
inserts (BD Falcon, Franklin Lakes, NJ). FXa (1 U/ml) or
PBS (control), were added to the bottom well and cell
migration was assessed as described before.39 Briefly,
fluorescence values representing the number of cells on
the bottom side of the insert were read during 30 cycles
(each cycle comprising four readings spanning 2 min-
utes) at 37°C on a Series 4000 CytoFluor multiwell plate
reader (Perseptive Biosystems, Framingham, MA). The
raw fluorescence data were corrected for background
fluorescence and fading of the fluorophore, and the data
were plotted with GraphPad Prism-4 (San Diego, CA).
Wound Scratch Assay
Cells were plated in six-well plates and maintained in
DMEM supplemented with 10% FCS. After the cells
reached 80 to 90% confluence, a wound was created in
the center of the cell monolayer by a sterile plastic pipette
tip. Immediately thereafter, the cells were washed with
PBS to remove floating cellular debris and reincubated
for an additional 18 hours with either serum-free medium
(for use as a negative control), DMEM medium supple-
mented with 10% FCS (as positive control), or serum-free
medium containing FXa. When indicated, cells were pre-
incubated with PP1 (10 mol/L), U0126 (10 mol/L), or
TAP (200 nmol/L) 30 minutes before wounding the cells.
The ability of cells to proliferate and migrate into the
wound area was assessed after 18 hours by comparing
the 0- and 18-hour phase-contrast micrographs of six
marked points along the wounded area at each plate.
The percentage of nonrecovered wound area was calcu-
lated by dividing the nonrecovered area after 18 hours by
the initial wound area at 0 time.
Cytokine/Chemokine Assay
IL-6, MCP-1, interferon-, tumor necrosis factor (TNF)-,
and IL-10 were measured using the BD Cytometric bead
array mouse inflammation kit (Becton Dickinson, Franklin
Lakes, NJ) as described before.40 Detection limits were
10 pg/ml.
Statistics
Statistical analyses were conducted using GraphPad
Prism version 4.00 software. Data are expressed as
means  SEM. Comparisons between two conditions
were analyzed using Mann-Whitney t-tests.
Results
Expression of PAR-1 and PAR-2 by NIH3T3 and
C2C12 Cells
For efficient signal transduction of FXa, it is essential that
its cellular receptors are expressed. Therefore, we as-
sessed the presence of PAR-1 and PAR-2 on the NIH3T3
and C2C12 fibroblast cells used in this study. As shown
in Figure 1A, both NIH3T3 (lane 1) and C2C12 (lane 2)
cells constitutively expressed PAR-1 and PAR-2.
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PAR-1 and PAR-2 Expressed by NIH3T3 and
C2C12 Are Functional
We next determined whether the expression of PAR-1
and PAR-2 was associated with functional responses in
both cell lines. As read-out we examined the phosphor-
ylation of ERK1/2, which is widely used as a surrogate
marker for PAR-1 and PAR-2 activation.32 Cells were
serum-starved for 4 hours, stimulated with thrombin (1
U/ml corresponding to 10 nmol/L), a specific PAR-1 ag-
onist; trypsin (200 nmol/L), a specific PAR-2 agonist; or
PBS as negative control. As shown in Figure 1B for
C2C12 cells, stimulation with thrombin (lane 2) or trypsin
(lane 3) induced strong phosphorylation of ERK1/2 as
compared to the negative control (lane1). Similar results
were obtained with NIH3T3 cells (data not shown).
Hence, both PAR-1 and PAR-2 are functionally active on
the fibroblasts.
FXa Elicits Signal Transduction in NIH3T3 and
C2C12 Cells
To assess the capacity of FXa to induce intracellular
signaling in fibroblasts, we examined FXa-induced phos-
phorylation of ERK1/2. Figure 1C shows that signaling
induced by FXa was already detectable at 0.25 U/ml
(lane 2). ERK1/2 phosphorylation strongly increased us-
ing 0.5 U/ml FXa (lane 3) and was maximal at 1 U/ml (lane
5). The same results were obtained in NIH3T3 cells (data
not shown). To verify the specificity of ERK1/2 phosphor-
ylation induced by FXa, cells were preincubated with
TAP, an FXa inhibitor, or hirudin, a thrombin inhibitor. As
shown in Figure 1D for C2C12 cells, pretreatment with
TAP (lane 2), but not with hirudin (lane 3), almost com-
pletely inhibited FXa-induced ERK1/2 phosphorylation.
Similar results were obtained with NIH3T3 cells (data not
shown). Hence, FXa specifically induces ERK1/2 phos-
phorylation, which is independent of thrombin formation.
FXa Signals via PAR-2 Activation
To identify the receptor by which FXa induces signaling,
we tested whether the activation of PAR-1 is required for
FXa signaling. Cells were treated with FXa in the absence
or presence of the PAR-1-blocking antibody ATAP2. As
shown in Figure 1E, ERK1/2 phosphorylation was strongly
induced by FXa (lane 3) independently of the blocking
antibody (compare lanes 3 and 6). In contrast, nearly
70% of ERK1/2 phosphorylation induced by thrombin
(lane 2) was inhibited by antibody treatment (lane 5).
These results suggest that PAR-1 activation is not re-
quired for FXa-mediated signaling (in contrast to throm-
bin-mediated signaling) and that PAR-2 is likely to be
involved. To confirm the involvement of PAR-2, we stud-
ied FXa-induced signaling in thrombin- or trypsin-desen-
sitized fibroblasts. To validate the experimental set-up,
we first verified the specificity of our desensitization ex-
periments. As shown in Figure 1F, thrombin desensitiza-
tion abolished subsequent stimulation by thrombin (lanes
1 to 4) but not by trypsin (lanes 5 to 8). Reciprocally,
Figure 1. FXa elicits specific phosphorylation of ERK1/2 in fibroblasts via
PAR-2 activation. A: Western blot analysis on cell lysates of NIH3T3 (lane 1)
and C2C12 (lane 2) cells showing that both cell lines constitutively express
PAR-1 and PAR-2. Actin was used as a loading control. B: Serum-starved
C2C12 cells (4 hours) treated with PBS (lane 1), thrombin (lane 2), or trypsin
(lane 3) for 30 minutes. Western blot analysis of phospho-ERK1/2 indicates
the functionality of both PARs. C: Effect of different concentrations of FXa on
the phosphorylation of ERK1/2 in C2C12 cells. Cells stimulated for 30 minutes
with PBS (lane 1) and FXa (lanes 2 to 5). D: Top: Western blot of C2C12
cells pretreated for 30 minutes with 200 nmol/L TAP (lane 2) or 100 nmol/L
hirudin (lane 3) and stimulated for 30 minutes with PBS (lane 1) or 1 U/ml
FXa (lanes 2 to 4) indicate that FXa-induced ERK1/2 phosphorylation is
specific. Bottom: Densitometric analysis of three independent Western blots
(mean  SEM). E: FXa-induced ERK1/2 phosphorylation is not mediated by
PAR-1. Western blots of C2C12 cells incubated for 30 minutes with PBS
(lanes 1 to 3) or the anti-PAR-1 antibody ATAP2 (lanes 4 to 6), which were
subsequently stimulated for 30 minutes with PBS (lane 1), 1 U/ml thrombin
(lanes 2 and 5), or 1 U/ml FXa (lanes 3 and 6). F: FXa-induced ERK1/2
phosphorylation is mediated by PAR-2. Lanes 1 to 16: Western blots of
fibroblasts exposed for 150 minutes (desensitization) to thrombin (lanes 1 to
8) or trypsin (lanes 9 to 16), subsequently stimulated with thrombin (lanes
1 to 4 and 13 to 16) or trypsin (lanes 5 to 12) for the indicated time points.
Western blots of fibroblasts exposed for 150 minutes to serum-free control
medium (lanes 17 to 20), thrombin (lanes 21 to 24), or trypsin (lanes 25
to 28) subsequently stimulated with FXa (1 U/ml) for the indicated time
points. B–F: Total ERK1/2 is used as a loading control. G: PAR-2-specific
siRNA causes loss of receptor-stimulated ERK1/2 phosphorylation. Left:
Western blot of C2C12 cells transfected with control siRNA or PAR-2 siRNA.
Right: Western blot of C2C12 cells transfected with control siRNA (lanes 1
to 4) or PAR-2 siRNA (lanes 5 to 8), stimulated with FXa for the indicated
time points (minutes). Actin served as a loading control. Results presented
are representative of three independent experiments.
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trypsin pretreatment prevented subsequent ERK1/2
phosphorylation when the fibroblasts were treated with
trypsin (lanes 9 to 12) but not when treated with thrombin
(lanes 13 to 16). Because thrombin and trypsin indeed
specifically desensitized cells, we next assessed FXa-
induced signaling in desensitized cells. As shown in Fig-
ure 1F, FXa still induced ERK1/2 phosphorylation in
thrombin-desensitized cells (lanes 21 to 24). In contrast,
fibroblasts pretreated with trypsin failed to respond to
subsequent FXa stimulation (lanes 25 to 28 as compared
to lanes 17 to 20), indicating both agonists activate the
same receptor (ie, PAR-2). Similar results were obtained
with NIH3T3 cells. To confirm that PAR-2 is the receptor
mediating FXa signaling, cells were transfected with
PAR-2 siRNA. As shown in Figure 1G, PAR-2 siRNA, but
not control siRNA, impaired FXa-induced phosphoryla-
tion of ERK1/2. Taken together, these results strongly
suggest that PAR-2 mediates FXa signaling in fibroblasts.
FXa Increases -SMA and Desmin Expression
in Fibroblasts
We assessed the consequences of PAR-2-mediated FXa-
induced signaling for processes involved in wound heal-
ing and fibrosis, which are both characterized by the
formation of a myofibroblast-enriched provisional ECM.
Therefore, we examined whether FXa induced the differ-
entiation of fibroblasts into myofibroblasts. Because
-SMA expression is a hallmark characteristic for the
conversion of fibroblasts into myofibroblasts, we as-
sessed -SMA levels in the fibroblast cells. As shown in
Figure 2A, growth-arrested NIH3T3 fibroblasts (lane 1)
expressed low constitutive levels of -SMA, whereas the
differentiated C2C12 cells expressed higher basal levels
(lane 3). Stimulation of NIH3T3 cells with FXa strongly
increased -SMA expression in a time-dependent (lanes
4 to 8) and dose-dependent (lanes 9 to 13) manner,
indeed suggesting that FXa induces the differentiation of
fibroblasts into myofibroblasts.
In addition to -SMA expression, the intermediate fila-
ment protein desmin might be induced during fibroblast
differentiation into myofibroblast.41 Therefore, we also
determined desmin expression in NIH3T3 fibroblasts. As
shown in Figure 2B, FXa also induced a time-dependent
(lanes 1 to 5) and concentration-dependent (lanes 6 to
10) expression of desmin, further supporting the hypoth-
esis that FXa induces fibroblast differentiation.
FXa Enhances Profibrotic Protein Production by
C2C12 Myoblasts
We next examined FXa-induced synthesis of the profi-
brotic cytokine TGF-. As shown in Figure 2C, C2C12
cells constitutively expressed very low levels of TGF-.
Stimulation with FXa showed a time-dependent increase
in TGF- levels (lanes 1 to 5), with maximal levels
reached at 24 hours (lane 5). TGF- was already induced
by 0.5 U/ml FXa, but maximal expression was observed
using 1 U/ml indicating a dose-response effect (lanes 6 to
10). Similar results were observed in the NIH3T3 cells,
although protein synthesis was slightly less efficient in
these cells (data not shown).
Fibronectin is one of the first matrix proteins produced
in response to cell injury and inflammation. Therefore, we
investigated whether FXa induced fibronectin levels in
C2C12 cells. As shown in Figure 2D, FXa increased
fibronectin levels in a time-dependent (lanes 1 to 5) and
dose-dependent (lanes 6 to 10) manner. FXa induced
fibronectin synthesis in NIH3T3 cells also, although to a
lesser extent (data not shown). As shown in Supplemen-
tary Figure S1 at http://ajp.amjpathol.org, PAR-2, but not
Figure 2. FXa induces a profibrotic and proinflammatory phenotype in
fibroblasts. A: FXa increases -SMA expression in NIH3T3 fibroblasts. Lanes
1 and 3: Constitutive expression of -SMA. Lanes 4 to 8: Cells treated with
1 U/ml FXa. Lanes 9 to 13: Cells treated for 24 hours with various concen-
trations of FXa. B: FXa increases desmin expression in NIH3T3 fibroblasts.
Lanes 1 to 5: Cells treated with 1 U/ml FXa. Lanes 6 to 10: Cells treated for
24 hours with various concentrations of FXa. C: FXa stimulates TGF-
production in C2C12 cells. Lanes 1 to 5: Cells treated with 1 U/ml FXa. Lanes
6 to 10: Cells treated for 24 hours with various concentrations of FXa. D: FXa
induces fibronectin production. Lanes 1 to 5: Cells treated with 1 U/ml FXa.
Lanes 6 to 10: Cells treated for 24 hours with various concentrations of FXa.
A–D: -Actin served as loading control and results are representative of three
independent experiments. E: FXa induces the secretion of MCP-1 and IL-6.
IL-10, interferon-, TNF-, IL-6, and MCP-1 expression in supernatants of C2C12
cells stimulated with FXa for 24 hours. Shown is the mean  SEM (n  4).
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control, siRNA transfection inhibited fibronectin synthesis
in C2C12 cells stimulated with FXa.
FXa Enhances the Expression of
Proinflammatory Mediators
To determine the potential proinflammatory effect of FXa,
the levels of TNF-, interferon-, IL-6, IL-10, and MCP-1 in
the supernatant of C2C12 fibroblasts stimulated with FXa
were determined. As shown in Figure 2E, FXa did not
modify the expression of IL-10, TNF-, and interferon-.
In contrast, FXa induced IL-6 expression in a dose-de-
pendent manner. IL-6 levels were detectable after stim-
ulation with 0.25 U/ml FXa, whereas maximal levels were
obtained at a concentration of 0.75 U/ml. Finally, FXa
strongly enhanced the expression of MCP-1, which
peaked at a FXa concentration of 1 U/ml.
FXa Stimulates Fibroblast Proliferation
Because fibroblast proliferation is an important process
in wound healing, we assessed the functional conse-
quences of FXa-induced signaling on fibroblast prolifer-
ation. As shown in Figure 3A (left), FXa enhanced the
proliferation of NIH3T3 cells by 334 10% after 24 hours.
This induction was sustained after a 48-hour incubation
(319  17%) and further increased after 72 hours (600 
35%). As shown in Figure 3A (right), FXa also stimulated
proliferation of C2C12 fibroblasts (195  6% after 24
hours, 202  4% after 48 hours, and 140  6% after 72
hours), but to a lesser extent (approximately three times
less proliferation than in NIH3T3 fibroblasts). Further-
more, we demonstrated that the effect of FXa on cell
proliferation was concentration-dependent. As shown in
Figure 3B, a 24-hour incubation with FXa enhanced
C2C12 proliferation by 168  6% at a concentration as
low as 0.25 U/ml, whereas maximal induction of prolifer-
ation was observed using 1 U/ml (191  5%).
To verify that FXa-induced cell proliferation is specific,
cells were preincubated with TAP for 2 hours and subse-
quently incubated with FXa for 24 hours. As shown in Figure
3C, TAP pretreatment almost completely inhibited the FXa
effect on cell proliferation. Furthermore, we verified the in-
volvement of ERK1/2 in FXa-induced cell proliferation by
pretreatment with the ERK1/2 inhibitor U0126. As shown in
Figure 3C, ERK1/2 inhibition abolished FXa-induced prolif-
eration. To assess the role of PAR-2 in FXa-induced cell
proliferation, cells were transfected with PAR-2 and/or con-
trol siRNA. As shown in Figure 3D, PAR-2 siRNA blocked
FXa-induced proliferation, whereas control siRNA did not
modify the FXa effect on proliferation.
FXa Enhances Fibroblast Migration
Next to proliferation, another important process in wound
healing and fibrotic disease is the recruitment of fibro-
Figure 3. FXa induces NIH3T3 and C2C12 pro-
liferation. A: Cell survival of NIH3T3 and C2C12
cells seeded in medium containing 1% FCS
treated with FXa or PBS. B: Proliferation of
C2C12 cells stimulated for 24 hours with differ-
ent FXa concentrations. C: Proliferation of
C2C12 cells pretreated with 200 nmol/L TAP or
10 mol/L U0126 for 2 hours, then stimulated for
24 hours with 1 U/ml FXa. D: Proliferation of
C2C12 cells transfected with control or PAR-2
siRNA and incubated for 24 hours with 1 U/ml
FXa. Results are shown as mean  SEM of two
independent experiments performed in octupli-
cate. **P  0.01; ***P  0.001.
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blasts toward the site of injury/inflammation. Therefore,
we assessed transmigration of NIH3T3 cells toward a
gradient of FXa. As shown in Figure 4A (left), FXa en-
hanced NIH3T3 migration by 249 23%, as compared to
PBS-negative controls. FXa also enhanced C2C12 cell
migration as compared to the PBS control (195  19%;
Figure 4A, right), but again to a lesser extent as com-
pared to the NIH3T3 fibroblasts. Again, FXa exerted its
effect in a concentration-dependent manner: As shown in
Figure 4B, 0.25 U/ml FXa was already a powerful che-
moattractant inducing migration by 146  18%, but max-
imal induction was observed at 1 U/ml FXa (199  20%).
A crucial mediator involved in cell migration is the
nonreceptor protein tyrosine kinase FAK (focal adhesion
kinase). When activated, FAK phosphorylates and/or as-
sociates with other cytoskeletal components, including
Src, and this complex is involved in actin stress fiber
formation and cytoskeletal reorganization. Therefore, we
studied the effect of FXa on the FAK/Src pathway. As
shown in Figure 4C for C2C12 cells, FXa induced phos-
phorylation of FAK with maximal phosphorylation at 20
minutes (lane 6). In addition, FXa induced a robust phos-
phorylation of Src, which also peaked at 20 minutes. To
assess further the importance of the FAK/Src pathway in
FXa-induced migration, cells were pretreated with PP1, a
Src-inhibitor, before performing the migration assay. As
shown in Figure 4D, PP1 pretreatment abolished the FXa
effect. Taken together, these data suggest that FXa in-
duces fibroblast migration via the FAK/Src pathway. Sim-
ilar results were obtained with the NIH3T3 cells.
FXa Mediates Cytoskeletal Reorganization and
Stress Fiber Formation
To confirm the activation of the FAK/Src pathway by FXa,
we used fluorescent microscopy on C2C12 cells stimu-
lated with FXa. As shown in Figure 4E, after 15 minutes of
stimulation, spikes (indicated by asterisks) representing
phosphorylated tyrosine residues could be observed at
Figure 4. Effect of FXa signaling on migration and
cytoskeletal reorganization of NIH3T3 and C2C12
cells. A: Migration of NIH3T3 and C2C12 cells
toward DMEM (control) or DMEM supplemented
with FXa. Results represent the mean  SEM (n 
3). B: Migration of C2C12 cells in the presence of
FXa. Results are shown as mean  SEM and are
representative of two independent experiments
performed in duplicate. C: FXa (1 U/ml) induced
phosphorylation of FAK and Src. -Actin serves as
loading control. The blots are representative of
two independent experiments. D: Inhibition of Src
abolishes FXa-induced stimulation of cell migra-
tion, as demonstrated by pretreatment of cells with
PP1. Results represent the number of cells mi-
grated as percentage of the control and are shown
as mean  SEM (n  3). *P  0.05; **P  0.01;
***P  0.001. E: Fluorescent microscopy of FXa
stimulated C2C12 cells (for 15 minutes) showing
that FXa induces phosphorylation of tyrosine res-
idues. Stress fibers are indicated by arrows and
the spikes by asterisks. F: Effect of FXa (15-
minute incubation) on stress fiber assembly and
tyrosine-phosphorylation in the absence or pres-
ence of PP1. Red, actin; blue, nucleus; green,
phosphotyrosine. Experiments were repeated
twice.
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the cell membrane. Concomitant with the activation of
these kinases, FXa induced actin cytoskeletal reorgani-
zation with an increase in stress fiber formation (indicated
by arrows) as compared to the control. To assess the
involvement of FXa-induced FAK/Src activation in stress
fiber formation, cells were pretreated with PP1 and sub-
sequently stimulated with FXa. As shown in Figure 4F,
pretreatment with PP1 reduced the amount of cells with
stress fibers and with phosphorylated tyrosines at the
membrane as compared to the previous conditions (Fig-
ure 4E). Overall these data confirm the involvement of the
FAK/Src pathway in FXa-mediated cytoskeletal reorgani-
zation leading to cell migration.
FXa Facilitates Wound Healing
To assess further the relevance of FXa-induced prolifer-
ation and cell migration, we examined the effect of FXa in
wound scratch assays. In such assays, C2C12 cells are
grown to confluence in monolayers, and their ability to
migrate into and across a denuded area of the monolayer
is followed throughout time. Control-treated cells hardly
migrated into the wounded area within 18 hours (Figure
5A, control), whereas FXa-treated cells did migrate into
the wounded area within this time period (Figure 5A,
FXa). Both FXa-treated cells as well as 10% FCS-treated
cells (positive control) reduced the wound size by 50%
within 18 hours as compared to no significant reduction in
wound size for control-treated cells (Figure 5, A and D).
To assess the role of ERK1/2 phosphorylation in FXa-
induced wound healing, cells were pretreated with
U0126 before FXa treatment. As shown in Figure 5E,
ERK1/2 inhibition abolishes the effect of FXa on wound
healing. Furthermore, cells were transfected with PAR-2
and/or control siRNA to assess the role of PAR-2 in FXa-
induced wound healing. As shown in Figure 5F, PAR-2
siRNA strongly reduced FXa-induced wound healing,
whereas control siRNA did not modify the FXa effect.
As indicated before, FXa induces stress fiber formation
via the FAK/Src pathway and inhibition of Src abolished
FXa-induced fibroblast migration. Indeed, fluorescent
staining of cells in the wound scratch assay confirmed
the induction of stress fibers of cells treated with FXa or
10% FCS, as compared to control-treated cells (Figure 5,
B and C). Importantly, PP1 treatment abolished the effect
of FXa on wound healing (Figure 5, A and D), which
suggests that during the first hours after wound induction,
fibroblasts migrate, whereas proliferation becomes prom-
Figure 5. FXa facilitates wound healing in a wound scratch assay. A: Wound size of C2C12 fibroblast monolayers after treatment with either PBS (control), FXa
(1 U/ml), FCS (10%), FXa/TAP (200 nmol/L), or FXa/PP1 (1 mol/L) for 18 hours. Shown are photographs of representative microscopic fields. B: Actin staining
of fibroblasts treated with PBS (control), FXa (1 U/ml), or FCS (10%) after wound induction. C: Detail of the effect of FXa, in the presence or in the absence of
TAP or PP1, on stress fiber formation. D: Quantification of the results depicted in A as described in the Materials and Methods section. E: Involvement of ERK1/2
in FXa-mediated wound healing. Quantification of wound size of fibroblast monolayers after treatment with either PBS (control), FXa (1 U/ml), or FXa/U0126 for
18 hours. F: Wound size of C2C12 cells transfected with control or PAR-2 siRNA, after treatment with either PBS (control) or FXa (1 U/ml) for 18 hours. Results
are shown as mean  SEM of two independent experiments performed in octuplicate. **P  0.01; ***P  0.001.
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inent only later. To confirm that FXa-induced stress fiber
formation is specific and mediated by Src, we pretreated
the cells with PP1 or TAP before incubating them with FXa
for 18 hours. As shown in Figure 5C, both inhibitors
strongly diminished FXa-induced stress fiber formation.
Discussion
In this study, we demonstrated that FXa initiated both
proinflammatory and fibroproliferative responses in fibro-
blasts via PAR-2 activation. The signaling effects of FXa
were specific and required its proteolytic activity. We also
demonstrated that FXa acted as a chemoattractant. The
recruitment of fibroblasts, as well as their subsequent
proliferation and synthesis of the ECM are essential in
wound healing but are also central features in patholog-
ical mechanisms leading to tissue fibrosis and remodel-
ing. The consequences of FXa on fibroblast activation
were shown by using a wound scratch model in which
FXa induced wound healing. The Src inhibitor PP1, which
inhibited migration, also prevented FXa-induced wound
healing suggesting that cell migration occurs before pro-
liferation during the wound healing process.
ERK1/2 phosphorylation is widely used as a surrogate
marker for PAR-1 and PAR-2 activation.32 Indeed, FXa-
induced PAR-2 cleavage results in phosphorylation of
ERK1/2 also in our cell lines. As the activation of ERK1/2
has been closely associated with cellular prolifera-
tion,33,34 protein synthesis, and more recently wound
healing,36 it is tempting to speculate that the ERK1/2
pathway is critically involved in mediating the profi-
brotic effects of FXa. The fact that the ERK1/2 inhibitor
U0126 completely blocked FXa-induced proliferation
(Figure 3C) and wound healing (Figure 5E) strongly
suggests that the profibrotic response induced by FXa
is ERK1/2-dependent.
We established a potential role for coagulation FXa
signaling in the progression of tissue fibrosis/wound heal-
ing. Fibroblasts can become exposed to coagulation pro-
teases after vascular damage, and activation of the co-
agulation cascade occurs in many pathological conditions
involving wound healing and fibrosis. Moreover, there are
a number of potential mechanisms that may lead to in-
creased expression of FXa in inflammatory contexts like
atherosclerotic plaque formation or bleomycin-induced
lung injury. For instance, FXa may leak into the connec-
tive tissue from the vascular compartment as a result of
chronic activation of the coagulation cascade, after ex-
tensive and continued endothelial injury.
Because activation of the coagulation cascade is rel-
evant to organs where the interstitial compartment is in
close contact with the microvasculature bed, one could
hypothesize from our data that locally generated FXa first
acts as a chemoattractant and contributes to the initiation
of fibroblast migration toward the wound or the site of
inflammation. Further exposure of the fibroblasts to FXa
leads to fibroblast activation, which includes enhance-
ment of the expression of -actin, TGF-, fibronectin, and
secretion of IL-6 and MCP-1, all of which are implicated in
tissue fibrosis and wound healing (Figure 6). Of these,
IL-6 and MCP-125 expression has already been reported
in fibroblasts and SM cells after stimulation with FXa. IL-6
and MCP-1 expression are suggested to contribute to
fibrosis and wound healing as the expression and secre-
tion of IL-6 correlates with fibrosis in the liver,42 skin,43
and lung.44 The development of subepithelial fibrosis in
transgenic mice with targeted overexpression of IL-6 in
the lung,45 as well as the significant reduction of fibrosis
in IL-6-deficient mice in a model of hepatic fibrosis,46 also
argues for an important role of IL-6 in fibrosis. MCP-1
stimulates and induces the recruitment of monocytes that
in turn secrete cytokines and chemokines thereby pro-
moting inflammation and fibrosis. In addition, MCP-1-
deficient mice show less skin fibrosis,47 and anti-MCP-1
therapy attenuates intimal hyperplasia and vein graft
thickening by inhibiting vascular SM cell proliferation.48
Our finding that FXa enhanced MCP-1 secretion by fibro-
blasts supports the view that FXa enhances MCP-1-in-
duced infiltration of inflammatory cells during tissue
remodeling.
We observed that FXa induced a time- and concentra-
tion-dependent increase in -SMA expression, which is
the hallmark of differentiated myofibroblasts.2 The pres-
ence of myofibroblasts, associated with excessive ECM
Figure 6. Proposed role of FXa in wound healing and fibrosis. After activa-
tion of the coagulation cascade (1), FXa induces fibrosis via thrombin gen-
eration (2) or via PAR-2-dependent signaling (3). Signaling leads to fibroblast
proliferation (4) and differentiation into myofibroblasts (5) followed by the
secretion of MCP-1, IL-6, TGF-, and fibronectin (6). Ultimately this leads to
the accumulation of ECM thereby disrupting the tight balance between
production and degradation of ECM, leading to wound healing and fibrosis.
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protein biosynthesis, hypercontractility, and organ-de-
structive remodeling, has been extensively documented
in active fibrotic lesions and vascular remodeling.49,50
Differentiation of fibroblasts into myofibroblasts contrib-
uted to the progression of, among others, resteno-
sis,6,51,52 as well as intimal hyperplasia and vein graft
remodeling53 or atherogenesis.2,54 Therefore, the finding
that FXa led to activation of fibroblasts and to the appear-
ance of a myofibroblast phenotype provides additional
support for the notion that FXa is an important mediator in
tissue remodeling.
We also observed a significant increase in TGF- ex-
pression in fibroblasts exposed to FXa. Because TGF- is
a well established mediator of interstitial fibrosis,7 our
observation supports the hypothesis that FXa plays a
pathogenic role in the progression of fibrotic diseases.
TGF- is known to induce fibroblast proliferation, differ-
entiation into myofibroblasts,55 and to enhance fibronec-
tin expression. However, it is likely that the expression of
these proteins by FXa via PAR-2 activation does not
depend on the autocrine effect of TGF-. Indeed, the time
courses for fibronectin, -SMA, and TGF- expression
did not differ significantly, suggesting that newly synthe-
sized TGF- did not play a significant role in FXa-induced
fibronectin and -SMA expression. However, it is likely
that TGF- plays a contributing role to these processes at
later time points.
Fibronectin is a major component of the ECM, expres-
sion of which markedly increases after tissue injury.56 In
keeping with its properties in connective tissue remodel-
ing that takes place during wound healing and fibrosis,
increased fibronectin expression occurs in pulmonary
fibroproliferative disease.57 Furthermore, there is a cor-
relation between atherosclerotic plaque development
and fibronectin expression,58 and fibronectin deposition
increases after angioplasty during vascular remodel-
ing.59 Because aberrant accumulation of ECM is primar-
ily responsible for the destruction of architecture and loss
of function during organ remodeling, FXa-induced fi-
bronectin expression likely contributes to profibrotic
responses.
We showed that FXa mediates its effects via PAR-2 by
using several approaches. First, we showed that a PAR-
1-inhibiting antibody did not block the FXa response,
suggesting that PAR-1 was not involved in mediating FXa
effects. Second, we showed that trypsin but not thrombin
desensitized FXa-mediated cellular effects, thereby sug-
gesting that PAR-2 activation mediated these effects.
Finally, to assess definitely the role of PAR-2, we trans-
fected cells with PAR-2 siRNA and showed that FXa
effects on cell proliferation, migration (determined in a
wound scratch assay), protein synthesis, and ERK1/2
phosphorylation were diminished. FXa-induced signaling
has been documented in many cell types originating from
different species; however, the receptor involved re-
mained controversial. In human coronary artery SM cells,
FXa signaling was mediated via PAR-2 exclusively23 or
via the activation of PAR-1 and PAR-2.60 Other studies
suggest that in human and murine fibroblasts FXa signals
exclusively via PAR-1.22 Finally, studies using rat, human,
and rabbit vascular SM cells showed that FXa signaled
independent of PARs.24,27 Importantly, the profibrotic
and proinflammatory effects induced by FXa-dependent
PAR-2 signaling are not redundant of the profibrotic ef-
fects of thrombin, including fibronectin, IL-6, MCP-1, and
TGF- expression, which are mediated by PAR-1.15,16
The studies described in this paper were performed
using murine fibroblasts, and one could therefore argue
that our data are less informative for fibrosis in humans.
However, FXa also induces phosphorylation of ERK1/2
and synthesis of profibrotic and proinflammatory proteins
in human dermal fibroblasts (Supplementary Figure S2 at
http://ajp.amjpathol.org). Furthermore, these human der-
mal fibroblasts show increased proliferation and en-
hanced wound healing after FXa stimulation. It therefore
seems that the profibrotic effects of FXa are not species-
specific and hold true for human cells as well. Obviously,
future experiments should elucidate the in vivo relevance
of FXa in fibrotic disease.
In conclusion, we have demonstrated that coagulation
of FXa stimulates proinflammatory and fibroproliferative
responses in fibroblasts and their differentiation into myo-
fibroblasts. Further studies are needed to assess the in
vivo relevance of these results, but it can be hypothesized
that these responses, which are mediated by PAR-2, may
help explain the extent of fibrosis and remodeling ob-
served in association with activation of the coagulation
cascade. Although therapies that specifically block
PAR-1 activation partly limit the progression of fibrosis,
combined strategies targeting both PAR-1 (induced by
thrombin) and PAR-2 (induced by FXa) activation may be
more effective.
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Fibrosis represents the end-stage of a broad range of disorders affecting organ function. These disorders are
often associated with aberrant angiogenesis, but whether vascular abnormalities during ﬁbrosis are
characterized by excessive or diminished neo-vascularization remains questionable. Strikingly, activation of
the coagulation cascade is frequently observed in association with the progression of ﬁbroproliferative
disorders. As we recently showed that coagulation factor (F)Xa induced ﬁbrotic responses in ﬁbroblasts, we
hypothesized that FXa might indirectly induce angiogenesis by triggering ﬁbroblasts to secrete proangiogenic
factors. In the present study, we show that although FXa induces p42/44 MAP Kinase phosphorylation in
endothelial cells, it has no direct effect on endothelial cell proliferation, protein synthesis and tube formation.
In contrast, conditioned medium of ﬁbroblasts stimulated with FXa enhanced endothelial cell proliferation,
extra cellular matrix synthesis, wound healing and endothelial tube formation. FXa induced VEGF production
by ﬁbroblasts and a VEGF neutralizing antibody blocked the indirect effect of FXa on proliferation and
realignment of endothelial cells identifying VEGF as a crucial player in angiogenesis during coagulation
factor-induced ﬁbrosis. Overall, our results establish a link between the coagulation cascade and angiogenesis
during ﬁbrosis.
© 2009 Elsevier B.V. All rights reserved.
1. Introduction
Fibrotic disease constitutes the end-stage of a broad range of
pathologies affecting organ function [1]. Fibrosis might occur in many
differentorgans, but ismost commonly observed in the skin [2], liver [3],
lung [4], kidney [5] and heart [6]. At the cellular level, ﬁbrosis involves
aberrant ﬁbroblast proliferation and accumulation of extracellular
matrix (ECM) impairing normal organ function. Strikingly, activation
of the coagulation cascade is frequently observed in associationwith the
progression of ﬁbroproliferative disorders. For instance, post-ischaemic
renal damage is associatedwith ﬁbrin deposition [7].Moreover, alveolar
ﬁbrin deposition after acute lung injury leads to accelerated pulmonary
ﬁbrosis [8]. Physiologically, activation of the coagulation cascade is
initiated when vascular injury exposes tissue factor (TF) to the
circulating blood. Upon such vascular injury, TF is exposed to the
blood allowing complex formationwith circulating (activated) factor (F)
VII (FVIIa). The TF/FVIIa complex in turn activates FX into FXa. FXa
converts prothrombin into thrombin which in turn cleaves ﬁbrinogen
into ﬁbrin, leading to the formation of a clot [9].
A mechanistic link between activation of the coagulation cascade
and the progression of ﬁbrosis is provided by the ability of activated
coagulation factors to proteolytically cleave and activate protease-
activated receptors (PARs), a family of G-protein-coupled receptors. Four
PARs (PAR-1 to -4), of which PAR-1, PAR-3 and PAR-4 can be activated by
thrombin, have been identiﬁed so far. The TF/FVIIa complex can activate
PAR-2 only, and FXa is able to activate PAR-1 and PAR-2 [10]. The role of
thrombin in ﬁbrotic processes has been extensively studied in vitro
[11–14], and thrombin signaling via PAR-1 plays indeed a crucial role in
the progression of ﬁbrosis [15,16]. Recently, we and others showed that
FXa also triggers ﬁbro-proliferative responses in ﬁbroblasts and smooth
muscle (SM) cells. FXa enhanced cell proliferation and migration, it
induced the secretion of pro-ﬁbrotic and pro-inﬂammatory cytokines
and stimulated ECM deposition [17–22].
Increasing evidence suggests that vascular endothelial growth
factor (VEGF) is a major regulator of ﬁbrosis and tissue remodeling
(like for instance asthma) [23,24]. Generally, ﬁbroblasts of the
connective tissue produce very low levels of VEGF but during ﬁbrosis
activated ﬁbroblasts secrete increased VEGF levels [25]. VEGF is a
potent angiogenic protein [26] involved in the formation of new
capillary blood vessels by a sequence of complex and precisely
programmed events that include proliferation and migration of
endothelial cells (ECs) into the surrounding tissue, the reconstruction
of a matrix and the assembly of ECs into capillary tubes [27].
Angiogenesis is instrumental during embryogenesis, tissue repair
after injury and the female reproductive cycle: indeed, even if during
adulthood most blood vessels remain quiescent, ECs retain their
remarkable ability to rapidly divide in response to physiological
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stimuli. However, angiogenesis requires very tight regulation and a
disbalance between pro- and anti-angiogenic factors is intrinsically
linked to disease progression. For instance, regression of angiogenesis
contributes to the progression from adaptive cardiac hypertrophy to
heart failure [28]. Also, in women with preeclampsia, increased levels
of anti-angiogenic proteins are identiﬁed in the placenta [29,30] and
serum [30–33]. In contrast, aberrant neo-angiogenesis is well known
to be responsible for tumor growth and metastasis [34,35].
The associations between modulation of angiogenesis and the
progression of the heterogeneous group of ﬁbrotic diseases are
numerous and very complex. Numerous studies report changes in
VEGF production and consequently in the density of the vascular
network during ﬁbrosis but contradictory both regression and/or
expansion of the vasculature has been observed. For instance, during
idiopathic pulmonary ﬁbrosis (IPF) both increased [36–40] and
decreased VEGF levels have been observed [41,42]. Also with respect
to vascular density, both increases [43–45] and decreases [45,46]
within ﬁbrotic lesions of IPF patients have been observed. Overall,
these studies pinpoint VEGF as a crucial player in angiogenesis during
ﬁbrosis. However, whether regression or proliferation of the vascular
network is a cause or consequence of ﬁbrosis remains elusive.
Consequently, it also remains questionable whether angiogenesis
accompanying ﬁbrosis is beneﬁcial of deleterious. Further elucidation
of the molecular mechanisms modulating VEGF production is there-
fore of critical importance for understanding the relationship between
angiogenesis and ﬁbrosis.
Next to its role in ﬁbrosis, the coagulation cascade is well-known to
be a crucial regulator of angiogenesis [47], and the role of individual
coagulation factors in angiogenesis has been especially studied during
the progression of cancer. For instance, TF/FVIIa and thrombin both
induce angiogenesis during cancer progression [35,48,49]. In contrast,
FXa does not seem to affect angiogenesis as, for instance, it does not
promote tube formation in vitro [50]. Interestingly, we recently
showed that FXa induced ﬁbro-proliferative responses in ﬁbroblasts,
whereas it has also been shown that FXa, but not thrombin or the
TF/FVIIa complex, induced VEGF release by human lung ﬁbroblasts
[20]. Consequently, we hypothesized that FXa might indirectly induce
angiogenesis by triggering ﬁbroblasts to secrete pro-angiogenic
factors thereby establishing a link between activation of the coagula-
tion cascade, angiogenesis and ﬁbrosis. To prove or refute this
hypothesis, we transferred medium of FXa-stimulated ﬁbroblasts to
endothelial cells, and examined the consequences on cell viability,
protein synthesis and tube formation.
2. Materials and methods
2.1. Cell lines, cell culture and reagents
The murine endothelial cells 2H11 and the murine ﬁbroblast cell
lines C2C12 and C3H10T1/2 were purchased from American Type
Culture Collection (ATCC, Manassas, VA), and maintained in Dulbec-
co's minimal essential media (DMEM) supplemented with 10% FCS
according to routine procedures. Unless speciﬁed otherwise, cells
were washed twice with phosphate-buffered saline (PBS), then serum
starved overnight or for 4 h for 2H11 and C2C12 or C3H10T1/2
respectively prior to stimulation. Human FXa was obtained from
Kordia (Leiden, the Netherlands). VEGF-A blocking antibody (aVEGF)
was obtained from R&D Systems (Minneapolis, MN).
2.2. Preparation of conditioned media (CMs)
Murine ﬁbroblasts were grown in DMEM in the presence of 10%
FCS until 70–80% conﬂuence. The growth mediumwas then removed,
cell layers were washed twice with PBS and cells were cultured for
48 h in either serum-free medium supplemented with PBS (CM) or
174 nM FXa (CM FXa). Fibroblast-conditioned media were centrifuged
at 14,000 rpm for 15 min, ﬁltered through 0.22 μM ﬁlters and stored
at −20 °C until use.
2.3. Western blot
Cells were lysed in Laemmli lysis buffer, incubated for 5min at 95 °C,
and whole cell lysates were separated by 10% SDS-PAGE. After
electrophoresis, proteins were transferred onto immobilon-P PVDF
membranes (Millipore, Billerica, MA). Membranes were incubated
overnight at 4 °C with primary antibodies to β-actin, MMP-9, MMP-2,
ICAM-1, VEGF-A, ﬁbronectin (all Santa Cruz, CA) and p42/44 MAP
Kinase (total and phosphor-speciﬁc; Cell Signaling Technology (Beverly,
MA)) in TBS with 0.1% Tween (TBS-T)/1% BSA. All secondary HRP-
conjugated antibodies were from DakoCytomation (Glostrup, Den-
mark). Blots were imaged using Lumilight Plus ECL substrate (Roche,
Basel, Switzerland) on a GeneGnome imager (Syngene, Cambridge, UK).
2.4. Viability assay (MTT)
104 cells per well were seeded onto 96-well plates in DMEM
supplemented with 1% FCS, and were treated with FXa (174 nM) or
PBS as control. To determine the effect of the conditionedmedia (CMs)
on cell viability, cells were seeded directly in the different CMs. Cell
viability was determined at the indicated intervals using a MTT assay
as described previously [51].
2.5. Anoikis
To induce anoikis, cells were plated in the different CMs on culture
plates coated with polyHEMA (10 mg/ml). At the indicated time
points, cells were harvested and viability was determined by MTT
assays.
2.6. Wound scratch assay
Wound scratch assays were performed as described previously
[21]. Brieﬂy, cells were plated in six-well plates and maintained in
DMEM supplemented with 10% FCS. After the cells reached 80 to 90%
conﬂuence, a wound was created in the center of the cell monolayer
by a sterile plastic pipette tip. Immediately thereafter, the cells were
washed with PBS to remove ﬂoating cellular debris and re-incubated
for an additional 24 h with CM or CM FXa. The ability of cells to
proliferate andmigrate into thewound areawas assessed after 24 h by
comparing the zero and 24 h phase-contrast micrographs of at least 3
marked points along the wounded area at each plate. The percentage
of non-recovered wound area was calculated by dividing the non
recovered area after 24 h by the initial wound area at zero time.
2.7. Endothelial cell morphogenesis assay
Murine endothelial cells (5⁎104) were resuspended in 0.3ml of the
indicated medium, and plated on 24-well plates pre-coated with
growth factor-reduced (GFR) Matrigel (0.15 ml). After 16 h at 37 °C/5%
CO2, each well was examined for endothelial cells alignment using a
phase contrast microscope. For quantiﬁcation of endothelial tube
formation, the number of tubes was counted in each well by blindly
scoring (by two independent investigators) at least 7 different ﬁelds
were by two observers.
2.8. RNA isolation and MLPA procedure
After 0–8 h of the indicated treatment, total RNAwas isolated using
Trizol (Invitrogen, Carlsbad, CA) according to manufacturer's recom-
mendation. Next, 100 ng total RNA was used for the MLPA reaction as
described previously [52,53]. Brieﬂy, MLPA is a multiplex ligation-
dependent ampliﬁcation procedure (RT-MLPA), which accurately
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quantiﬁes a comprehensive set of genes in a one-tube assay. The high-
throughput in combination with the limited amount of RNA necessary
makesMLPA an ideal technique to screen for gene expression changes in
a predeﬁned pathway. In the current study, the following genes were
analyzed: Apaf, Apaf-Xl, Bad, Bak, Bax-1, Bax-2, Puma, Bcl-2, Bcl-2A1,
Bcl-Xl, Bim, Bcl-W, Bcl-G, Bcl-Rambo, Bid, Bik, NIAP, IAP1, IAP2, XIAP,
Survivin, Apollon, Livin, Bmf, NIP-3, NIX, Flip, FLT, HRK, MAP1, Mcl1-S,
Mcl1-L, PARN, AIF, Noxa, GUS, PI-9 and Diablo.
2.9. Statistical analysis
The data are expressed asmean±standard error and Student's t test
is used to determine signiﬁcance (Pb0.05 was considered signiﬁcant).
3. Results
3.1. FXa induces phosphorylation of p42/44 MAP kinase in
endothelial cells
It is well known that endothelial cells express both PAR-1 and
PAR-2 [54] and FXa might thus inﬂuence angiogenesis through direct
PAR-mediated signaling in endothelial cells. As p42/44 MAP Kinase
phosphorylation is a downstream target of PAR cleavage [55], ECs
were either stimulated with 174 nM FXa (as this concentration is
commonly used to decipher the signaling effects of FXa in vitro
[21,51,56,57]) for 0–60min or for 30minwith different concentrations
of FXa. Subsequently, the activation of p42/p44 MAP kinase was
determined using western blotting. As evident from Fig. 1A, FXa
induces a time- (left panel) and concentration- (right panel)
dependent activation of p42/p44 MAP kinase. FXa has thus the
potential to directly induce signal transduction in ECs.
3.2. FXa has no direct effect on the angiogenic phenotype of
endothelial cells
Angiogenesis is associated with EC proliferation, EC realignment to
form tubes or lumen-like structures, and ECM synthesis. Hence, we
determined the effect of FXa on the proliferation of endothelial cells.
Cellswere incubated for 0 to 48 hwith 174 nMFXa, as this concentration
had a maximal effect on cell signaling or with PBS and cell viability was
determined at the indicated time points. As shown in Fig.1B, FXa did not
signiﬁcantlymodify EC viability. Next, we determined the direct effect of
FXa on the synthesis of ECM proteins or matrix-degradation proteases.
FXa did not induce the expression of ﬁbronectin or matrix metallopro-
teinase (MMP) -2 and -9 (which are crucial proteins of angiogenesis) by
endothelial cells (data not shown). Finally, FXa did not modify
endothelial cell realignment or reorganization in tubes (Fig. 1C). Thus,
although FXa does induce intracellular signaling in ECs, it does not
markedly inﬂuence their angiogenic phenotype.
3.3. CM FXa enhances viability of ECs and stimulates tube formation
As FXa had no direct functional consequences on endothelial cells,
we next assessed whether FXa might modify angiogenesis indirectly
via activation of ﬁbroblasts. To this end, CM collected from C3H10T1/2
ﬁbroblasts stimulated with FXa (CM FXa) was compared to CM of PBS-
treated ﬁbroblasts for its angiogenic properties. We ﬁrst compared the
effect of both CMs on EC survival. Cells were seeded directly in CM or
CM FXa and cell viabilitywasmeasured at the indicated time points. As
shown in Fig. 2A, CM FXa enhanced viability by 168±4.5% after 48 h
(P=0.0002), whereas CMdid not have this effect (105±1.5%). The same
results were observed with CM FXa prepared from C2C12 ﬁbroblasts
(data not shown). During angiogenesis, ECs need to detach from the
ECM to migrate and therefore need to survive without attachment
(anoikis) during this period. Therefore, 96-well plates were coated
with poly-HEMA and EC viability was determined. As shown in Fig. 2B,
loss of adhesion rapidly affected cell viability. However, CM FXa
signiﬁcantly enhanced cell viability after 2 h by 116.1±5.2% (P=0.028)
as compared to CM. The same results were observed with CM FXa
prepared from C2C12 ﬁbroblasts (data not shown). Next, we
determined the effect of CM FXa on ECM protein synthesis. To this
end, ECs seeded in CM and CM FXa were assayed for ﬁbronectin
synthesis. Indeed, CM FXa enhanced ﬁbronectin production, whereas
CMdidnot induceﬁbronectinproduction (Fig. 2C). Both CMFXa aswell
as CM did not induce MMP-2/-9 synthesis (data not shown).
We next assessed the effect of the different CMs onwound closure,
which involves both proliferation and migration. As shown in Fig. 2D,
CM had no effect on the size of the wound, whereas CM FXa signi-
ﬁcantly induced wound healing as evident from the reduced wound
size. Finally, we explored whether CM FXa provoked the alignment of
endothelial cells or the formation of lumen-like structures. As shown
in Fig. 2E, ECs incubated in CM FXa aligned to form lumen-like
Fig.1. FXa has no direct effect on the angiogenic phenotype of ECs. (A) FXa induces direct signaling in ECs. Quiescent ECs were stimulated for 0–60minwith 174 nM FXa (left panel), or
for 30 min with 0–174 nM FXa (right panel). Cell lysates were assayed for western blot for p42/44 phosphorylation using total p42/44 as loading control. (B) FXa-induced direct
signaling has no functional consequence on EC survival. Serum-starved ECs were incubated for 0–48 h with 174 nM FXa, or PBS as a negative control. Cell survival was determined
using MTT assays. Shown are the results of a representative experiment, which was repeated 3 times in octuplicate with similar results. Values are mean±SEM. (C) FXa has no direct
effect on EC alignment. ECs (5⁎104) were resuspended in serum-freemedium, supplemented with PBS (C neg) or with FXa, and plated ontoMatrigel as described in theMaterials and
methods section. Shown are representative pictures of an experiment which has been performed 3 times with similar results.
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structures and anastomosing tubes with multicentric junctions.
Quantiﬁcation showed that CM FXa enhanced tube formation by
185±16.8% (P=0.0013) as compared to control CM. This capillary-like
network of ECs induced by CM FXa appears to be less organized than
that induced by conditioned medium obtained from ﬁbroblasts
cultured with 10% FCS (data not shown), possibly suggesting a
relatively disorganized angiogenesis. The same results were observed
with CM FXa prepared from C2C12 ﬁbroblasts (data not shown). Since
we showed that FXa had no direct effect on endothelial cell survival,
realignment or protein synthesis, these results strongly suggest that
the observed effects of CM FXa on angiogenesis are not due to FXa
present in the CMs but rather that FXa exerts a powerful indirect pro-
angiogenic effect through the activation of ﬁbroblasts.
3.4. Characterization of the anti-apoptotic effect exerted by CM FXa
As indicated above, CM FXa enhanced viability and alignment of
endothelial cells. To assess whether this is due to modiﬁcations in the
apoptotic balance induced by CM FXa, we performed MLPA gene
expression analysis. To this end, RNA isolated from endothelial cells
stimulated for 8 h with CM FXa or CM prepared from C3H10T1/2
ﬁbroblasts was isolated. To determine possible direct effects of FXa on
the mRNA levels, ECs were incubated for the same period in serum-
free medium (SF) or serum-free medium containing 174 nM of FXa.
Through expression proﬁling of 39 genes involved in apoptosis using
MLPA, we observed that a single anti-apoptotic gene was induced by
CM FXa. CM FXa induced expression of the anti-apoptotic protein
Bcl-2 (induction of 183±35% (P=0.002)) as compared to the ECs
stimulated with CM (Fig. 3A). Importantly, ECs stimulated with FXa
directly did not modify the expression of this anti-apoptotic gene
(Fig. 3B), which is in line with the absence of a direct effect of FXa on
endothelial cell survival (Fig. 1B).
3.5. FXa induces a pro-angiogenic phenotype in ﬁbroblasts through
VEGF expression
The pro-angiogenic effect of CM FXa on ECs implies that FXa
induces the release of a pro-angiogenic factor by ﬁbroblast responsible
Fig. 2. CM FXa induces a pro-angiogenic phenotype in ECs. (A) CM FXa promotes EC proliferation. Survival of ECs seeded in CM or CM FXawas determined using MTTassays. Shown is
the mean±SEM of 5 different experiments performed in octuplicate. ⁎⁎⁎Pb0.001. (B) CM FXa inhibits anoikis. ECs resuspended in CM or CM FXa were seeded in plates coated with
poly-HEMA. Cell survival was determined at the indicated time points using MTT assays. Shown is the mean±SEM of 2 different experiments performed in septuplicate. ⁎Pb0.05 (C)
CM FXa enhances ﬁbronectin secretion by ECs. ECs seeded in CM or CM FXa for 24 h were lysed and lysates were used for western blot to determine ﬁbronectin expression. Actin
served as loading control. Shown is a representative picture of an experiment performed three times with similar results. (D) CM FXa enhances wound closure in ECs. Wound size of
ECs treated with CM or CM FXa was analyzed 24 h after wounding the endothelial monolayer as described in Materials and methods section. Shown is the mean±SEM of 2 different
experiments performed in triplicate. ⁎⁎Pb0.005. (E) CM FXa promotes endothelial tube formation. ECs (5⁎104) were resuspended either in CM or in CM FXa and plated onMatrigel as
described in Materials and methods. After 16 h, tube formationwas assessed. (Top panel) Representative pictures of an experiment performed 3 times. (Bottom panel) quantiﬁcation
of tube formation. Show is the mean±SEM of 3 different experiments. ⁎⁎Pb0.005.
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for the induction of both viability and tube formation. As VEGF, one of
the most potent pro-angiogenic proteins, is synthesized in lung and
dermal ﬁbroblasts stimulated with coagulation factors VIIa, Xa and
thrombin [20,58], we focussed our attention on VEGF. First, we
veriﬁed that FXa induced the release of VEGF by C3H10T1/2 and C2C12
ﬁbroblasts. Fibroblasts were incubated in serum-free medium for 24 h
with different concentrations of FXa. As shown in Fig. 4A for C3H10T1/
2 ﬁbroblasts, FXa induced VEGF synthesis in a concentration-
dependent manner in both cell lysates and supernatants. Similar
results were observed for C2C12 cells (data not shown).
To determine the contribution of VEGF released by ﬁbroblasts to
the pro-angiogenic effect of FXa on endothelial cells, we added an
antibody that neutralizes the bio-activity of VEGF to CM and CM FXa.
As shown in Fig. 4B, CM FXa signiﬁcantly enhanced cell viability as
compared to CM (167.2±8.2%, P=0.0002), and this effect is approxi-
mately 2-fold reduced in the presence of the VEGF blocking antibody
(from 167.2±8.2% to 134.7±8.5%; P=0.0047). Importantly, the bloc-
king antibody did not affect EC viability in CM (107.2±5.6%). As shown
in Fig. 4C, CM FXa also signiﬁcantly promotes tube formation
(163.6±14%) as compared to CM. The addition of the VEGF blocking
antibody did not modify tube formation by CM (82.2±11.24%), but it
completely blocked CM FXa-induced tube formation (from163.6±14%
to 62±9.3%; P=0.0001). Hence, FXa-induced VEGF production by
ﬁbroblasts seems to account for the pro-angiogenic phenotype
resulting in proliferation and realignment of ECs.
4. Discussion
In the present study, we demonstrate that FXa induces an indirect
pro-angiogenic phenotype of ECs through activation of ﬁbroblasts.
Although FXa directly induced signaling in ECs, FXa had no direct
effect on EC proliferation and/or tube formation. This is in line with a
previous study [50], showing that FXa did not promote tube formation
in vitro. In contrast, CM FXa enhanced the viability of both adherent
cells and cells in anoikis likely via the expression of the anti-apoptotic
protein Bcl-2. Furthermore, CM FXa induced ECM synthesis (as shown
Fig. 3. CM FXa enhances the expression of Bcl-2 in ECs. ECs were serum-starved overnight after which the serum-free medium was replaced by CM or CM FXa (A), or serum-free
mediumwith (FXa) or without (SF) FXa. After 24 h incubation, mRNAwas isolated and assayed for expression of pro- and anti-apoptotic genes as described in Materials andmethods
section. On 37 genes analyzed, CM FXa only induced Bcl-2 expression.
Fig. 4. FXa-induced pro-angiogenic effects of ﬁbroblasts are mediated via VEGF production. (A) Quiescent C3H10T1/2 ﬁbroblasts were stimulated for 24 h with the indicated
concentrations of FXa. Subsequently, supernatant was harvested and cells were lysed. Both supernatant and cell lysates were assayed by western blot for VEGF production. ICAM-1
served as loading control. Shown are representative pictures of an experiment done three times with similar results. (B) Effect of a VEGF-neutralizing antibody on EC survival. ECs
were seeded in the different conditioned media, with (white bars) or without (black bars) VEGF-neutralizing antibody. Cell viability was determined after 24 h incubation using an
MTT assay. Shown is the mean±SEM of 2 different experiments. n.s.: non signiﬁcant,⁎Pb0.05, ⁎⁎Pb0.005, ⁎⁎⁎Pb0.001. (C) Effect of a VEGF-neutralizing antibody on endothelial tube
formation. ECs were seeded in the different conditioned media, with (white bars) or without (black bars) VEGF-neutralizing antibody, and plated onto Matrigel. After 16 h, tube
formation was quantiﬁed as described in the Materials and methods section. Shown is the mean±SEM of 2 different experiments. n.s.: non signiﬁcant, ⁎⁎Pb0.005, ⁎⁎⁎Pb0.001.
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by the release of ﬁbronectin), wound healing, and endothelial tube
formation. The induction of these responses by CM FXa as compared
to CM suggested that FXa stimulated the secretion of one or more
growth factors by ﬁbroblasts. Indeed, FXa induced the secretion of
VEGF by ﬁbroblasts and a VEGF blocking antibody diminished the
effect of CM FXa on EC proliferation and tube formation.
Our results might be relevant for physiological wound healing but
more importantly they establish a link between activation of the
coagulation cascade, ﬁbrosis and aberrant angiogenesis. Indeed,
ﬁbroblasts are exposed to coagulation factors following vascular injury,
but activation of the coagulation cascade also occurs inmany pathologi-
cal conditions such as ﬁbrosis. In patients suffering from lung ﬁbrosis
for instance, thrombin levels and zymogen FX levels are increased and
these patients also represent with enhanced ﬁbrin deposition [8].
Alternatively, FXa may be secreted by macrophages at sites of inﬂam-
mation, or FXa may leak into the connective tissue from the vascular
compartment as a result of chronic activation of the coagulation
cascade, after extensive and continued endothelial injury [59].
Recent data suggest that FXa plays an important role in ﬁbrotic
processes. As opposed to TF/FVIIa and thrombin, FXa activates PAR-2
thereby eliciting various and complex signaling events. We and others
showed that, in ﬁbroblasts, FXa induces the synthesis of ECM proteins
such as ﬁbronectin and collagen [17,21]. FXa also stimulated
ﬁbroproliferative responses in ﬁbroblasts and induced ﬁbroblast
differentiation into myoﬁbroblasts [21]. Here, we demonstrate that
the responses induced by FXa on ﬁbroblasts also modify the
angiogenic balance, thereby establishing a link between activation of
the coagulation cascade, the progression of ﬁbrosis and the induction
of angiogenesis. Interestingly, our data show that FXa-induced
signaling is not redundant of TF/VFIIa and/or thrombin signaling as
the latter coagulation factors directly induce angiogenic effects on
endothelial cells via PAR-1 activation [35,48,49]. FXamight does play a
dual role in angiogenesis. Via its procoagulant effects, FXa induces
thrombin formationwhich on its turn directlymodiﬁes the angiogenic
phenotype of endothelial cells. Through its signaling properties
however, FXa activates ﬁbroblasts (in a PAR-2 dependent manner
[60]), to secrete VEGF thereby indirectly affecting the endothelium.
Chronic ﬁbroproliferative disorders are associated with aberrant
angiogenesis, but the exact underlying mechanism is still elusive
[61,62]. An important outstanding question is whether the primary
vascular abnormality during ﬁbrosis is actually excessive or dimi-
nished neo-vascularization [62]. Consequently, the role of angiogen-
esis (beneﬁcial versus harmful) and the effect of modiﬁcations to the
VEGF balance during ﬁbrosis remain questionable. Three hypotheses
have been put-forward however. Based on observations that attenu-
ating vascular remodeling is associated with reduced pulmonary
ﬁbrosis in animal models [36–40], it was postulated that angiogenesis
contributes to the progression of ﬁbrosis. Another hypothesis emerged
from the results of studies showing that both VEGF levels [41,42] and
vascular density are decreased within ﬁbrotic lesions as compared to
non-ﬁbrotic regions [43–46]. In a murine model of interstitial renal
ﬁbrosis, decreased vascular density was associated with renal
impairment, whereas infusion of VEGF improved renal function and
decreased interstitial renal ﬁbrosis [63,64]. Moreover, VEGF gene
transfer in rabbits results in reduction of bleomycin-induced pulmo-
nary hypertension, suggesting a protective effect [65]. Based on these
observations it is suggested that angiogenesis limits or counteracts
ﬁbrosis. Finally, it has been suggested that aberrant angiogenesis
accompanying ﬁbrosis is just an epiphenomenon and thus not play a
physiological role [62]. Our present study supports the hypothesis that
ﬁbrosis causes angiogenesis, implying that angiogenesis is not only a
passive bystander during ﬁbrosis. Whether this (indirect) induction of
angiogenesis by FXa is beneﬁcial or deleterious during ﬁbrosis is
obviously impossible to predict based on our current data. One could
argue that FXa generation resulting in ﬁbroblast proliferation and
VEGF release subsequently inducing angiogenesis might be beneﬁcial
for the restoration of tissue function during ﬁbrosis (as discussed in
[66]). However, it is noteworthy that VEGF has proﬁbrotic and
ﬁbroproliferative effects [67–70] and might thus aggravate ﬁbrosis.
Recently, it was shown that during airway remodeling (which shares
common features with ﬁbrotic disease like, among others, coagulation
cascade activation, exaggerated ﬁbroblast proliferation and ECM
deposition) in asthmatic patients, VEGF up-regulates thrombin levels,
which in turn enhances bFGF release thereby amplify the ﬁbrotic
process. This latter notion that FXa-induced angiogenesis would be
deleterious in pulmonary ﬁbrosis is supported by recent data showing
that inhibition of coagulation signiﬁcantly reduced bleomycine-
induced ﬁbrosis [15]. Although not targeting FXa speciﬁcally, these
data suggest that inhibiting coagulation-induced angiogenesis is
beneﬁcial. In agreement, low molecular weight heparin (dalteparin;
FXa inhibitor with some residual thrombin inhibition) treatment of
patients with idiopathic pulmonary ﬁbrosis had a beneﬁcial effect on
survival [71]. Overall, these data suggests that FXa-induced angioge-
nesis is detrimental in ﬁbrosis although future in vivo experiments
should conﬁrm this hypothesis.
Obviously, one should keep in mind that angiogenesis is a
complicated multi-step process. All individual steps are obviously
not solely orchestrated by VEGF, and angiogenesis is the result of
cooperation between VEGF and other angiogenic factors which must
collaborate in perfect harmony to form functional vessels. Different
models of vascular formation have shown that VEGF initiates the
formation of vessels by vasculogenesis or angiogenic sprouting while
other angiogenic factors, such as angiopoietins, are required for
further remodeling and maturation of this initially immature
vasculature [61]. Angiopoietins regulate angiogenesis by activating
or blocking the activation of Tie-2, a surface receptor tyrosine kinase
generally restricted to endothelial cells. Especially, angiopoietin-2
(ang-2) is expressed in areas undergoing vascular remodeling and is
involved in neovascularization. It has been proposed that in the
presence of VEGF, Ang-2 may maintain the endothelium in a more
plastic state [72]. Whether FXa alsomodulates the expression of ang-2
by ﬁbroblasts, or the expression of the VEGF receptor and/or Tie-2 by
endothelial cells (as been shown for thrombin [73]), is currently not
known.
Induction of a pro-angiogenic phenotype by coagulation factor
induced-signaling in ﬁbroblasts might also be of importance in other
pathological conditions. For instance, many epithelial tumors are
characterized by the local accumulation of myoﬁbroblasts in the
stroma reaction (i.e. local ﬁbrosis associated with malignant tumors
[74]). Myoﬁbroblasts control tumor angiogenesis by creating a pro-
angiogenic microenvironment thereby facilitating EC recruitment, as
shown in [75] for melanoma cells. Thus, differentiation of ﬁbroblasts
into myoﬁbroblasts by FXa [21] and/or thrombin [76] subsequently
inducing angiogenesis might be an additional link between activation
of the coagulation cascade and disease progression.
Overall, the release of pro-angiogenic factors by FXa-stimulated
ﬁbroblasts may link the coagulation cascade to vascular remodeling
during ﬁbrosis. Obviously, this conclusion is based on in vitro data only
and the in vivo relevance of our ﬁndings needs further assessment.
Future studies aiming at a detailed in vivo understanding of the
interplay between activation of the coagulation cascade, the progres-
sion of ﬁbrosis and the role of angiogenesis in these processes are
needed to establish the importance of our ﬁndings.
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It has become clear that vitamin K-dependent coagulation factors in general and factor 
X in particular are principal players in pathophysiology. Hence understanding its 
biology better as well as its role in pathophysiology may provide exiting insights in 
both the understanding of human and animal physiology in general and provide clues 
to improved therapy in particular. This general line of thinking has been the guiding 
line for this thesis.  
This realization has led me the biology of especially factor X and to a lessen extent 
factor VII and factor II, concentrating on their production, their cell biology, and their 
role in physiology. To this end, following a literature study on the molecular genetics 
and pathophysiology of coagulation FVII and FX inherited deficiencies (chapter 2), I 
start in the nucleus with a study on the regulation of splice site selection in the FVII 
gene as its intron 7 provides an excellent for such a study, with repetition of the intron 
7 splice donor site (chapter 3). The data obtained led us to conclude that oriented 
scanning seems to be the leading mechansism for splice site selection in mammals, 
thus these data may have substantial importance outside the field of factor VII 
deficiency and provide further knowledge as the nuclear molecular biology in 
mammals in general. 
Next, having explored largely the control of coagulation factor VII production by  
studying the consequences of FVII deficiencies,  I went on to investigate, now in the 
Netherlands the cell biological effects of coagulation FVIIa and FXa (because of their 
structural similarity, see chapter 2). Being there, it turned out that factor VII is a 
relatively minor player in pathophysiology and its downstream target, factor X (which 
acts as the point of convergence of the intrinsic and extrinsic pathways of 
coagulation) should actually be the focus point of relevant research. This notion was 
confirmed in the work (mainly chapter 8) in which I generated comprehensive 
descriptions of the signaling of the three most prominent vitamin K-dependent 
coagulation factors (factor VIIa, Xa and thrombin/IIa). All three coagulation factors 
generate their own signaling fingerprint (chapter 8). The consequences of thrombin 
action in pathophysiology are now well understood and do not merit further 
explanation at this place. Strikingly, whereas FVIIa induced a very clear signaling 
response in the cells, however, the functional consequences of such intracellular 
signaling on cell pathophysiology remained unclear. We could only demonstrate that, 
at least in some cells types, FVIIa induces apoptosis (chapter 4) although others were 
without reaction in this respect, which suggested cell-type specific signaling. 
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Interestingly, we could not further detect a role of FVIIa on cell biology at the protein 
production level, nor at the cell survival modulation (excepted in a very few cell 
types), nor on migration or on other processes participating into pathology.  
By contrast, we showed that FXa elicits specific effects on the modulation of cell 
survival or migration: for instance, we observed that following PAR-1 activation in 
cancer cell types, FXa induces cell apoptosis, and inhibit cell migration, leading us to 
hypothesize that PAR-1 acts as a Janus faced receptor (according to the agonist 
interacting with it) (chapter 6 and 7). By contrast, in fibroblast, FXa via PAR-2 
activation induces extracellular matrix protein synthesis, fibroblast proliferation and 
migration and differentiation into myofibroblasts (chapter 9). All these events are 
interestingly linked to tissue fibrosis and remodeling. It seems that PAR-2 is a crucial 
intermediate in the fibrotic process, and allowed us to explain the relative impotency 
of thrombin inhibition in fibrotic processes. Indeed, via its pro-coagulant action it 
generates thrombin (thus activating PAR-1), while directly proteolytically targeting 
PAR-2, leading to a direct stimulation of the compensatory responses that finally lead 
to fibrosis.  
 Recently, accordingly, it has become evident that PAR-2 has a prominent role 
of PAR-2 in the progression of a variety of pathological processes, especially 
inflammation and fibroproliferative disorders. High expression of pulmonary PAR-2 
is observed in acute and chronic lung injury suggesting that PAR-2 participates in 
inflammation and fibroproliferation during lung fibrosis. In renal interstitial fibrosis, 
α-SM actin and PAR-2 expression is correlated, whereas PAR-2 expression is 
increased in biopsies of patient with IgA nephropathy and the kidney of rats subjected 
to experimental glomerulonephritis. PAR-2 expression is enhanced in human 
coronary atherosclerotic lesions and in a murine model of vascular injury, neointima 
formation was markedly reduced in PAR-2 deficient mice. Consistently, in 
Inflammatory Bowel Disease (IBD), overexpression of PAR-2 is widely documented. 
On a functional level, in irritable bowel syndrome (IBS) elevated colonic lumenal 
serine protease activity is observed and evokes a PAR-2-mediated colonic epithelial 
barrier dysfunction, whereas experimental colitis is strongly attenuated in PAR2-
deficient mice. Conversely, in experimental rodents colonic administration of PAR-2 
agonists up-regulated PAR-2 expression and induced an inflammatory reaction 
characterized by granulocyte infiltration, increased wall thickness, tissue damage, and 
elevated T-helper cell type 1 cytokine. Thus most investigators assume an important 
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role for PAR-2 in pathology and accordingly many diseases are accompanied by 
activation of the coagulation cascade. Therefore, the results presented in chapter 9 
provide a link between coagulation cascade activation, disease progression and 
highlight the role of FXa in these processes, as thrombin is a poor activator of PAR-2 
(in fact, this activity is almost undetectable in in vitro settings).  
PAR2 expression in the endothelial compartment may well be an important 
factor bringing about this vascular response in disease. Endothelial barrier function 
breaks down after both PAR-1 and PAR-2 stimulation. Unlike thrombin, factor Xa 
stimulates both PAR isotypes, suggesting a non-redundant role of factor Xa in this 
response  in a PAR-2-dependent fashion. Accordingly, in a variety of endothelial in 
vitro systems has shown that factor Xa induces a wide array of proinflammatory 
responses (importantly PAR-1 ligation stimulates endothelial proliferation whereas 
PAR-2 does not, hence the difference between Xa and thrombin in targeting PAR 
subtypes is extremely important). The generation of floxed PAR-1  and PAR-2 mice 
will allow endothelium knock out of these receptors and thus should prove 
exceedingly useful for determining the actual physiological contribution of the two 
PAR isoforms for extravasation. 
Our data are strongly supported by experiments which I have now initiated in 
which I directly test the effect of genetic deficiency for PAR-2 in a murine model of 
bleomycin-induced lung fibrosis. Intratracheal administration of bleomycin gives in 
wild type animals. Activation of the coagulation cascade is commonly observed in the 
lungs of patients with both acute and chronic inflammatory and fibrotic lung 
disorders, as well as in animal models of these disorders. The aim of this study was to 
examine the contribution of coagulation FVIIa and FXa receptor, Protease-activated 
receptor-2 (PAR-2), during the acute inflammatory and chronic fibrotic phases of lung 
injury induced by the intratracheal instillation of bleomycin in mice. Granulocyte 
infiltration were attenuated in PAR-2 deficient mice (PAR-2 ko) compared to the 
wild-type (wt) mice). PAR-2 ko mice were also protected from bleomycin-induced 
fibrosis. The mean percentage areas of fibrosis in lung were reduced from 29.7±5.3% 
to 9.2±2.3% (P<0.05) 7 days after bleomycin instillation, and from 40.3±7% to 
22±3.7% P<0.05) 14 days after bleomycin instillation respectively in PAR-2 ko and 
wt mice. This reduction in fibrosis extent was also evident from total lung collagen 
and Fibronectin (Fn) accumulation reduced from 260±34% to 166.5±22 % (P<0.05) 
and from 155±17% to 116.6 ± 13.24% (P<0.05) respectively in wt and PAR-2 ko 
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mice as compared to control. Furthermore, the levels in the lung of alpha-smooth 
muscle alpha-actin, which is a hallmark of fibroblast differentiation into 
myofibroblasts, was also significantly reduced. Thus the data obtained in this thesis 
seem to be of in vivo relevance in a bona fide model of fibrosis as well. 
From the preceding, it is obvious that coagulation factor-induced signaling 
may add to vascular remodeling, asthma, fibrosis and cancer. From a clinical 
perspective, FXa seems to be an attractive therapeutic angle, especially in view of the 
amplified nature of coagulation factor interaction and fibrin formation. As a 
consequence, FXa inhibitors are more efficient at smaller doses than anticoagulants 
targeting thrombin. Furthermore, it is evident that inhibiting the coagulation cascade 
upstream thrombin formation is most effective due to incomplete down regulation of 
thrombin formation by direct thrombin inhibitors. Of the upstream targets, FXa seems 
preferable as it is positioned at the crossroad between intrinsic and extrinsic pathways 
of the coagulation cascade. Clinical trials using specific FXa inhibitors should be able 
to prove or refute the concept that specific FXa inhibitors are preferable in this type of 
clinical setting. I therefore eagerly await the results of these ongoing clinical trials 
involving fondaparinux (first approved specific FXa inhibitor) in non-small cell lung 
cancer . 
Because of the kaleidoscopic cellular effects induced by FXa in both 
physiology and pathophysiology, it is clear to me that FXa is more than a passive 
bystander in the coagulation cascade. Arguably, FXa might direct essential processes 
during tissue remodeling, fibrosis, cancer and pathological angiogenesis. Indeed, 
inhibiting FXa in animal models of restenosis, asthma and cancer is beneficial, 
underscoring FXa importance in disease. I urge the reader however to realise that it is 
problematic to determine whether FXa inhibition is beneficial due to inhibition of 
signal transduction or due to diminished thrombin generation. A further 
comprehension of the molecular programmes evoked by FXa, the receptor(s) involved 
and the consequence on pathophysiology is a major task lying ahead of us. Indeed, 
although recent work highlights the biological importance of FXa signaling in health 
and disease, several outstanding issues remain unresolved. Most importantly, it is to 
determine whether specific factors such as FVIIa, FXa and thrombin fulfil specific or 
redundant roles in pathophysiology and what the mechanism that confers specificity 
might be. Indeed, one could think of exploiting such effects for pharmacological 
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intervention in specific pathological contexts. Furthermore, the clinical relevance of 
FXa inhibitors should be proven in controlled clinical trials.  
Once we completely understand the molecular effects induced by FXa and its 
associated pathophysiological consequences, novel FXa inhibitors specifically 
targeting it signaling properties might emerge as therapeutic options in a broad range 












Naast de bijdrage aan het voorkomen van bloedverlies na een vaatwandbeschadiging, 
spelen individuele bloedstollingsfactoren een belangrijke rol in de celbiologie. Deze 
bloedstollingsonafhankelijke rol van stollingsfactoren is voor het eerst beschreven aan 
het eind van de zeventiger jaren. Trombine, een van de belangrijkste stollingsfactoren, 
bleek niet alleen een krachtig mitogen voor fibroblasten maar leidde ook tot de 
migratie van fibroblasten (beide essentiele processen tijdens wondgenezing). Het 
achterliggende mechanisme waarmee trombine deze directe cellulaire processen 
bevorderde is pas in de jaren negentig opgehelderd na de identificatie van een 
trombine receptor. Deze receptor, genaamd protease-geactiveerde receptor-1 (PAR-1), 
bleek te behoren tot een familie van receptoren gekenmerkt door het feit dat deze 7-
transmembraan receptoren worden geactiveerd middels proteolytische splitsing.  
Direct na de identificatie van PAR-1 bleek ook het weefselfactor/factor VIIa complex 
(initiator complex voor de bloedstolling) specifieke cellulaire processen te induceren. 
Deze processen waren echter niet afhankelijk van PAR-1 maar van een ander 
familielid van de PAR-receptoren te weten PAR-2. In de hier opvolgende jaren zijn 
een groot aantal studies beschreven die hebben laten zien dat de cellulaire processen 
geïnduceerd door trombine-gemedieerde PAR-1 activatie of weefselfactor/FVIIa-
gemedieerde PAR-2 activatie een belangrijke rol spelen bij wondgenezing, 
botontwikkeling maar ook bij kanker, ontsteking en angiogenese.  
Op een of andere onduidelijke reden is stollingsfactor Xa, de factor geactiveerd door 
weefselfactor/FVIIa en verantwoordelijk voor de activatie van trombine, lange tijd 
beschouwd als een relatief onbelangrijke passieve doorgever van het stollingssignaal. 
Het is nu echter duidelijk dat FXa weldegelijk belangrijk is en een cruciale rol speelt 
in de celbiologie. In het onderliggende proefschrift beschrijf ik mijn onderzoek naar 
de celbiologische eigenschappen van FXa en FVIIa. Naast theoretische 
verhandelingen over de bestaande literatuur (hoofdstuk 2 en 5) karakteriseer ik het 
mechanisme van splice-site selectie in FVIIa (hoofdstuk 3) en de activatie van de 
transcriptiefactor CREB door deze stollingsfactor (hoofdstuk 4). Vervolgens worden 
een aantal anti-kanker effecten van FX bestudeerd:  het moleculair mechanisme van 
geprogrammeerde celdood door factor X wordt in kaart gebracht (hoofdtuk 6)  en de 
effecten op celmigratie komen aan bod in hoofdstuk 7. Verdere karakterisatie op 
biochemisch niveau van de effecten van de drie stollingsfactoren door middel van 
peptide spitstechnologie gebeurd in hoofdstuk 8. De resultaten wezen erop dat 
stollingsfactoren het herstel van weefsel na beschadiging orkestreren en inderdaad 
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laten we in hoofdstuk 9 pro-fibrotische effecten zien, terwijl de daarmee 
geassocieerde angiogenetische response in hoofdstuk 10 aan bod komt. Het 
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